

While the Office of Science and Technology commissioned this review, the views are those of the authors, are independent of Government and do not constitute government policy.

Neuroscience and Drugs of Addiction

Trevor W. Robbins

Department of Experimental Psychology and MRC Centre for Behavioural and Clinical Neuroscience
University of Cambridge

Rudolf N. Cardinal

Department of Experimental Psychology and MRC Centre for Behavioural and Clinical Neuroscience
University of Cambridge

Patricia DiCiano

Department of Experimental Psychology and MRC Centre for Behavioural and Clinical Neuroscience
University of Cambridge

Peter W. Halligan

School of Psychology
Cardiff University

Kim G. C. Hellemans

Department of Experimental Psychology and MRC Centre for Behavioural and Clinical Neuroscience
University of Cambridge

Jonathan L. C. Lee

Department of Experimental Psychology and MRC Centre for Behavioural and Clinical Neuroscience
University of Cambridge

Barry J. Everitt

Department of Experimental Psychology and MRC Centre for Behavioural and Clinical Neuroscience
University of Cambridge

| | |
|---|-----------|
| EXECUTIVE SUMMARY | 3 |
| 1. INTRODUCTION | 5 |
| 2. NEUROPSYCHOLOGY OF REINFORCEMENT LEARNING AND ADDICTION | 8 |
| 3. THE NEURAL SYSTEM BASIS OF REINFORCEMENT LEARNING: RELEVANCE TO NATURAL MOTIVATION AND DRUG ADDICTION | 11 |
| 4. NEUROBIOLOGY OF RELAPSE | 17 |
| 5. NEUROADAPTATIONS – INTRACELLULAR CASCADES | 20 |
| 6. VULNERABILITY TO ADDICTION | 24 |
| 7. HARMS CAUSED BY DRUGS OF ABUSE | 30 |
| 8. DRUG ADDICTION: A SOCIAL COGNITIVE NEUROSCIENCE PERSPECTIVE | 32 |
| 9. THE MIND/BRAIN INTERFACE: NEUROBEHAVIOURAL ECONOMICS OF ADDICTION | 35 |
| 10. FUTURE IMPLICATIONS: NEW DRUGS, THEIR IMPACT AND MANAGEMENT | 41 |
| ACKNOWLEDGEMENTS | 45 |
| FIGURES AND FIGURE LEGEND | 41 |
| REFERENCES | 46 |

EXECUTIVE SUMMARY

Brain science is at the core of our future understanding of how drugs affect behaviour, and their consequent impact on society. Extraordinary advances in the last three decades have meant that we now understand much about the connectivity of the brain and how its functionality depends on chemical messages passing between nerve cells, or neurons, in the form of neurotransmitters they release which bind to receptors. Psychoactive substances exert their effects by affecting the regulation of neurotransmitters or simulating their actions at their receptors, and subsequently within the nerve cell itself, often in highly specific ways. We understand how many drugs work in molecular terms and where they may work, at least initially, in the brain. Moreover, we now understand in broad terms how different parts of the brain work at a systems level to produce behavioural and cognitive output.

Major advances have been made on two fronts. First, our understanding of the major neural components of the 'reward' or reinforcement system in the brain in animals has improved. This mediates the influence both of events such as food and sex on learning, and of drugs of abuse. Second, understanding has improved in cognitive neuroscience, elucidating how the human brain processes information, particularly within the cerebral cortex. Convergence between these areas is beginning to enable us to understand the neurobiological underpinnings of the effects of psychoactive substances in humans, even within a societal context. For example, the emerging theme of neuroeconomics promises to reveal how the cognitive apparatus of the brain constrains the assumptions of rational decision making in traditional economic theory. A complementary advance has been the application of some aspects of neural decision-making theory to the explanation of the behaviour of individual substance abusers.

Our burgeoning understanding of how psychoactive substances affect brain function includes a growing realisation of their long-term effects, both neural and behavioural. Vulnerability or susceptibility to some actions of psychoactive substances, including cognitive enhancement and dependence, appear to depend on individual differences based on genetic or environmental, including developmental, factors. It is becoming clear that the future impact of neuroscience will be realised through interactions with diverse disciplines such as cognitive and social psychology, physics, molecular biology and genomics. This expansion of knowledge is influencing our attitudes to such important areas as the treatment of mental illness, the potential for augmenting cognitive function through psychoactive substances, and the study of drug use and abuse. Thus, the concept of addiction itself is undergoing radical change. Although many in society still view drug

Neuroscience and Drugs of Addiction

abuse as a social or moral problem best handled through the criminal justice system, the growing scientific evidence suggests instead that addiction is a chronic, relapsing and treatable brain disorder that can result from the prolonged effects of drugs on the brain.

1. INTRODUCTION

Communication within the brain depends on the release of neurotransmitter substances. Many agents, including drugs but also nutrients and transcranial magnetic or deep brain stimulation, exert their effects through chemical neurotransmission. Many psychoactive drugs work on chemical systems that not only control behaviour, but also respond to behavioural change. Many forms of behaviour, ranging from transcendental meditation to compulsive eating or gambling, may regulate the functioning of the chemical systems of the brain.

In the last 50 years or so, our list of chemical neurotransmitter substances in the brain has lengthened from two to over 60 [1; 2]. The neurotransmitters include amino acids and monoamines and, structurally more complex, neuropeptides. The list is likely to be extended, leading to further drug development. The discovery of new neurotransmitters goes hand in hand with the mapping of the neurons that contain them in the brain. These substances are not distributed homogeneously in the central nervous system (CNS), but are contained within defined tracts and clusters of cells, which may be organised in a complex arrangement to form interconnected brain systems. Moreover, at the synapses between neurons, these substances interact as ligands with complex protein molecules called receptors on the neuronal membranes, to which they bind and thus transduce their chemical signals. There are often several distinct receptor subtypes for a given neurotransmitter, and these are also widely distributed within the brain, generally but not always matching the mapping of the neurotransmitter systems themselves. Further complexity is conferred by variations in protein subunits making up the receptors. The many functional effects of drugs such as nicotine and benzodiazepines, for example, diazepam, can be attributed in part to different receptor subtypes operating preferentially in different brain regions. The discovery of 'orphan' receptors without obvious neurotransmitter ligands in different brain regions indicates the possibility of further discoveries of new psychoactive substances [3; 4]. In the past, the discovery of psychoactive drugs has often pre-dated the discovery of the endogenous neurotransmitter ligand (e.g. endorphin and enkephalins in the case of opiates such as morphine and heroin, and β -carbolines in the case of the benzodiazepines), as well as the brain receptors upon which they act [1].

The biophysical actions of neurotransmitters at specific receptors range from short-lived electrochemical effects at ion channels to slower cellular signalling via receptors linked to biochemical cascades (e.g. 'second messengers') and gene transcription. The old adage of one neurotransmitter per neuron has long been disproved by discoveries that many of the actions of the 'classical' neurotransmitters, such as acetylcholine (ACh), noradrenaline (NA), serotonin (5-HT) and dopamine (DA), are augmented by co-released peptides [1]. The chemical neurotransmitters affect the functioning of dense, but generally highly organised, sets of connections, conveniently referred to as neuronal networks. They do this either by affecting fast signalling, whether excitatory or inhibitory, within the network, or by slower and spatially more diffuse modulations across the nodes of the network. An individual neuron is subject to many different influences from distinct neurotransmitter systems. The activity of a particular cell and thus of entire networks can be adjusted by variations in the syntax of chemical messages impinging on the cell.

Several neurological and neuropsychiatric disorders have chemical pathologies for which a strategy of pharmacological replacement of deficient systems has been adopted. L-DOPA medication of Parkinson's Disease is the classic example, where the loss of DA-containing cells of the substantia nigra leads to the characteristic motor symptoms. L-DOPA remediates some of the cognitive deficits associated with Parkinson's Disease [5], but also produces some undesirable cognitive and emotional side-effects, including for some patients a drive to abuse the drug [6]. L-DOPA's therapeutic effects also tend to diminish with long-term treatment, leading to a gamut of other attempts to treat the disorder,

which include other dopaminergic drugs, deep brain stimulation, neurosurgery and the neural transplantation of embryonic nigral cells [7]. Especially in view of the ethical problems posed by the last-named, a future approach will almost certainly involve the use of stem cells engineered to produce DA. A similar approach to the treatment of Alzheimer's Disease with cholinergic drug treatments (including nicotine) has proved less successful, although such treatment does improve some functions, notably attention [8]. The future strategy (as with the treatment of stroke) is likely to hinge on neuroprotection, preventing through drug treatment the neuronal loss occurring as a consequence of the initial pathology [9].

Many other disorders that result in cognitive or mood-related deficits are now treated with drugs. These include depression, treated with monoamine reuptake inhibitors such as the selective 5-HT reuptake inhibitors (SSRIs), schizophrenia, treated by DA receptor blockers, and attention-deficit hyperactivity disorder (ADHD), which is treated effectively with amphetamine-like stimulant drugs such as methylphenidate (Ritalin) [10]. A number of cognitive disorders arising from brain dysfunction have been treated on an experimental basis. These include Korsakoff's Syndrome (arising from alcoholism), which has been treated with drugs affecting noradrenergic transmission; acute brain injury (treated with DA receptor agonists); and stroke (treated with amphetamine). While the molecular bases of these drugs' actions at the cellular level are well defined, the mechanistic basis of any of these therapeutic effects is less clear. The most effective anti-psychotic drug, clozapine, is also one of the least specific in pharmacological terms. Antidepressants such as the SSRIs may work via effects on neurogenesis in the hippocampus [11]. Nevertheless, given the therapeutic efficacy of most of these drugs, and strong evidence from animal models of cognitive function, there is optimism that cognitive and mood-related disorders will continue to respond to interventions based on psychoactive substances.

One of the most promising developments from experimental neuroscience has arisen from a neuronal model of learning called long-term potentiation (LTP). This can occur in subtly different forms in many forebrain regions, but has been investigated most intensively in the hippocampus [12]. LTP crucially depends on the excitatory amino-acid neurotransmitter glutamate, and its actions at the α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and N-methyl-D-aspartate (NMDA) receptor subtypes. Several agents affecting glutamate transmission have been developed, including some (such as the AMPA-kines), which have been shown to have positive effects on learning in the laboratory both for normal animals and humans, and have been subject to preliminary clinical trials [13]. Some NMDA receptor antagonists, such as ketamine, have recently been shown to have significant abuse potential [14]. In a more speculative vein, drugs enhancing the transcription factor cyclic adenosine monophosphate (cAMP) response element binding protein (CREB) could also emerge from advances in the application of basic neuroscience [15].

The phenomenon of beneficial effects in normal subjects who lack discernible brain dysfunction is not restricted to drugs affecting glutamate receptors. In specific situations, which may include the infusion of drugs locally to specific brain regions in experimental animals and the engagement of particular cognitive functions, many positive drug effects have been reported for compounds acting on the classical cholinergic, noradrenergic, serotonergic or dopaminergic systems [16]. Only some of these systems have also been associated with drug dependence. Thus, the positive effects of cholinergic drugs on attention and aspects of mnemonic function are not accompanied by mood-altering effects of potential recreational use.

Predicting psychopharmacological efficacy is often confounded by the surprising emergence of new substances, which may have initially appeared to be innocuous or which were initially established in some other functional context. The effective anti-narcoleptic modafinil [17] has stimulant-like actions, but does not appear primarily to

affect the brain neurotransmitters implicated in the effects of stimulant drugs such as amphetamine and methylphenidate. This drug has mild beneficial effects on tests of short-term memory and planning, as well as an anti-impulsive action, both in normal adults and in patients with ADHD [18]. Its beneficial effects on vigilance and other aspects of human performance have led to its well-publicised use by the military.

These effects indicate again the possibility of cognitive enhancement in intact individuals. Increasing evidence of individual variability in intellectual function in normal subjects that occurs as a function of genotypical variation [19] and in association with factors such as fatigue or under-arousal in the workplace may promote self-medication. But, although modafinil emerged from a scientific programme of drug development, we do not know how it works. The fact that modafinil is not widely abused indicates that it is feasible to dissociate stimulant from reinforcing actions of drugs of abuse. Whether this dissociation arises from the pharmacokinetic actions of the drug, which is relatively slow-acting, or its distinct neurochemical actions, is a theoretically, as well as practically, important issue.

Self-medication prompted by a perceived need to elevate the activation of particular brain neurochemical systems might also affect other domains of forebrain functioning. The need to enhance activation of the dopaminergic reinforcement ('reward') system might explain why individuals use cocaine and other psychomotor stimulants that operate primarily through this system. Such a view is consistent with evidence that euphoria produced by drugs such as cocaine and methylphenidate may depend on initially low levels of striatal DA (D2) receptors, as revealed by positron emission tomography, which may be indicative of low basal mood states [20] (Figure 1). It may also be relevant to the identification of individuals who indulge in certain behavioural addictions such as gambling [21]. Whether these individual differences arise from genetic or environmental influences is still to be determined.




Figure 1 Brain imaging of dopamine receptors during drug-induced euphoria in normal volunteers

(A) Distribution volume images of [¹¹C]raclopride at the levels of the striatum (left) and cerebellum (right) in a healthy male subject who reported the effects of methylphenidate as pleasant and in a healthy male subject who reported them as unpleasant. 100% = 25 ml/mg; 10% = 0.4 ml/mg. **(B)** D2 receptor levels (B_{max}/K_d) in 23 healthy male subjects who reported the effects of methylphenidate as pleasant, unpleasant, or neutral. B_{max}/K_d values were lower in subjects who reported the effects of methylphenidate as pleasant than in those who reported them as unpleasant. The horizontal lines represent the means for the B_{max}/K_d estimates for the different groups. (From [755].)

Reprinted, with permission, from *American Journal of Psychiatry*. Copyright (1999) American Psychiatric Association.

2. NEUROPSYCHOLOGY OF REINFORCEMENT LEARNING AND ADDICTION

Motivated action can be examined by studying instrumental conditioning, the process by which animals alter their behaviour when there is a contingency between their behaviour and a reinforcing outcome [22]. Reinforcement learning [23–25] has been studied for a long time [22; 26–30]. At its most basic level, it is the ability to learn to act on the basis of important outcomes such as reward and punishment. Events that strengthen preceding responses are called positive reinforcers, while events whose removal strengthens preceding responses are called negative reinforcers [31]. If reinforcers are defined by their effect on behaviour, then, to avoid a circular argument, behaviour cannot be said to have altered as a consequence of reinforcement [31]. However, to explain behaviour rather than merely describe it, internal processes such as motivation must also be accounted for. Central motivational states, such as hunger and thirst, account parsimoniously for a great deal of behavioural variability [32–34]. For example, water deprivation, eating dry food, hypertonic saline injection, and the hormone angiotensin II all induce a common state – thirst – that has multiple effects. Thirsty animals drink more water, drink water faster, perform more of an arbitrary response to gain water, and so on. The ideas of motivational state entered early theories of reinforcement. For example, it was suggested that events that reduce 'drive' states such as thirst are positively reinforcing [28]. However, on its own, this simple model cannot account for many instrumental conditioning phenomena, let alone 'unnatural' reinforcement such as drug addiction.

Modern neuropsychological theories recognise that many processes contribute to a simple act such as pressing a lever to receive food or a drug [35]. Rats and humans exhibit goal-directed action, which is based on knowledge of the contingency between one's actions and their outcomes, and knowledge of the value of those outcomes. These two representations interact so that we work for that which we value [35; 36]. Environmental stimuli provide information about what contingencies may be in force in a given environment [37–39]. Remarkably, the value system governing goal-directed action is not the brain's only one. This 'cognitive' value system exists alongside [40] the valuation process that determines our reactions when we actually experience a goal such as food, termed 'liking', 'hedonic reactions', or simply 'pleasure' [41]. Under many normal circumstances, the two values reflect one another and change together. However, the fact that they are different means that animals must learn which outcomes are valuable in a given motivational state, a process referred to as incentive learning. For example, rats do not know that to eat a particular food while sated is not as valuable as to eat the same food while hungry until they have actually eaten the food while sated [42].

Just as there is more than one value system, there is more than one route to action, and not all action is goal-directed. With time and training, actions can become habitual [43], that is, elicited by direct stimulus–response (S–R) associations. S–R habits are less flexible than goal-directed action because their representation contains no information about what the final outcome will be and cannot alter quickly if the desirability of a particular outcome changes. But they may help reduce the demands on the cognitive, goal-directed system in familiar settings.

Stimuli that predict reward may become conditioned stimuli (CSs), associated with the reward (unconditioned stimulus, US) through Pavlovian associative learning. Pavlovian CSs can influence instrumental behaviour directly (Pavlovian–instrumental transfer, PIT) and can serve as the goals of behaviour, termed 'conditioned reinforcement' [35; 36; 44–46].

Seen in this context, the major neuropsychological theories of drug addiction – none of them mutually exclusive – can be summarised as follows.

2.1 Direct positive effects of drugs; self-medication; tolerance

Drugs are taken for their positive effects. These may include euphoria, enhanced social experiences, enhanced intellectual or attentional performance, and an enhanced effect of other reinforcers such as food or sex [2; 47–49], as indicated in the Foresight project's Pharmacology and Treatments State-of-the-Science Review.

An aspect of this may be that people 'self-medicate' to achieve a desired level of mood, social performance, and so on [49–53], although the extent to which this occurs is debated [53; 54]. Furthermore, the effect of the drug depends on the user's expectations [55] and prior mood, and varies between people [56; 57].

Tolerance to pleasant drug effects may build up, requiring the user to take more drugs to achieve the same effect. Tolerance can be due to a decrease in drug bioavailability ('metabolic tolerance'), a reduction in the number or responsiveness of receptors or intracellular mechanisms ('pharmacodynamic tolerance'), or a compensatory mechanism ('behavioural tolerance') [2]. Tolerance may develop with chronic use, but in the case of cocaine, can develop in a single session [58], perhaps explaining cocaine 'bingeing'. Metabolic tolerance is seen with regard to barbiturates, ethanol and opiates [2]. Pharmacodynamic tolerance is seen with regard to a wide range of drugs, including barbiturates, ethanol, opiates, amphetamine, cocaine, nicotine, and caffeine [2]. Behavioural or conditioned tolerance has been observed with regard to opiates, ethanol, nicotine, benzodiazepines, and other drugs [59–63]. Since conditioned tolerance may be situation-specific [63] and the lethality of drugs may be increased if the environment changes, the opponent process model of addiction [64; 65] suggests that a key component of addiction is the development of behavioural [66] and neuroanatomical [67; 68] tolerance, which can counteract the effects of the drug [69].

2.2 Conditioning and sensitisation

CSs associated with the pleasant aspects of drug taking may act to promote it. Drug-associated cues including mood states, people, locations and abuse paraphernalia may induce some of the primary effects of drugs [70], but can also induce craving in addicts, and can trigger relapse [71–74]. Addicts may also work directly for drug-associated stimuli (conditioned reinforcement), leading them in turn to the drug itself.

Sensitisation ('inverse' or 'reverse' tolerance) occurs when repeated doses of a drug enhance one or more of its effects. Prototypically, moderate, spaced doses of amphetamine enhance the subsequent locomotor response to it [49; 75; 76]. Sensitisation can exhibit environmentally-specific conditioned properties [77] and changes in drug pharmacodynamics [78]. It has been suggested that the ability of drug-associated CSs to promote drug seeking or craving also sensitises as a consequence of repeated drug taking [75; 79].

2.3 Withdrawal and conditioned withdrawal

Some drugs, notably the opiates and alcohol, produce powerful physical withdrawal syndromes. Thus, it is possible to consider addiction within the framework of both rewarding and aversive consequences [80]. Withdrawal symptoms are improved by the drug, so the drug is taken to escape from withdrawal [47; 48]. However, demonstrations that the neural substrates mediating physical signs of dependence are separate from those of reward [81] support earlier behavioural evidence that physical dependence is not a necessary correlate of opiate addiction. In withdrawal, incentive learning operates for drugs of abuse just as for natural reinforcers. Just as hunger increases the hedonic impact of food [82], which teaches the animal that it is of more worth working for food when it is hungry [36], rats learn that heroin has a high value in the state of opiate withdrawal [83]. Hedonic impact may be a 'common currency' for determining the value of widely varying reinforcers [84]. Environmental stimuli may become associated with

withdrawal [85–88] and CSs for withdrawal may then provoke drug taking, just as withdrawal itself does [47; 48].

Drugs such as cocaine that do not produce obvious physical withdrawal syndromes may nonetheless have unpleasant after-effects on mood [72; 89–92] that may promote drug taking in the same way that physical withdrawal does. 'Opponent process' theories [64; 93–96] use the idea that a long-lasting unpleasant process opposes the euphoric effects of drugs and that, with chronic use, the euphoric effects diminish while the dysphoric process comes to dominate, leading to drug taking via negative reinforcement.

2.4 Habit learning

Drugs may activate habit-learning systems so that actions that led to the drug being used are reinforced directly, creating powerful S–R habits or 'involuntary' responding [97–101]. A hallmark of habitual responding is that it persists, even if the reinforcer's value is reduced [35]. Habits are sometimes thought of as 'compulsive' responding when they occur at an abnormally high level, since they do not depend on the current value of the goal. Alcohol seeking may primarily reflect habitual responding [102] and, while cocaine seeking can be goal-directed [103], under some circumstances responding for cocaine can be more habitual than responding for natural reinforcers [104]. Similarly, soon after acquisition, cocaine seeking is readily suppressed by an aversive CS, but this suppression is lost after prolonged experience of cocaine [105]. Craving and habits both capture something of the casual definition of addiction as 'compulsive' behaviour (e.g. [106–108]).

2.5 Individual vulnerability

People who become drug addicts may be more vulnerable than other people to one or more of these neuropsychological effects, as well as being more predisposed to try drugs of abuse in the first place. Vulnerability to drug effects is discussed in greater detail in Section 6.

2.6 Comparison of drug taking to alternative activities

From a behavioural-economic perspective, addicts weigh up the benefits and costs of drug taking. They may do so rationally [109; 110], or may exhibit decision-making flaws characteristic of humans, such as focusing inappropriately on short-term rather than long-term goals and being inconsistent in their choices [111–117]; see Section 10.

Drug addicts may be predisposed to act even more for short-term benefit than other people, or drugs may induce decision-making deficits [20; 118–125]. There is some evidence that self-control deficits may be a reversible consequence of cigarette dependence [121; 123].

None of these theories, or indeed levels of explanation, is adequate on its own [126]. For example, although heroin may be taken to alleviate withdrawal, heroin self-administration can persist in the absence of withdrawal [81; 127], and although heroin has euphoric effects, humans will work for doses that they cannot subjectively distinguish from a placebo [128]. To seek a single theory of drug addiction is to miss the point that drugs of abuse have many effects, people take drugs for many reasons, and those reasons vary between people.

3. THE NEURAL SYSTEM BASIS OF REINFORCEMENT LEARNING: RELEVANCE TO NATURAL MOTIVATION AND DRUG ADDICTION

Considerable progress has been made in establishing some of the mechanisms by which neural structures respond to appetitive and aversive events. To some extent, these structures can be compared directly to the psychological processes known to influence animals' responding for rewards.

A number of limbic cortical and subcortical structures in the brain play a role in assessing the value of reinforcers and of the stimuli that predict them, and in actions directed at obtaining those reinforcers or stimuli [44] (**Error! Reference source not found.**). Their relevance to addiction has been considered many times before (e.g. [49; 129]), and influential theories of addiction have postulated that drugs of abuse 'short-circuit' or 'hijack' the neural mechanisms underlying reward or motivation [80; 130–133].

3.1 *The role of DA in the nucleus accumbens in motivation and learning*

The discovery that rats would work hard to stimulate regions of their brain electrically (intracranial self-stimulation, or ICSS) [134] was historically important. Many sites that support ICSS lie on the path of dopaminergic neurons from the substantia nigra pars compacta (SNc) and ventral tegmental area (VTA) to limbic sites including the ventral striatum (nucleus accumbens, Acb), and ICSS is substantially reduced after Acb DA depletion [135]. The rate at which rats learn to respond for ICSS is correlated with the degree of potentiation of synapses made by cortical afferents onto striatal neurons, a potentiation that requires DA receptors [136]. The discovery that deep brain stimulation and transcranial magnetic stimulation can influence cognition, affect and motor performance in humans means that we cannot discount this means of altering brain function. Deep brain stimulation of the subthalamic nucleus has been successful with severe Parkinson's Disease, and may have applications in obsessive compulsive disease and clinical depression [137], but care is needed as the stimulation can be self-administered, and in the case of Parkinson's Disease, dramatic emotional sequelae have been reported [138].

3.2 *DA; motivation, reward and pleasure*

An early suggestion was that Acb DA mediated the pleasurable aspects of reward [139–141]. There is now strong evidence against this simple idea. Certainly, DA is released in response to appetitive reinforcers (e.g. [142–152]), intra-Acb DA agonists are reinforcing [153], animals may adjust their drug-taking to maintain high Acb DA levels [154], and some aspects of naturally- and drug-reinforced responding depend on Acb DA (e.g. [155–162]). However, Acb DA does not mediate 'pleasure' [20; 147; 163; 164], though its release may correlate with activity in other systems that do, and reinforcement operates in its absence [155; 165]. Measured by microdialysis techniques, DA is also released in response to aversive stimuli, CSs that predict them, and other salient stimuli (see e.g. [149; 166; 167]), which would be consistent with a more general motivational role. CSs that have been paired with reward also elicit approach [168]; this effect also depends on the Acb [169–171] and its DA innervation. DA may also be involved in learning this approach response, again perhaps under the control of the central nucleus of the amygdala (CeA) [130; 159; 172–174] (see **Error! Reference source not found.**). Acb DA also contributes directly to subjects' motivation to work hard [156–158].

Hedonic assessment of rewards themselves, or 'liking', does not depend on dopaminergic processes [147; 160; 175; 176]. Instead, it involves opioid mechanisms in the nucleus accumbens shell (AcbSh) and other systems in the pallidum and brainstem [177; 178]. Intra-Acb μ opioid agonists also affect food preference, increasing the intake of highly palatable foodstuffs like fat, sweet foods, salt, and ethanol [179–183], while chronic ingestion of chocolate induces adaptations in endogenous Acb opioid systems [184].




Figure 2 Brain systems subserving drug addiction: current status

Schematic representation of limbic circuitry, including cortex, ventral striatum, and pallidum, which tentatively localises functions involved in addiction discussed in the text including: (i) processing of discrete and contextual drug-associated conditioned stimuli – basolateral amygdala and hippocampal formation, respectively, with a special role of the basolateral amygdala in mediating conditioned reinforcement and the central amygdala in Pavlovian (or conditioned) arousal; (ii) goal-directed actions ('action–outcome' associations) – involving the interaction of the prefrontal cortex with other structures, perhaps including the nucleus accumbens; (iii) 'habits' (S–R learning) – dorsal striatum. Both (ii) and (iii) involve interactions between cortical projections to striatal domains, modulated by DA. (iv) 'Executive control' – prefrontal cortical areas; (v) subjective processes, such as craving, activate areas such as orbital and anterior cingulate cortex, as well as temporal lobe structures including the amygdala, in functional imaging studies; (vi) 'behavioural output' is intended to subsume ventral and dorsal striatopallidal outflow via both brainstem structures and re-entrant thalamo–cortical loop circuitry; (vii) 'spirals' refers to the serial, spiralling interactions between the striatum and mid-brain DA neurons that are organised in a ventral-to-dorsal progression [281]; (viii) sensitisation refers to the enhancement of drug and conditioned responses that is a consequence of earlier drug exposure and is at the heart of theories of addiction and relapse. The neural basis of stress-induced relapse, which involves the bed nucleus of the stria terminalis, central amygdala and their noradrenergic innervation is not illustrated. Blue arrows: glutamatergic pathways; orange arrows: GABA-ergic pathways; red arrows: dopaminergic pathways. The transmitter used by central amygdala neurons is less certain, but is probably glutamate and also a neuropeptide(s). Abbreviations: BLA: basolateral amygdala; CeN: central nucleus of the amygdala; VTA: ventral tegmental area; SNc: substantia nigra pars compacta; DGP, dorsal globus pallidus; LH, lateral hypothalamus; NAc, nucleus accumbens; rft, reinforcement; VGP, ventral globus pallidus. This diagram is modified from [49] and [99].

However, the notion that 'pleasure' can be mediated by receptors in a subcortical nucleus is perhaps too simple. Activity in this circuitry is probably subject to further processing in cortical (particularly prefrontal cortical) circuits, before attribution and accompanying subjective commentary [49].

3.3 DA and learning

The notion that DA 'stamps in' the learning of S-R connections has considerable support. It has acute effects that modulate corticostriatal transmission, and also lasting effects. The combination of presynaptic and postsynaptic activity normally induces long-term depression of corticostriatal synapses, but if the same pattern of activity is paired with a pulse of DA, the active synapses are strengthened [185]. Natural reinforcers, drugs of abuse, and CSs that predict either, trigger increases in DA release in the Acb [146–150]. DA neurons fire to unexpected rewards, or to unexpected stimuli that predict reward [142–145]. DA neuron firing may be a teaching signal used for learning about actions that lead to reward [143]. The Acb similarly responds to anticipated rewards [186–197]. Other parameters of tonic DA neuronal firing may signal reward uncertainty, possibly relevant to the understanding of gambling behaviour [198; 199].

Targets of DA neurons certainly influence instrumental behaviour. Structures that learn from the DA 'teaching signal' probably include the dorsal striatum and the prefrontal cortex (PFC) (see **Error! Reference source not found.**), but much attention has focused on the Acb. Blockade of NMDA glutamate receptors in the nucleus accumbens core (AcbC) has been shown to retard instrumental learning for food [200], as has inhibition or overstimulation of protein kinase A (PKA) within the Acb [201]. Concurrent blockade of NMDA and DA D1 receptors in the AcbC synergistically prevents learning [202]. Once the response has been learned, subsequent performance is not impaired by NMDA receptor blockade within the AcbC [200]. Furthermore, infusion of a PKA inhibitor [201] or a protein synthesis inhibitor [203] into the AcbC after instrumental training sessions impairs subsequent performance, implying that PKA activity and protein synthesis in the AcbC contribute to the consolidation in memory of instrumental behaviour.

However, it is clear that the Acb is not required for simple instrumental conditioning but rather is implicated in providing extra motivation for behaviour, especially when it is triggered by Pavlovian CSs, or when reinforcers are delayed or require substantial effort to obtain. Rats with Acb or AcbC lesions acquire lever-press responses on sequences of random ratio schedules at normal or slightly reduced levels [204; 205] and are fully sensitive to changes in the action–outcome contingency [204–206]. Thus, the Acb is not critical for goal-directed action (see [44]). Instead, it appears to be critical for some aspects of motivation that promote responding for rewards in real-life situations. For example, the Acb plays a role in promoting responding for delayed rewards [207; 208] and is required for Pavlovian CSs to provide a motivational boost to responding [174; 205], i.e. for PIT. PIT has sometimes been termed 'wanting' [79; 209], although 'wanting' could equally refer to the instrumental incentive value underpinning true goal-directed action or Pavlovian arousal itself. PIT can be further enhanced by injection of amphetamine into the Acb [209] and depends on DA [160], possibly under the control of the CeA [174]. Other motivational effects of Pavlovian CSs also depend on the Acb, for example, the capacity of CSs to act as conditioned reinforcers of instrumental behaviour.

The neural basis of conditioned reinforcement has been investigated using the 'acquisition of a new response' procedure, in which subjects work only for a conditioned stimulus that has previously been associated with a natural reinforcer such as food or water. From these studies, it is clear that the basolateral amygdala (BLA) and AcbC are important in the ability to respond normally for conditioned reinforcement [169; 210–212]. In naturalistic situations, rewards are frequently available only after a delay, require considerable effort to achieve, and are signalled by environmental stimuli. Thus, the Acb is central to a

number of processes that require motivation [213]. Functional neuroimaging evidence supports this conclusion in humans [191; 214].

3.4 Action–outcome contingency knowledge, planning and value: the PFC and the amygdala

The PFC (specifically, prelimbic cortex) is required for rats to represent the contingencies between actions and their outcomes [215; 216]. Acquisition of instrumental responses on a simple schedule is disrupted by blocking NMDA and DA D1 receptors in the PFC [217]. This is relevant to evidence from cognitive neuroscience that sectors of the human PFC are important for volitional processes (see Section 8.1.3 and **Error! Reference source not found.**).

The PFC is also involved in extinction [218], the cessation of responding when a CS or response is no longer paired with reinforcement. Extinction is not 'unlearning' but involves the learning of new, inhibitory associations (see [219; 220]). Lesions of the ventral medial PFC interfere with the extinction of Pavlovian conditioned freezing in the rat [221–223]. The PFC interacts with the amygdala, an important site of CS–US association in this task (see [224; 225]), and may suppress conditioned freezing when it is no longer appropriate [218; 226–228].

The orbitofrontal cortex (OFC) is part of the PFC with a particular role in the assessment of reinforcer value. It has bidirectional connections to the amygdala and both are heavily implicated in the retrieval of the value of primary reinforcers based on information from CSs [44; 229–232]. In humans, the OFC and the amygdala are also activated during extinction of Pavlovian conditioning [233]. The amygdala regulates the DA signal to the Acb [44; 130; 174; 234; 235]. Goal-directed action requires that action–outcome contingencies interact with the incentive value of goals [35; 36] and the connection between the amygdala and the PFC [236] may provide this functional link [237–240].

3.5 Relevance to drug addiction

It has been suggested that these motivational and learning processes are particularly significant in some addictions, and that their modification may have therapeutic potential. The existence of dissociable parallel brain systems mediating associative control over addiction sits comfortably within the classic dichotomy of behaviour between Pavlovian [241] and instrumental learning [30]. A number of influential theories of addiction have postulated the existence of multiple parallel processes, each with its own independent, but interacting, neural system [80; 130–133].

DA systems are affected by virtually all of the major classes of drugs of abuse, ranging from the psychomotor stimulants to opioids, alcohol and nicotine, as well as by natural reinforcers such as food. Some abused drugs are particularly potent in this regard. Both food and drugs of abuse increase Acb DA, but the DA response to drugs of abuse may not habituate to the same extent as that to food [242; 243]. Sensitisation occurs following psychostimulant administration directly into the VTA, which induces hypersensitivity to DA in the Acb [244] and enhances the response to the Pavlovian CSs associated with reward [79; 245; 246]. In animal models of drug-seeking behaviour controlled by drug-associated stimuli [212], lesions of the AcbC or disruption of its glutamatergic neurotransmission reduce drug seeking [247; 248], probably by reducing the motivational impact of the CSs. DA D3 receptors are particularly concentrated in the Acb and amygdala [249], and D3 receptor antagonists [250; 251] and partial agonists [252; 253] reduce cue-controlled cocaine seeking or relapse to cocaine taking in animal models. Some manipulations that reduce drug seeking or the reinstatement of drug taking in animal models, such as DA D3 receptor antagonists, do not reduce food seeking in a similar manner [250; 251]. It is not yet clear to what extent sensitisation contributes to human addiction [254], but it has been suggested that a sensitised response to drug-

associated cues contributes to drug craving – that this 'incentive motivational' system becomes sensitised [75]. In present animal models, drug sensitisation enhances responding for food, or responding to CSs for food [79; 246; 255], but in human addiction, responding for non-drug reinforcement declines relative to that for drug reinforcement [256]. However, pre-treatment with psychomotor stimulants results in animals being willing to work harder for cocaine and this may reflect an effect of sensitisation on the motivation to seek drugs [257].

The well-known ability of psychomotor stimulants to potentiate conditioned reinforcement [258], depends on the integrity of the dopaminergic innervation of the Acb, especially the AcbSh [169]. This might be one possible basis for understanding why psychomotor stimulant drugs are themselves reinforcing. They enhance the reinforcing effects of environmental stimuli. The importance of conditioned reinforcers is that they allow the mediation and maintenance of long chains of behaviour, including drug-seeking behaviour, over delays to primary reinforcement.

Although potent as conditioned reinforcers when presented contingently, CSs paired with drug infusions do not increase drug seeking when presented non-contingently to animals [259–261]. Thus, conditioned reinforcement appears to be reliant on the contingency between the response and the CS [262]. The reliance of drug seeking and taking on drug-associated conditioned reinforcers is underscored by further findings that cocaine self-administration is lower in the absence of any contingent CS [263]. Indeed, nicotine self-administration in animals is difficult to acquire in the absence of conditioned reinforcers [264], suggesting that conditioned reinforcers may form part of a powerful stimulus complex, along with the drug, in maintaining drug use. Similarly, conditioned reinforcement maintained by CSs previously paired with oral alcohol can be persistent [265] and the ability to maintain responding is independent of the drug [266], suggesting that this type of drug seeking has a habitual quality. The impact of conditioned reinforcement on drug seeking is persistent and relatively impervious to extinction. It can maintain responding independently from the drug with which it was paired, suggesting that it may depend on a separate neural system from that which mediates the effects of the drug itself [265; 267].

In experimental models of addictive behaviour in which drug-associated conditioned reinforcers support and maintain prolonged bouts of seeking behaviour [212], the functional integrity of a neural system involving the BLA and AcbC is of major importance (see **Error! Reference source not found.**). Thus, lesions of the BLA or AcbC, but not the AcbSh, greatly impair the acquisition of cocaine-seeking behaviour [268; 269]. There is also neurochemical specificity in these BLA and Acb mechanisms. DA receptor blockade, but not AMPA receptor blockade in the BLA, reduces established cue-controlled cocaine seeking. The reverse is true in the AcbC, where AMPA, but not DA, receptor blockade has this effect [270]. It has additionally been established that disconnection of the BLA and AcbC by blocking DA receptors in the BLA on one side of the brain and AMPA receptors in the AcbC on the other has the same effect of dramatically reducing cocaine seeking [270]. These data provide the strongest evidence that the BLA and AcbC function serially as components of a neural system that mediates these conditioned influences on drug seeking (see **Error! Reference source not found.**).

In functional imaging studies of human drug addicts, the amygdala is consistently activated by exposure to cocaine-, heroin-, food- and sex-associated stimuli in a way that is correlated with drug craving (e.g. [239; 271]). Other regions commonly activated by drug-associated stimuli include the anterior cingulate cortex, the OFC and occasionally the Acb [271–274]. These data show that in both animals and humans, limbic cortical–ventral striatopallidal circuitry is associated with emotional learning and in processes related to drug craving, addiction and relapse.

3.6 Habits and the dorsal striatum

The development of S–R habits may depend on dorsal striatal plasticity [275], which may in turn depend on DA receptors [136; 185]. The balance between habits and goal-directed behaviour may also be regulated by the prelimbic and infralimbic cortex [276], subdivisions of the rat PFC. Recent functional neuroimaging data in humans supports the hypothesis that the ventral and dorsal striatum are also involved differentially in Pavlovian and instrumental learning [277].

Dorsal striatal DA release to CSs is a correlate of well-established cocaine-seeking [148]. By contrast, such DA release is not seen in the AcbC region [278]. Consistent with the electrophysiological data [145], DA release is only observed there when the CS is presented in a surprising context. Comprehensive studies of chronic cocaine self-administration in monkeys indicate a progressive involvement of limbic, association and sensorimotor striatal domains, with autoradiographic changes evident first in the ventral and then in the dorsal striatum [279; 280]. These data support the notion that there may be a stage of S–R or action–outcome learning that precedes S–R habit learning. These phases may be mediated respectively by the ventral and dorsal striatum, either successively, or more probably in a temporally overlapping manner, possibly via the recently characterised 'cascading' neural connectivity that links these different corticostriatal loops [281] (see **Error! Reference source not found.**). Thus, drug addiction is conceived in terms of a switch between these modes of learning, operating across the corticostriatal circuitry, from ventral striatal (i.e. Acb) to dorsal striatal domains.

4. NEUROBIOLOGY OF RELAPSE

A key feature of drug addiction is the high propensity to relapse, even after protracted periods of abstinence. The prevalent animal model of relapse utilises the so-called extinction–reinstatement procedure recently reviewed by Shaham and colleagues [282] in a double issue of *Psychopharmacology* (volume 168, issues 1–2) devoted to this subject. The usual form of this procedure is to train rats to press a lever to self-administer a drug and then to extinguish the instrumental act of lever pressing by omitting drug infusions. Following extinction, three manipulations generally accepted to be of importance in precipitating relapse in abstinent human drug addicts can 'reinstatement' drug-seeking responses by increasing lever pressing, although the drug remains unavailable. They are: exposure to drug-associated stimuli; experimenter-administered drug; or 'stress,' usually an electric shock to the feet.

However, extinction of the instrumental act of drug self-administration is not generally a means by which human addicts achieve abstinence. Abstinence is more likely to arise through an active decision to abstain or through abstinence imposed by the law or by treatment. Moreover, since the extinguished response is so readily reinstated, it is unlikely that extinction training will provide an effective clinical approach to treatment. Extinction of the acquired properties of drug-associated stimuli through their non-reinforced exposure has been attempted as a therapeutic strategy, but with limited success [283; 284], most likely because cue exposure in the clinic is unlikely to reduce the properties of drug cues in the original drug-associated environment.

Neurobiologically, these ways of inducing relapse in the extinction–reinstatement model depend on both common and discrete elements of limbic cortical–ventral striatopallidal circuitry. Most studies have involved the reinstatement of cocaine-seeking behaviour, but there are also studies with heroin and nicotine.

4.1 Drug-cue-induced reinstatement

The neural basis of cue-induced reinstatement has been reviewed extensively [282; 285]. It is prevented by reversible or permanent inactivation of the BLA and reversible inactivation of the dorsomedial PFC [285–287]. Inactivation of the OFC also attenuates cue-induced reinstatement of drug seeking [288]. Systemically injected D1 and D3 DA receptor antagonists block cued reinstatement [261; 289], as do intra-BLA, but not intra-Acb, infusions of D1 DA receptor antagonists [290]. This is consistent with the effects of D1 and D3 DA receptor antagonism in the BLA on cocaine seeking measured under a second-order schedule [270]. Perhaps surprisingly, inactivation of the Acb does not attenuate cue-induced reinstatement [285], yet this structure is important for conditioned reinforcement and other Pavlovian influences on instrumental behaviour, while AMPA receptor blockade attenuates cocaine seeking under a second-order schedule [248].

Although limbic cortical–ventral striatopallidal systems are implicated in the conditioned control of drug seeking and reinstatement after extinction, much remains to be established in terms of the processes occurring in cortical and subcortical structures and the ways in which different subsystems interact. While the BLA mediates reinstatement following exposure to discrete, cocaine-associated stimuli, the hippocampus may underlie the motivational impact of contextual stimuli (see Figure 2). Theta-burst stimulation of the hippocampus, a form of experimental deep brain stimulation, has been shown to reinstate extinguished cocaine seeking in a manner that depended on glutamate transmission in the VTA. It was suggested that this might mimic the process by which reinstatement occurs when animals are placed in a context associated with drug taking, rather than in response to discrete cocaine cues [291]. Indeed, dorsal hippocampal inactivation attenuates context-induced reinstatement of drug seeking, as does inactivation of the dorsal mPFC [292]. These data are in accord with the suggestion of a differential involvement of the amygdala in conditioning to discrete, and the hippocampal formation in conditioning to

contextual, stimuli [293; 294]. Moreover, electrophysiological and *in vivo* neurochemical studies have demonstrated that hippocampal, amygdala and PFC projections interact in the Acb in a way that is modulated by mesolimbic DA and that, in turn, can modulate the release of DA [295–299]. Thus, hippocampal, amygdala and PFC mechanisms may influence drug seeking through their convergent projections to the Acb, perhaps competing for access to response strategies subserved by different cortical–striato–pallido–thalamo–cortical re-entrant loops (see Figure 2). The mPFC is clearly important in reinstatement – whether induced by cues, contexts, drugs or stress – following extinction of the instrumental seeking response [292; 300]. Determining the psychological process that the mPFC subserves in these settings is an important goal.

The vigour of conditioned reinstatement of cocaine seeking increases with the duration of withdrawal [301], suggesting that neuroadaptations to chronic cocaine self-administration and withdrawal interact with the motivation to seek cocaine when cocaine cues are present in the environment. These findings may provide insight into the possible mechanisms that underlie the persistence or 'incubation' of cocaine seeking reported to occur over time in abstinent cocaine addicts. The mechanisms underlying this incubation effect have been shown to depend on the up-regulation of the extracellular signal-regulated kinase (ERK) signalling pathway specifically within the CeA [302]. Thus, exposure to cocaine-associated stimuli increased cocaine seeking and also ERK phosphorylation in the CeA, but not BLA, substantially more after 30 days than after one day of cocaine withdrawal, so the incubation effect was correlated with ERK up-regulation in the CeA. Inhibition of ERK phosphorylation in the CeA, but not BLA, after 30 days of withdrawal greatly decreased cocaine seeking, whereas stimulation of ERK phosphorylation in the CeA, but not BLA, increased cocaine seeking after one day of withdrawal. Thus, the mechanisms mediating drug-cue-induced relapse and its enhancement during protracted withdrawal appear to depend on two dissociable mechanisms in the BLA and CeA, respectively.

4.2 Drug-induced reinstatement

Drug-induced reinstatement by 'priming' (i.e. non-contingent or experimenter-administered cocaine or heroin – often given intraperitoneally and not intravenously) can be attenuated by D1-like dopamine receptor antagonists [303]. In neuroanatomical studies, it has been shown that drug-induced reinstatement can be blocked by inactivation of the VTA, dorsal mPFC, AcbC and ventral pallidum, called the 'motor subcircuit' by Kalivas and colleagues [285; 286; 300] (see Figure 2). Moreover, DA receptor antagonists infused into the mPFC or AcbSh also attenuate drug-induced reinstatement (see [282]). Antagonists at AMPA, but not NMDA, receptors in the Acb block reinstatement induced by systemic or intra-mPFC cocaine and, by contrast, AMPA receptor agonists infused into the Acb reinstate cocaine seeking [304; 305]. The effects of cocaine or heroin to reinstate extinguished responding are mimicked by systemic injections of D2, but not D1, receptor agonists [306] and by infusions of cocaine, amphetamine or DA itself directly into either the Acb or mPFC [300; 305; 307]. Antagonists at μ opiate receptors prevent the effects of heroin and alcohol, but not cocaine, on reinstatement [303; 308] and a cannabinoid CB1 receptor antagonist has also been shown to prevent the reinstatement effects of cocaine [309].

4.3 Stress-induced reinstatement

Reinstatement can be induced by several stressors, including footshock, food deprivation and also CNS administration of corticotrophin-releasing factor (CRF); see [282]. Inactivation of the dorsal mPFC prevents footshock-induced reinstatement. This area of the PFC is commonly involved in cued, drug and stress-induced reinstatement [310]. Additional and unique neural circuitry appears to be critical for the effects of stress, including the CeA, the bed nucleus of the stria terminalis (BNST) and the noradrenergic medullary tegmentum which innervates these structures [311–313]. Thus, the following manipulations all block stress-induced reinstatement: intra-BNST, but not intra-

amygdala, infusions of a CRF antagonist; systemic and intracerebroventricular, but not intra-locus coeruleus, injections of an alpha-2 noradrenergic receptor agonist; intra-BNST and intra-amygdala alpha-2 noradrenergic receptor antagonists; and destruction of the ventral noradrenergic bundle originating in the medullary noradrenergic cell groups (see [282] for review). The CRF-containing projections between the CeA and the BNST have also been shown to be a critical link between these structures in mediating stress-induced relapse [282]. Thus, two neural systems implicated in stress responses in general – one utilising NA and the other CRF – are implicated, along with the mPFC, in mediating relapse induced by footshock stress in the extinction–reinstatement procedure. The generally accepted mechanism is that stress activates the medullary noradrenergic neurons and leads to activation of the CRF system within the BNST and possibly the CeA (see [282; 285] for reviews). How this subcortical neuroendocrine mechanism interfaces with the mPFC is not altogether clear, nor is how this impinges on limbic cortical–ventral striatopallidal circuitry.

One of the reasons for developing and studying the neural basis of relapse in experimental animals is to develop treatments that will promote abstinence. Intensive experimental investigation of this area has yielded detailed information on the neural systems and neurochemical mechanisms underlying cue-, stress- and drug-induced relapse. An important issue for resolution is the extent to which the effects on the reinstatement of cues, drug or stress actually depend on the prior process of instrumental extinction. If they do, their utility in human addiction, where this extinction process does not occur, may be slight. D3 DA receptor antagonists appear to have efficacy in both the cued-reinstatement procedure and in ongoing cue-controlled cocaine seeking, suggesting that this dopaminergic target might affect the conditioned process common to both. In addition, the gamma-aminobutyric acid (GABA)-B receptor agonist baclofen both attenuates drug seeking that depends on drug-associated conditioned reinforcers in rats [261] and also attenuates cue-induced activation of limbic cortical areas in cocaine-addicted humans [314]. New pharmacological treatments to prevent relapse may emerge from this rich preclinical data on experimental models of reinstatement in animals.

5. NEUROADAPTATIONS – INTRACELLULAR CASCADES

The chronic administration of drugs of abuse results in the induction of intracellular cascades within the limbic corticostriatal circuitry. Although different drugs act at different receptor targets on the cell surface, there is a degree of convergence in their downstream signalling pathways. Interaction between the drug and its target results in either the opening of a ligand-gated channel, or the activation of a receptor-linked G-protein [315], both of which induce intracellular cascades. One common action of drugs is the activation of the transcription factor CREB and components of the cAMP signalling pathway, such as adenylyl cyclase (AC) and PKA [316–327]. CREB regulates the transcription of genes whose promoters contain the CRE element, and is thought to be a site of convergence of intracellular cascades as it can be activated through phosphorylation at serine 133 by several different protein kinases [328; 329]. Therefore alterations in CREB and the cAMP signalling pathway may represent common neuroadaptations of different drugs of abuse.

Opiates and cannabinoids acutely inhibit AC and the cAMP signalling pathway [319; 330; 331], resulting in a decrease in phosphorylated CREB [320]. In contrast, acute administration of ethanol and stimulants increases the activity of the cAMP signalling pathway [324; 332]. However, in all cases, there is a common chronic up-regulation of the cAMP signalling pathway that is accompanied by tolerance to the acute intracellular response to drugs of abuse [317; 320; 331; 333; 334]. The switch from acute inhibition to chronic up-regulation of the cAMP pathway with repeated opioid administration is poorly understood, though it is known to involve adaptations in G-protein properties resulting from their persistent stimulation [335], and neuroadaptive changes in protein kinase systems [336]. Furthermore, few downstream targets have been identified that mediate the functional effects of cAMP and CREB up-regulation. Among the proteins whose levels are increased by chronic drug administration in a CREB-dependent manner are AC, tyrosine hydroxylase (TH), the rate-limiting enzyme in DA synthesis, and the opioid peptide dynorphin [317; 318; 337–339]. Dynorphin stimulates κ -opioid receptors, resulting in an inhibition of DA release [340], and the effects of CREB up-regulation on drug reward are blocked by κ -opioid antagonists [317; 333]. Dynorphin mRNA levels are increased in the striatum of cocaine abusers *post-mortem* [341]. Therefore neuroadaptations in cAMP signalling, resulting in dynorphin up-regulation, may partially underlie tolerance to the effects of drugs of abuse.

Repeated intermittent administration of addictive drugs results in sensitisation of, rather than tolerance to, some of the behavioural and rewarding effects of drugs. The VTA is required for the initiation of behavioural sensitisation [342], and long-lasting adaptations in the Acb are correlated with the expression of sensitisation [343–345]. Transient increases of GluR1 subunits of the glutamate receptor in the VTA are important for the triggering of sensitisation [346]. The resultant persistent increase in calcium signalling and calcium/calmodulin-stimulated (CaM) kinase activation have also been implicated in behavioural sensitisation [347]. CaM kinase II stimulates the mitogen-activated protein (MAP) kinase signalling pathway [348], which is known to be involved in sensitisation [349]. Sensitisation may also be mediated by a chronic drug-induced down-regulation of the *Homer* gene family. Developmental genetic knockout of *Homer1* or *Homer2* in drug-naïve rats mimics the sensitised response to acute drug administration observed in rats experiencing withdrawal [350]. Specifically, *Homer* down-regulation is critically important in the Acb, as localised antisense-mediated knockdown of *Homer1* expression in the Acb similarly induces sensitisation [351], and virally-mediated rescue of *Homer2* in the Acb of *Homer2* knockout mice reverses the drug-sensitised phenotype [350].

One neuroadaptation that has attracted particular interest is the up-regulation of the chronic Fos-related antigen Δ FosB. Levels of Δ FosB are increased in the Acb for up to four weeks following drug administration [352–354], and Δ FosB is also progressively up-regulated with repeated drug administration [355]. This suggests that it is involved in behavioural sensitisation, a hypothesis that is strongly indicated by the demonstration

that Δ FosB overexpression in the Acb sensitises behavioural and rewarding responses to cocaine and morphine [356], whereas a reduction inhibits responses to cocaine [357] and *fosB* knockout mice do not develop behavioural sensitisation [358]. Therefore, Δ FosB may be a 'molecular switch' [359], that enables the sensitisation of responses to drugs of abuse and long-term adaptations underlying addiction that persist through withdrawal. Again, the current challenge is to identify downstream targets of Δ FosB signalling, one of which may be cyclin-dependent kinase 5 (cdk5) [360; 361].

On withdrawal from drugs, which may be precipitated experimentally by the administration of an antagonist, there is a further increase in the activity of the cAMP signalling pathway beyond the level observed during tolerance [319; 320]. This reflects a state of dependence on drugs of abuse whereby, when in withdrawal, the molecular cascades underlying reward are altered, resulting in an amotivational state [317; 333; 362–365]. Mice deficient in CREB display reduced opiate dependence [339; 366; 367] showing that cAMP signalling is important for both tolerance and dependence. A focus for current and future research is the characterisation of the downstream targets of CREB, such as dynorphin, that are required for the development of tolerance and dependence.

Neuroadaptations implicated in drug-induced reinstatement (Section 4) include the expression of AGS3 (activator of G protein signalling 3), the blockade of which prevents cocaine-induced relapse to cocaine seeking [368], and a lowering of extracellular glutamate through reduction of cystine–glutamate exchange, the restoration of which also prevents cocaine-primed relapse [369]. Drug-cue-induced reinstatement exhibits a time-dependent increase through withdrawal, with cue-induced cocaine-, methamphetamine-, heroin- and sucrose-seeking behaviours incubating over time [301; 370–372]. Molecular changes that correlate with this incubation effect may be important for cue-induced relapse to drug seeking. With short periods of withdrawal, transient increases are observed in tyrosine hydroxylase activity and cdk5 protein levels in the VTA [373; 374], and more persistent increases in PKA activity occur in the Acb [325; 373; 374]. However, the closest correlate of incubation appears to be the progressive up-regulation of brain-derived neurotrophic factor (BDNF) protein in the VTA [375; 376]. BDNF appears to be involved in the persistence of the incubation effect rather than being critical for incubation itself, evidenced by the demonstration that intra-VTA infusion of BDNF protein increases cocaine seeking over and above the incubation-related elevation [377].

BDNF has a well-established role in hippocampal LTP and learning and memory [378–380]. Therefore there is a similarity between the molecular mechanisms of drug addiction and learning and memory that also applies to the other intracellular cascades described, particularly the involvement of CREB [381]. Furthermore, drugs of abuse induce changes in the VTA and Acb that are reminiscent of the influential cellular models of learning and memory LTP and long-term depression (LTD) [12]. One important issue that concerns research into both drug addiction and learning and memory is the longevity of both processes. All the molecular neuroadaptations described thus far are impermanent, and though some are indeed long-lasting, none can account for the compulsion and relapse that are observed months or even years after withdrawal. It is increasingly thought that morphological changes in synaptic structure are the only process by which the plasticity underlying both drug addiction and learning and memory can become near-permanent [362]. BDNF is necessary for the neuronal growth and synaptic remodelling associated with learning and memory [379; 380; 382; 383], and its putative role in incubation, as well as sensitisation [349; 384], suggests that morphological plasticity may be critically involved in drug addiction.

Many genes have been implicated in synaptic plasticity [355; 385–387], and recently the involvement of cdk5 in addiction-related permanent plasticity has attracted great attention. Cdk5 is regulated by Δ FosB [360; 361], providing a link between the longest-lasting molecular adaptation and permanent plasticity [388], while cdk5 mediates the proliferation of striatal dendritic spines in response to the chronic administration of cocaine

[360; 389]. Such structural changes are likely to involve neurofilaments, which are elements of the cytoskeletal architecture of neurons [390; 391]. There is evidence for hyperphosphorylation of neurofilament proteins both in rodents and in human opiate addicts *post-mortem* [392–394]. The mechanisms underlying neuroadaptations in synaptic morphology will be a focus of future research into the long-lasting plasticity mediating drug addiction.

Synaptic morphology can also be altered by the production of new neurons. Called neurogenesis, this process is increasingly believed to play a role in drug-induced neuroadaptation. The few studies that have been conducted suggest that chronic exposure to drugs of abuse decreases neurogenesis in the hippocampus [395–399]. A parallel is found in studies of depression, in which decreased hippocampal neurogenesis is observed [11; 400; 401]. In contrast, learning and memory are associated with an increase in hippocampal neurogenesis [402; 403], and one action of antidepressant drugs is to increase hippocampal neurogenesis and neuronal growth [401; 404; 405]. This may suggest a potential avenue for the treatment of addiction. Some antidepressants may work partly by increasing neurogenesis. Antidepressants are sometimes, but not always, effective medications for drug dependence [406; 407].

Though further delineation of the molecular pathways involved in drug addiction will be a focus of future research, an important challenge will be to integrate the resulting information as the same molecular candidates are implicated in several aspects of drug addiction. BDNF is associated with incubation, relapse, sensitisation and permanent plasticity. Furthermore, neuroadaptations occur throughout the limbic corticostriatal circuitry. Although molecular changes have been localised to particular brain areas, their relevance to behaviour is only beginning to be determined in a spatially localised manner. Array technology has recently been used both *in vitro* and *in vivo* to produce large sets of information on the up-regulation of genes following the administration of drugs of abuse [408–412], but it will be several years before it can be established whether such neuroadaptations are merely correlative, or critical for the development of addiction.

The similarity between the molecular processes implicated in drug addiction and those firmly established in learning and memory will guide future research. One exciting prospect is the possible manipulation of drug-associated memories long after they have been acquired. Studies of fear conditioning have demonstrated that previously learned memories for stimulus-aversive outcome associations can be disrupted in a retrieval-dependent manner, so that they are not expressed subsequently in retrieval tests [413]. This impairment of the reconsolidation of memories has also been observed in several other learning and memory paradigms [414–418], including a study of appetitive incentive learning [419], and also in humans [420], and may be extended to drug addiction. Drug-associated environmental stimuli elicit strong craving and increase the chance of relapse in abstinent individuals. The potential to reduce the impact of these cues through disrupting the reconsolidation of their association with addictive drugs may be a future avenue of research. Stimulus-addictive drug associations are supported by the same neuroanatomical substrates as both appetitive and aversive associations [235; 421], further underlining the similarity between addiction and learning, and the up-regulation of *Zif268* in the amygdala is strongly correlated with the reconsolidation of both stimulus-drug and stimulus-footshock associations [422; 423], providing a prospective target for functional studies. *Zif268* has recently been shown to be a specific marker of the reconsolidation of hippocampal-dependent contextual fear memories [424]. Moreover, it appears that the molecular mechanisms of consolidation and reconsolidation are doubly dissociable, at least in the hippocampus [424] (Figure 3). It may be possible to target the reconsolidation of previously-learned maladaptive memories that are important in drug addiction [425].

'one-trial contextual fear learning'




Figure 3 Memory consolidation and reconsolidation processes: neural and molecular basis

The consolidation and reconsolidation of contextual fear memories are mediated by independent cellular processes. Rats are fear conditioned to a novel context (**A**), and infused into the dorsal hippocampus with antisense oligodeoxynucleotides (ODN) 90 minutes before conditioning or memory reactivation (**B**). Subsequently, tests for long-term memory show that BDNF is required specifically for consolidation (**C**), whereas *Zif268* is necessary only for reconsolidation (**D**). Based on data reported in [424].

6. VULNERABILITY TO ADDICTION

A significant proportion of the population take drugs of abuse at least once in their lifetime. Many individuals are capable of maintaining prolonged recreational use. Only a few develop a true addiction [426]. In the past few decades, the identification of the factors that determine these individual differences in propensity for addiction has become one of the major targets of drug-abuse research. Emerging data from both clinical and animal experiments suggest that there exist 'vulnerable' phenotypes and genotypes that are more predisposed to drug abuse [427]. Elucidating the nature of these vulnerabilities could help prevent addiction in the predisposed population.

6.1 Individual differences in humans

Enormous differences in the subjective and reinforcing effects of drugs in humans are well-documented [56; 428; 429]. Individuals who prefer the effects of amphetamine to placebo show increased ratings of euphoria and positive mood, compared to anxiety and depression in subjects who choose placebo over amphetamine [56]. Recent advances in imaging technology have yielded exciting information about the neural correlates of these subjective differences. In one recent report, the intensity of the high induced by methylphenidate was significantly correlated with levels of released DA. Subjects who had the greatest increase perceived the most intense high [430]. Further, the magnitude of decrease in D2 receptor availability is significantly associated with the positive reinforcing effects of the psychomotor stimulant methylphenidate [430] (Figure 1), and release of DA in response to *d*-amphetamine correlates with self-reports of 'drug wanting' and the personality trait of novelty seeking [431]. In support of these findings, rhesus monkeys with extensive cocaine self-administration history show significant decreases in D2 receptor densities throughout the striatum compared to monkeys with a history of food reinforcement [279] (**Error! Reference source not found.**). These data suggest that pre-existing differences between subjects in the rate of DA release and/or D2 receptor distribution may play a role in the predisposition to drug abuse. The cause and exact nature of these functional differences is not known.

6.2 Animal models in the study of individual differences

Individual differences in conditioned and unconditioned responses to drugs of abuse have been reliably demonstrated in animals [432]. In particular, the propensity to acquire intravenous self-administration (IVSA) in rats can be predicted by the behavioural reactivity of an individual rat to a stressful situation, such as exposure to a novel environment (e.g. [433–435]). In this model, the propensity to develop self-administration can be represented by dividing animals into subgroups based on their locomotor response to a novel environment. Animals with an activity score above the mean for the entire group, so-called 'high responders' (HRs), show enhanced acquisition of psychostimulant IVSA [433–436] compared to animals with an activity score below the median of the group, the 'low responders' (LRs).

Further studies show that individual differences in drug intake originate from vertical shifts in the dose–response curve for intravenous cocaine self-administration, and these vertical shifts can be predicted by reactivity to novelty [427]. Comparing HR to LR groups also shows differences in drug-mediated behaviours, such as increased locomotor response to systemic administration of cocaine, amphetamine, and morphine [437–440], enhanced psychostimulant-induced behavioural sensitisation [441–443], and stronger contextual conditioning to drugs [443].

Behavioural differences between HRs and LRs appear to be mediated by differences in dopaminergic neuronal structure and function. For example, HRs show increased cocaine- [441], amphetamine- [444], and stress- [445] induced DA levels in the Acb, as well as a

higher 3,4-dihydroxyphenylacetic acid (DOPAC)/DA ratio in this region [446]. Data from electrophysiological studies demonstrate higher basal firing rates and bursting activity of DA neurons in the ventral tegmental area and, to a lesser extent, the SNc in HRs [443]. Structurally, HRs have increased dopamine transporter (DAT) numbers [441] and greater B_{max} for D1 binding sites [447] in the Acb. Regulatory mechanisms of the mesolimbic DA system also differ between HRs and LR rats. Recent data indicate that HRs express lower levels of tyrosine hydroxylase levels and cholecystokinin-mRNA, part of the intrinsic inhibitory input to dopaminergic VTA neurons, but higher levels of preproenkephalin-mRNA, part of the extrinsic facilitating input to these neurons [448].

These behavioural and neurochemical differences are accompanied by differences in activity of the hypothalamic–pituitary–adrenal axis (HPA), the system primarily activated under stressful situations. Animals designated as HR have higher novelty-induced corticosterone secretion compared to LR rats [446], and self-administration of amphetamine is positively correlated with corticosterone levels after two hours of exposure to stress [446]. The work of Piazza and his colleagues suggests that individual differences in vulnerability to addiction can be modelled in animals, and that these differences are related to altered structure and function of the DAergic and HPA systems. Nonetheless, the developmental cause of these behavioural and neural differences is not known.

6.3 Environmental influences on the developing brain

Environmental experience may contribute to individual differences in vulnerability to drug addiction. Early adverse experience, such as childhood sexual or physical abuse, is one of the most important biological and environmental factors that are associated with vulnerability to substance abuse [449]. The prevailing view is that these stressors influence the development of neural systems that underlie the expression of behavioural and endocrine responses to stress and reward. Although clinical data confirm a relationship between early adverse experience and substance abuse, it is not known whether this relationship is direct or indirect. Recent developments using animal models of early adverse environmental experience have been important in elucidating the causal nature of this relationship.

6.4 Effects of disrupted maternal care

One animal model of early adverse experience takes the form of disrupted maternal care, whereby infant rats experience repeated episodes of prolonged maternal separation (MS) during the first two weeks after birth. This consistently gives rise to profound behavioural, neural and endocrine differences in adult animals. It leads to increased behavioural reactivity in response to stressors [450–452], and these behaviours are accompanied by altered structure and function of neural regions involved in HPA activation [453–456].

Recent work using these models has attempted to form a causal relationship between disrupted maternal care, reactivity to stressors, and individual differences in susceptibility to drug self-administration [457]. The data suggest that such separation leads to alterations in reward-related behaviours, such as a blunted response to both negative and positive contrast effects [458], attenuated locomotor activity to both a novel environment and *d*-amphetamine [459], and, in maternally separated females, blunted acquisition of a conditioned anticipatory locomotor response to food [460]. MS rats also show altered acquisition and maintenance of cocaine self-administration when tested as adults, with dose- and gender-dependent effects [460], and other studies report enhanced acquisition of cocaine self-administration [461]. These behaviours are accompanied by structural differences in the mesolimbic DA system [462]. One recent finding demonstrates that maternal separation leads to an enhancement of both stress-induced sensitisation to amphetamine and acute Acb DA release following stress and cocaine [463]. This study

also reported increased levels of D3 receptor mRNA in the AcbSh, but not AcbC, of MS rats.

These findings dovetail nicely with data from a non-human primate model of disrupted maternal care. When infant rhesus macaques are peer-reared (PR), rather than mother-reared, they exhibit a constellation of neurobehavioural dysfunctions at adulthood, such as reduced exploration and increased fear-related behaviours [464], as well as marked increases in HPA activity following stressful situations [465]. PR rhesus macaques consume more alcohol than mother-reared subjects, but interestingly, acute stress in the form of social separation increases alcohol consumption in mother-reared animals to the level of their PR counterparts [466]. Excessive alcohol consumption in PR animals also correlates positively with plasma cortisol levels [466] and negatively with cerebrospinal fluid 5-hydroxyindoleacetic acid (CSF 5-HIAA) concentrations in infancy and adulthood [467]. An interesting recent finding is that a functional variant of the rhesus serotonin transporter-linked polymorphism (rh5-HTTLPR) interacts with rearing condition and gender to influence adrenocorticotrophic hormone (ACTH) response to stress [468], suggesting differential sensitivity to stress dependent on a gene-environment interaction.

6.5 Effects of social isolation

Converging evidence suggests that early adverse social experience, like maternal separation, may influence susceptibility to the effects of drugs. Like maternal separation, isolation rearing of infant rats (housed singly in small, opaque cages) leads to disruptions in a variety of reward-related behaviours when these animals are tested as adults. Isolation-reared rats show enhanced stereotypy to *d*-amphetamine and apomorphine [469; 470], are more sensitive to the effects of negative and positive contrast in sucrose intake tests [471], and show increased locomotor activity following administration of psychostimulants [472; 473]. It is also noteworthy that these animals show sustained hyperactivity in a novel environment [462], a finding that converges with data from the maternal separation and HR/LR models. Isolation rearing also increases self-administration of a variety of abused drugs [471; 474-479], depending on dose, being more sensitive to low doses [480-484].

Isolation rearing also alters the structure and function of regions involved in drug reinforcement. It leads to a reduced DOPAC/DA turnover in the frontal cortex, but a larger turnover in the Acb and striatum [485-487]. Isolation rearing also leads to decreased opiate receptor binding in the frontal cortex, hippocampus, periaqueductal grey, and striatum [488; 489], down-regulation of 5-HT in the hippocampus [483; 486; 487; 490-495], and up-regulation in catecholamine systems in the Acb [483; 487; 496-501].

6.6 Protective effects of enriched environment

There is some suggestion that the behavioural and neural deficits observed following social-isolation rearing or maternal separation may be reversed or altered by some period of enrichment rearing in which the animal is housed in a large, socially and environmentally complex environment. In one recent study, C57BL/6 mice, an inbred strain considered 'addiction-prone' (see below), were more resistant to both cocaine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) following enrichment rearing, and showed different patterns of *c-fos* expression in the striatum compared with mice raised in standard conditions. Further, after MPTP treatment, enriched mice showed less DA loss, less DAT binding, and increased BDNF expression in the striatum [502]. In another instance, environmental enrichment during the peripubertal period completely reversed the effects of maternal separation on both HPA and behavioural responses to stress, with no effect on CRF mRNA expression [503].

6.7 Effects of early drug exposure

Another important question is whether early exposure to drugs of abuse can influence individual differences in propensity to drug addiction. It is well established that prenatal exposure to cocaine, heroin, marijuana, nicotine or alcohol can have profound effects on cognitive and motor function in adolescence and adulthood [504–509], and there is some suggestion that this exposure influences propensity to addiction [506; 507; 510; 511]. However, longitudinal or retrospective clinical studies are often problematic due to the high incidence of confounding variables. Thus, animal models are important in elucidating the individual contribution of early drug exposure to adult vulnerability to addiction.

Data using animal models suggest that prenatal drug exposure has a profound effect on behaviour and neurochemistry when these animals are tested as adults, and that these changes may predispose to addiction. Converging evidence using a variety of techniques suggests that prenatal exposure to alcohol [512–514], nicotine [515–517], opioids [518; 519], or cocaine [520–525] produces persistent cognitive and neural deficits in adults. In particular, these data suggest that prenatal exposure to drugs of abuse leads to down-regulation and tolerance in neural systems involved in drug reward.

Although these changes may indirectly influence propensity to addiction, only a few studies have addressed the question of whether prenatal exposure to drugs of abuse affects later drug self-administration. Prenatal cocaine exposure in rodents increases IVSA for moderate doses of cocaine [526; 527], but the rate of cocaine intake does not differ between cocaine and saline-exposed animals [527]. This result suggests that prenatal exposure to cocaine does not alter the reinforcing value of cocaine, a finding that is consistent with a study examining addiction-prone versus addiction-resistant rat strains [528]. Another important question is whether prenatal exposure to drugs of abuse facilitates the development of drug dependence in general. In one study, prenatal exposure to morphine enhanced rates of heroin and of cocaine self-administration [529].

Adolescence is another period during which the brain undergoes many complex changes that can have a prolonged impact on decision-making and cognitive processes [530; 531]. In addition, adolescents are more likely to experiment with illicit drugs, which may be due in whole or in part to the increase in sensation and novelty seeking that is characteristic of adolescence [532]. Recent clinical data suggest that adolescent exposure to drugs of abuse is associated with increased risk of addiction in adulthood [533; 534]. Not unlike the data from prenatal exposure papers, studies using animal models suggest that rodents with adolescent exposure to drugs such as methylphenidate [535; 536], nicotine [516; 537–539], cannabinoids [540], MDMA (ecstasy) [535; 541], and alcohol [542; 543] also show behavioural and neural changes indicative of tolerance to these and other drugs, which persist into adulthood. Substance-exposed adolescent animals tested as adults show a behavioural and neural profile that is different from that seen in adult animals administered a similar drug regime (e.g. [539; 540]). This suggests differential long-term neuroadaptive responses to drugs, possibly related to immature or still-developing plasticity mechanisms in the PFC. One potential confound for these studies is that the majority of them look at effects of non-contingent drug administration during the periadolescent period on later adult behaviour and neurochemistry. Future studies should aim at exploring how self-administration drug experience during adolescence influences drug-mediated behaviours and neural changes when tested in adulthood.

6.8 Genetic factors involved in vulnerability to addiction

Individual differences in genetic make-up critically influence susceptibility to addiction. Although some aspects of vulnerability may be unique to specific substances, most known genetic influences are common to all drugs of abuse. Recent estimates suggest that genetic components explain 40–60% of overall vulnerability to addiction [544–546]. These data do not support single-gene models for the inheritance of addiction vulnerability. Contributions from allelic variations in several genes are likely to be

involved. Genetic components do not necessarily impact on the initiation of drug use, but instead influence progression from regular use to dependence [544; 546]. Recent data are yielding information on which chromosomal regions, genes, haplotypes and allelic variants provide exactly what genetic influence on vulnerability to drug abuse.

Although there are numerous candidate genes influencing addiction and addictive behaviours, human studies have generally focused on identifying genes associated with dopaminergic function. A number of studies report a significant association between substance dependence and polymorphisms of dopaminergic receptor genes (DRD1, DRD2, DRD3, DRD4). Subjects with a history of drug use show increased frequency of homozygosity for the restriction polymorphism Dde 1 of the DRD2 gene [547], and several studies have demonstrated a link between the presence of the A1 allele of the DRD2 Taq 1 polymorphism and drug dependence [548–550]. Polymorphisms of the DRD3 gene have recently been identified in 96 rat strains and substrains [551], although there is good evidence that this gene does not play a major role in the genetic vulnerability to alcoholism [552; 553]. Novelty seeking, a personality trait often observed in addicts, is significantly associated with the 7-repeat allele of the DRD4 exonic polymorphism [554].

Individual differences in genetic polymorphisms have functional outcomes. Individuals homozygous or heterozygous for the 7- (or longer) repeat allele (DRD4 L) report significantly higher craving after consumption of alcohol compared to individuals classified as DRD4 S [555]. Further, although olanzapine reduces craving for alcohol in both DRD4 S and DRD4 L individuals, it only reduces cue- and alcohol-priming-induced craving in DRD4 L individuals [556].

6.9 Animal models used in the study of genetic neurovulnerability to addiction

The role of genetic factors in contributing to drug-related behaviours can be examined using inbred rodent strains, which, in contrast to outbred strains, provide a stable genotype. Two inbred rat strains that differ in responses to drugs of abuse are Lewis (LEW) and Fischer 344 (F344) rats. In comparison to F344 rats, LEW rats show greater behavioural responses to several drugs, including oral self-administration [557–559], intravenous acquisition of self-administration of morphine [560] and cocaine [561], place conditioning [562; 563], and locomotor sensitisation [563; 564].

These strains also differ in the properties of their mesolimbic DA systems. LEW rats have lower basal extracellular DA metabolite levels in the Acb [564; 565] and lower numbers of spontaneously active DA neurons in the VTA [566]. They also show a more prolonged elevation of DA levels in the ventral striatum following acute cocaine administration [564; 565]. At a biochemical level, LEW rats express higher levels of tyrosine hydroxylase in the VTA, but lower levels in the Acb, than F344 rats [567]. Finally, strain differences are also observed in HPA function. Although F344 have higher basal and stress-induced levels of glucocorticoids, LEW rats show a more prolonged elevation of corticosterone following exposure to a stressor [568].

Differences in susceptibility to the reinforcing properties of cocaine, amphetamine, morphine and ethanol have been described among inbred strains of mice [569–572]. A number of studies have demonstrated that mice belonging to the inbred strains C57BL/6 (C57) and DBA/2 (DBA) differ in their behavioural and neural responses to drugs of abuse [570; 573–578]. The data suggest that the C57 genotype can be characterised as 'drug-preferring' and the DBA genotype as 'drug-resistant'. Sensitivity to the unconditioned locomotor effects of amphetamine [569] and level of locomotor activity in a novel environment [576] are both susceptible to the influence of environmental manipulations such as food restriction when measured in these strains. These data provide information on genetic–experience interactions, and suggest a possible homology between these phenotypes and psychostimulant-induced place preference [576].

6.10 Influence of gender on vulnerability

Epidemiological data suggest a greater prevalence of substance-use disorders among men, but recent surveys show increased rates of substance dependence in women [579; 580]. These reports are supported by recent evidence that drug-dependent women are more vulnerable to the deleterious effects of drugs and show a faster progression to drug dependence. Women have a more pronounced subjective response to psychostimulants [581–583], become more rapidly addicted to cocaine, heroin and alcohol [584–587], and experience greater perceived severity of withdrawal from addictive substances such as nicotine [588]. Additionally, despite often having a shorter experience with drugs of abuse than men, substance-dependent women show either a comparable or increased severity of addiction [589; 590], as well as a faster progression to treatment entry [591].

Analogous differences are observed in experimental animals. Female rats show enhanced acquisition, but not necessarily maintenance, of drug-taking behaviour [592–595], and increased vulnerability to relapse [596; 597]. Although there are consistent sex differences during the acquisition phase of stimulant self-administration, the data are more equivocal with other abused drugs [598]. The discrepancies may be due in part to dose differences. Sex differences are more apparent when low doses are used [587; 594; 599]. In maternal separation, peer-reared and social-isolation models of early adverse environmental experience, female rodents show different behavioural and neural effects [452; 600; 601].

The nature of sex differences in vulnerability to drug abuse is not known. Although it is probable that psychosocial factors have an impact, converging evidence from animal studies suggest that fluctuating ovarian hormones have an important role in these differences. There is little experimental work done in this domain in humans, apart from the finding that the subjective response to amphetamines is increased during the follicular phase of the menstrual cycle [602; 603]. In rats, cocaine self-administration varies across the oestrous cycle [604], and high doses of oestradiol facilitate cocaine self-administration [605]. Moreover, the enhanced acquisition of cocaine self-administration in female rats is abolished in ovariectomised animals, but can be reversed with administration of oestradiol [606]. These data suggest that oestrogens facilitate dopaminergic function [607–609].

7. HARMS CAUSED BY DRUGS OF ABUSE

It is almost axiomatic that a suitably high dose of a psychoactive substance, administered either acutely or chronically, is likely to have deleterious effects. These can be transient or long-lasting, and impact on one or more of the body systems, including the brain itself. When the effects involve brain regions implicated in volition and executive control, such as the PFC, such damage may exacerbate the drive to abuse and addiction, and may retard attempts at rehabilitation.

Types of drugs vary in their toxicity. This issue is crucial to the regulation of drug use, but the definition of adverse drug effects is difficult and controversial. It is sometimes problematic to infer the causal effects of psychoactive substances in polydrug abusers and to distinguish them from possible premorbid factors present in the user prior to drug use. Studies in experimental animals which control the exposure to specific doses of particular drugs [610; 611] avoid many of these difficulties, but may be compromised by the difficulty of comparing drug doses between species and selecting for investigation the doses most relevant to human drug users. Moreover, when the studies are limited to the influence of sensitising regimens of drug administration on fine details of neuronal organisation, such as dendritic branching in different regions of the rat PFC, the effects are sometimes apparently inconsistent with toxic effects, reflecting instead possible effects on neuronal plasticity. Thus, repeated treatment with psychostimulant drugs produces long-lasting increases in dendritic branching and spine intensity in some brain regions [612]. However, it has also been reported that such effects subsequently limit the promotion of synaptic plasticity bestowed by housing in enriched environments [613]. Functional imaging studies of human abusers may likewise reveal abnormal patterns of brain activation (see Section 8.1.2), but in the absence of evidence of cognitive impairment in neuropsychological tests, the significance of these may be unclear.

Notwithstanding these difficulties, much is now known about the toxic sequelae of chronic drug use, whether on the brain itself or on behaviour and cognition, based on the evidence of *post-mortem* neuropathology, neuroimaging and neuropsychology [614] (see also Section 8). Thus, among stimulant drugs, high doses of methamphetamine can produce long-term neurochemical and structural changes, including neurotoxic effects on DA- and 5-HT-containing neurons in several animal species [615; 616]. It also reduces markers of DA and 5-HT function in the human brain, *post mortem* studies indicating a reduction in the striatal DAT and reductions in 5-HT markers within the OFC [617]. This evidence is complemented by recent evidence of changes in striatal markers following chronic cocaine self-administration in monkeys (**Error! Reference source not found.**) [279; 280]. However, an abiding question is whether such changes are permanent and whether they generalise to drugs of the same class, such as *d*-amphetamine and cocaine. It appears that chronic exposure to these agents can be associated with loss of grey matter in the PFC, impaired signs of brain activation in functional imaging, and impairment in certain aspects of cognition, including memory and executive function [125]. Similarly, the balance of evidence indicates some toxic effects of MDMA on 5-HT neurons based on studies using different techniques on rats, monkeys and humans [618; 619]. It may be significant that, in monkeys self-administering (generally lower) doses of MDMA, such toxic effects are much weaker [620]. However, the possible functional significance of these effects is elusive because of considerable heterogeneity of the chronic drug-abusing population. Recent findings indicate that a genetic polymorphism of the 5-HT transporter is associated with pathological scores on a clinical rating scale of depression in a group of chronic MDMA users [621]. MDMA abuse is also associated with a pattern of cognitive impairment, which, however, is subject to the caveats noted above [614].




Figure 4 Progressive changes in striatal dopamine receptors during chronic drug self-administration

Representative colour-coded autoradiograms depicting specific D1 binding using [³H]SCH-23390 at the level of the posterior ventral precommissural striatum of a control rhesus monkey (A) and from a representative monkey in the chronic 0.03 mg/kg cocaine per injection (B) and 0.3 mg/kg cocaine per injection (C) groups. The autoradiogram is scaled in fmol/mg wet-weight tissue. (From [279].)

Reprinted, with permission, from *Neuropsychopharmacology* 27: 35–46 (<http://www.nature.com/npp/index.html>). Copyright (2002) Macmillan Publishers Ltd.

There is little doubt about the potential devastating effects of chronic alcohol abuse on brain function. Alcohol dementia is a clearly defined syndrome associated with structural brain changes [622; 623]. Among the main actions of alcohol are the enhancement of GABA-ergic transmission in combination with a reduction of glutamatergic (including NMDA receptor) function [2], which are likely to promote sedation and impair learning and memory in regions such as the hippocampus. There is also conclusive evidence of foetal alcohol syndrome (FAS) produced by heavy drinking in pregnancy that leads to a pattern of physical malformations and mental retardation. Indeed, with a prevalence rate of about 0.2% in all live births (6% of alcoholic mothers) reported in the US [624], FAS is one of the leading causes of mental retardation. Recent experimental evidence suggests that exposure to alcohol in developing rats led to severe reductions of glutamate receptors of the AMPA subtype in the neocortex [625] (see also Section 6.7). These adverse actions on the brain and intellect, as well as the social burden of domestic violence arising from the heightened aggression produced by abuse, and overall greater morbidity and mortality, place alcohol among the most behaviourally toxic of all psychoactive substances. However, not all alcohol consumption has adverse effects. There is consistent evidence of significant beneficial health effects of drinking alcohol (and associated substances such as the polyphenols of red wine) in small amounts, which reduces the incidence of strokes and dementia [626].

By contrast with alcohol, the evidence for deleterious cognitive effects of cannabis intoxication is controversial. Any significant effects may depend on chronic use over many years in that small subpopulation of users who become addicted [614]. However, accumulating evidence suggests that cannabis can act as a triggering factor for schizophrenia [627].

8. DRUG ADDICTION: A SOCIAL COGNITIVE NEUROSCIENCE PERSPECTIVE

Until recently, the gap between social cognition and molecular and cellular neuroscience has seemed unbridgeable, given the complexities of linking social constructs such as theory of mind with simple causal neural networks [628]. However, the emergence of cognitive neuropsychology in the 1970s illustrated the potential of a productive synthesis between cognitive psychology and clinical neuroscience in addressing common questions of how the mind/brain works. Cognitive neuroscience will continue to prove important in evaluating the cognitive effects of drugs and the intellectual sequelae of chronic drug use. A similar initiative in 'social cognitive neuroscience' (SCN), embracing developments in 'affective neuroscience' and 'neuroeconomics' promises to be of considerable importance for understanding the nature of addiction in its social context.

SCN is a systematic and theoretically driven approach designed to aid understanding of social and emotional phenomena in terms of the interaction between motivations and social factors that influence behaviour; information-processing mechanisms that underlie social-level phenomena; and the brain mechanisms that instantiate cognitive-level processes [628–631]. The concern with neural substrates underlying normal social cognitive mechanisms links social neuroscience to the basic neurosciences and has been facilitated by the increasing availability of methodologies for investigating neural function in non-brain-damaged adults. SCN bridges the gap between social cognition and neuroscience by exploring how the brain influences social processes as well as how social processes influence the brain [632]. Of particular interest is the issue of whether the processes that give rise to social cognition are a subset of more general cognitive operations, or whether instead there are unique processes governing social cognition [628; 629].

Although still in its infancy, the SCN approach has already been successfully applied to a broad range of topics in the social sciences [628] and neuropsychiatric conditions which potentially include addiction [633]. It is proving possible to elucidate the neural and cognitive mechanisms underlying more complex social constructs such as volition [634]; attribution theory [628; 635; 636]; self-regulation [637]; cognitive reappraisal [638]; attitudes [636]; mental representation of self [639; 640]; reward [641]; beliefs [642]; emotions [643; 644], deception [645]; empathy [646]; theory of mind [647]; cognitive control [648]; intuition [649]; moral emotions [650]; and complex social and economic judgements such as decision making [651; 652].

8.1 *Addiction as a disorder of social cognition*

Viewed as a complex brain disorder, it is possible to consider the main behavioural characteristics of drug addiction in terms of at least four impairments of social cognition.

8.1.1 Impairment in the processing and representation of saliency or rewards. Many modern theories of drug use and dependence assign central prominence to the role of compulsive craving in drug use and relapse. Until recently it was believed that addiction was predominantly driven by reward processes mediated by limbic circuits [653]. However, results from recent neuroimaging studies implicate a highly interconnected network of brain areas including orbital and mPFC, amygdala, striatum and dopaminergic mid-brain in reward processing (see Sections 3 and 4). Distinct reward-related functions can be attributed to different components of this network. The OFC is involved in coding stimulus reward value and in concert with the amygdala and ventral striatum is implicated in representing predicted future reward. These frontal areas are frequently activated in addicted subjects during intoxication, craving and bingeing, but deactivated during withdrawal [654; 655]. The same regions are also involved in higher-order cognitive and motivational functions, such as the ability to track, update and modulate the salience of a reinforcer as a function of context and expectation and the ability to control and

inhibit prepotent responses. Cognitive theories have been influential by embedding craving within a network based on social learning theory [656; 657]. According to Goldstein and Volkow [658], these results imply that addiction involves brain areas associated with several cortically regulated cognitive and emotional processes including 'the overvaluing of drug reinforcers, the undervaluing of alternative reinforcers, and deficits in inhibitory control for drug responses'.

8.1.2 Impairment of social reasoning and decision making. The PFC has been implicated in guiding social cognition (decision making and inhibitory control) by eliciting emotional states that serve to bias cognition, a role that is further supported by investigations of normal decision making and social reasoning studies [628]. The effects of damage to medial and orbital PFC are consistent with a role for these regions in guiding the strategic adoption of someone else's point of view [647] and impaired performance in reasoning about social exchange [659]. Compromised decision making could contribute to the development of addiction and undermine attempts at abstinence. The behaviour of those addicted to drugs could be viewed as demonstrating faulty decision making, given their inability to discontinue self-destructive drug-seeking behaviours. A go/no-go response-inhibition task in which working memory demands are varied [660; 661] demonstrates that the compromised abilities of cocaine users to exert control over strong prepotent urges are associated with reduced activity in both anterior cingulate and right prefrontal cortices. The results suggest a neuroanatomical basis for this dysexecutive component in addiction, supporting the importance of cognitive functions in prolonging abuse or predisposing users towards relapse. Abnormalities in the PFC are found consistently in most drug-addicted subjects by using imaging studies [658; 662; 663]. Thus, one might expect that the disruptions of self-monitoring and decision-making processes observed in drug-addicted subjects [125; 664] might possibly arise from drug-dependent disruption of these prefrontal functions. However, as described in Section 7, an alternative possibility is that the deficits are not a consequence of drug taking, but that both arise from premorbid changes in the PFC. Furthermore, it is even possible that the drug-taking behaviour might arise from a propensity for self-medication.

8.1.3 Impairment of voluntary control. The issue of volition is central to social cognition since most consider willed action as essential to social democracy and to social constructs such as guilt, responsibility, accountability, law and sanctioning deviant behaviour. Drug addiction is typically portrayed as a compulsive drive to take drugs despite an awareness of their serious adverse consequences. The self-perceived 'loss of control' where the addict seems unable or unwilling to control their drug use is traditionally viewed as 'voluntary' notwithstanding studies showing long-lasting changes in the brain that could compromise crucial elements of the volitional system [665–667]. Campbell [668] has argued that addiction should be considered a disease of volition caused by a cognitive impairment involving an inability to recall the negative effects of the addictive behaviour.

Historically, however, the construct of 'will' has been generally defined as the capacity to choose what action to perform or withhold [669] and in a recent review Zhu [670] distinguishes three stages of volition: the mental act of decision making; the mental act of initiating voluntary action; and the mental activity of executive control. According to Zhu [670] the essential engagement of the anterior cingulate cortex in all three types of volition suggests a pivotal role in sustaining the volitional function. Other imaging studies implicate PFC, supplementary motor area and lateral PFC [669; 671].

Dysfunction in these regions has been associated with neuropsychiatric disorders of action including hysterical weakness, alien hand and schizophrenia [671; 672] and have also been found in relation to issues of deception and malingering [645; 673].

Spence and Frith [634] suggest that dorsolateral PFC and the brain regions with which it is connected are essential to performing willed action, and that diseases or dysfunction of these circuits may be associated with a variety of disorders of volition, such as Parkinson's Disease, 'utilisation' behaviour, 'alien' and 'phantom' limbs, delusions of 'alien control', and the passivity phenomena of schizophrenia.

The issue of impaired volition raises possible ethical questions about the capacity of addicted persons to give 'free and informed' consent to participate in studies that involve detecting neural abnormalities in addiction and treatments designed to reduce their addiction. Research involving persons who are cognitively or physically impaired in their decision making or volitional control would require special ethical consideration [674] because they may not be capable of providing informed consent. The view among addiction researchers has been that drug-dependent people are able to give free and informed consent to participate in research studies and clinical trials so long as they are not intoxicated or suffering acute withdrawal symptoms at the time that they give consent [675–677]. However, Cohen [678] controversially argues that 'the nature and pathology of untreated substance dependence make the condition inherently incompatible with a rational, internally uncoerced and informed consent on the part of those volunteering to receive addictive drugs in a non-therapeutic research setting.'

8.1.4 Impairment of awareness of the serious adverse consequences. Drug-addicted individuals use drugs despite apparently knowing their long-term physical and psychological consequences. Rinn *et al.* [679] tested the hypothesis of this lack of apparent awareness by suggesting that it was a product of cognitive failure rather than an emotion-driven rejection of the truth. In their study, they found persistent denial to be significantly correlated with greater impairment of executive function, verbal memory, visual inference and mental speed. Self-awareness deficits are also common after traumatic brain injury [680] and reflect a person's 'inability to recognise deficits or problem circumstances caused by neurological injury' [681]. Such awareness disorders are believed to reflect a complex interaction between neurological, psychological and social factors depending on lesion location and cognitive dysfunction [680].

9. THE MIND/BRAIN INTERFACE: NEUROBEHAVIOURAL ECONOMICS OF ADDICTION

9.1 Basic principles of behavioural economics

Behavioural economics, a merging of traditional economic theory with psychological studies of choice [682; 683], offers different perspectives on addiction. Much of economics is based on utility theory [25; 684], which assumes that agents are rational and exhibit reasonable attributes in their preferences. For example, one assumption is transitivity of preference: if an agent prefers A to B and B to C, then it must prefer A to C or it would easily be exploited by more rational agents. Given these assumptions, there must exist a utility function that assigns unidimensional values to real-world multidimensional events or outcomes, so that the agent prefers outcomes with higher utility. Psychologically and neurally, a similar process must also occur [685] if only to decide access to motor output. Agents can then use their knowledge about the world, and about the consequences of their actions (which may be uncertain), to act to maximise their expected utility [686]. Rational behaviour need not require complex, explicit thought. Conversely, if people are logical, we can infer their value system by observing their behaviour [687; 688].

A direct application of traditional economics to addiction is the calculation of elasticity of demand for goods, such as drugs. In a barter economy, and therefore in animal experiments, the 'price' of a commodity has no absolute meaning. We can speak of price only in terms of what other commodities an animal will give up to obtain the good, and that may depend on the specific commodities being traded [118; 687; 689]. In humans, elasticity has a more general meaning, since humans use a monetary economy. Money is a single commodity that is substitutable for almost all other (fungible) commodities, so we can calculate elasticity as the change in consumption as money price changes. Elasticity is defined as the proportional change in consumption divided by the proportional change in price. Elasticity is usually negative (we consume less as price goes up), so elasticities between -1 and 0 represent relatively 'inelastic' demand (consumption is not reduced much by price increases) and elasticities below -1 represent relatively 'elastic' demand (consumption is strongly affected by price).

9.2 Addiction in behavioural economic terms

An obvious way to think about addiction is that demand for drugs is inelastic compared to demand for other things. The more someone is addicted, the more inelastic their demand is – they will sacrifice other commodities (work, money, social interaction) rather than sacrifice the drug. Alcohol demand in rats can be more inelastic than demand for food [690; 691]. Yet drug demand is not completely inelastic, and addiction is not an all-or-nothing phenomenon. Most users of heroin, cocaine and alcohol do not use extremely large amounts, as the stereotype of an addict might suggest. Instead, most use infrequently, or 'chip' [692; 693]. Furthermore, over 75% of those dependent on an illicit drug recover [694; 695]. In fact, the elasticity of demand for cigarettes is typically about -0.4 [696; 697] – that is, if the price goes up by 10%, consumption goes down by 4%. When the price goes up, some people quit altogether and others smoke less. As for most commodities, elasticity varies with price. Smokers working for cigarette puffs in the laboratory are fairly inelastic when the price is low ($\epsilon = -0.56$), but become more elastic when the price goes up ($\epsilon = -1.58$) [698; 699]. Probably for this reason, elasticity is greater for poorer smokers, for whom cigarettes are proportionally more expensive [697]. In the UK, elasticity of demand for alcohol varies from -1.69 for wine through -0.86 for spirits to -0.76 for beer [700]. Participation price elasticities (the effect of price on the number of people using a drug) are about -0.90 to -0.80 for heroin and -0.55 to -0.36 for cocaine. Overall elasticities (the effect of price on the total amount consumed) are about -1.80 to -1.60 for heroin and -1.10 to -0.72 for cocaine [701]. Elasticity also varies with motivational state and other factors. Animals' demand for food is more

inelastic when they are hungry and if there are no alternative ways of obtaining food [702]. Similarly, demand for cigarettes is more inelastic when smokers have been abstinent [703]. From a policy perspective, it is also important to consider cross-price elasticity. If a policy reduces consumption of drug A, will the benefits be mitigated by increased consumption of drug B? In the case of alcohol and cigarettes, the two are either complements ($\epsilon < 0$) or independent, so reducing consumption of one tends to reduce (or not affect) consumption of the other [697]. Similar analyses have been conducted for other drugs and non-drug reinforcers [704].

9.3 Irrationality and its consequences for addiction

Some economists have described addiction as rational [109], in that addicts take the future consequences of their behaviour into account and have stable preferences. In rational addiction theory, addiction arises because the quantities of the addictive good consumed at different time periods are complements, which can lead to unstable states. This accounts for binges of consumption. Assuming rationality allows us to predict behaviour much better than not assuming it, unless we can predict the specific way in which people will be irrational [687]. A contribution of rational addiction theory [109; 110] was therefore to consider price as a major influence on the consumption of addictive drugs [705]. However, the premise that drug addicts choose rationally, maximising their total happiness, has been criticised [119; 705; 706]. Certainly, humans do not always choose according to rational norms. They deviate from the optimum when making decisions [707–710] because human cognitive abilities are limited ('bounded rationality') and because people frequently make choices that are not in their long-term interest ('bounded willpower').

In particular, humans and animals do not discount the future in a consistent way [111; 113]. It is rational to value future rewards somewhat less than immediate rewards (**Error! Reference source not found.a**). Steep temporal discounting (temporal 'myopia' or short-sightedness) leads to short-termism and impulsive choice (**Error! Reference source not found.b**). The shape of the temporal discounting function is also very important (**Error! Reference source not found.c**). Simple economic models assume exponential temporal discounting, which leads to preferences that are temporally consistent (what is preferred at time x is also preferred at time y). But animals and people actually exhibit hyperbolic temporal discounting [113; 711–714]. This leads to preferences [111–113; 715] that depend on when a choice is made (preference reversal; **Error! Reference source not found.d**). Therefore, many major behavioural economic theories of addiction [111–117] emphasise that addiction results from the maximisation of short-term rather than long-term utility [118; 705], with preferences that are inconsistent over time thanks to hyperbolic discounting, and that drug addictions [689] are bad because the short-term selection of drugs leads to lower long-term overall utility. Consumption of drugs reduces the value of future activities – the 'primrose path' to addiction (**Error! Reference source not found.**). Knowing that one is predisposed to be temporally inconsistent allows the use of self-control strategies [111; 119; 716], such as precommitment to a particular course of action, which improve long-term utility.

Economic theories of addiction are also relevant when considering the extent to which drug use is voluntary. The diagnostic criteria for drug dependence [256] include a compulsion to take a drug, yet drug use can be voluntary. Drug use certainly has utility to the user. It may take the form of euphoria, enhanced social experiences, or enhanced intellectual performance [2]. It is debatable whether even addicts take drugs involuntarily. Just because someone says they don't want to smoke and then later smokes doesn't mean they're smoking involuntarily – it might simply be that they're inconsistent [717; 718]. Furthermore, not everyone who smokes wants to give up. Appreciating these differences leads to a broader classification of addiction (Figure 7).

The fact that people do not act to maximise their total long-term expected reward can explain a number of otherwise counterintuitive results. For example, cigarette taxes can make smokers happier [719] because they serve as a valuable self-control device, helping them to avoid smoking. Such self-control strategies are not merely a human phenomenon [720–722]. Such short-termism can explain relapse [695]. Since one cigarette doesn't cause cancer and one shot of heroin doesn't condemn you to a junkie lifestyle, a person can correctly reason that since it's 'just for one last time', the drug is the better choice. A series of 'one-last-times' is a relapse.





Figure 5 Hypothetical models of reward discounting

Temporal discounting. **(a)** The value of a reward declines the more it is delayed. **(b)** Some individuals do not value future rewards very much (they discount steeply) and are impulsive. Others value future rewards more, and are self-controlled. **(c)** Animals and people tend to discount the future in a hyperbolic, not exponential, way. **(d)** This leads to preference reversal. If a subject chooses between a big reward and a small reward when both are a long way in the future, they'll choose the big one. But as time passes and they get closer in time to both, there may come a point at which preference reverses, they value the small reward more highly, and choose the smaller reward – they act impulsively.



Proportion of behaviour allocated to drug use
 $[drug\ consumption \div (drug\ consumption + other\ activities)]$

Figure 6 A behavioural economic model of drug addiction

Good now, bad in the long run – the 'primrose path' to addiction [114; 116; 118; 689]. At any point, drug taking has a higher value than other activities, so you take the drug. But drug taking lowers both the value of future drug taking (e.g. alcohol consumption causes tolerance, meaning that future alcohol isn't worth as much) and the value of other activities (e.g. the more alcohol you consume, the less you socialise and the worse you are at socialising; the more heroin you take, the worse you are at your job). So as you drink more, your total happiness goes down – you'd be better off not being an alcoholic. But even when you are an alcoholic, drinking now is worth more than not drinking now – for you are sensitive to local, not global, utility. As Rachlin [756] puts it: 'The alcoholic does not choose to be an alcoholic. Instead he chooses to drink now, and now, and now, and now. The pattern of alcoholism emerges in his behaviour ... without ever having been chosen.'




Figure 7 Skog's theory of drug addiction

Skog's [717] view of addiction. A person may be unaware that it is difficult for him or her to live without a drug. Such a person is enslaved, but unaware; Skog calls them 'naïve' addicts. He offers the example of a heavy drinker in Paris in World War II who had never realised that he was dependent on alcohol until rationing came along and he was limited to one litre of wine per week. Then there are those who know that life would be harder without, but are happy with this situation: 'happy' addicts, such as the 1950s smoker who thought that smoking was good for you (or at least, not bad). Those who are aware smoking is bad for you but feel no particular motivation to cut back are called 'subclinical' addicts by Skog. Finally, there are those who have tried and failed but are not trying at the moment, and those in an active struggle to quit.

9.4 From behavioural economics to neuroeconomics

Research into the neural basis of decision making and the way the brain processes economic variables is a large field. Some studies have sought neural correlates of utility [685] or hedonic evaluation [723] directly. Others have attempted to map the neural structures corresponding to psychological processes such as action–outcome contingency evaluation [215; 216], instrumental incentive value [724], S–R habits [276; 725], and PIT [160; 174; 205; 209]. Lesions have also been used to establish the contribution of different brain structures and neuromodulators to choices between reinforcers differing in size, probability, delay or the effort required to obtain them [157; 207; 726–738], while imaging studies have correlated human preferences with the activation of specific brain regions [240; 277; 739].

However, some basic psychological principles remain unknown. We have not discovered how the hyperbolic temporal discounting process operates neurally, or whether hyperbolic discounting is explicable as the overall effect of two different systems – for example, a cognitive, declarative system that exhibits minimal or exponential discounting, plus phenomena such as PIT or 'visceral factors' that make rewards more salient and promote their choice when they are immediately available [740–743]. Recently, such a two-factor model was used in the analysis of a functional magnetic resonance imaging (fMRI) study of choice involving rewards differing in magnitude and delays, with delays ranging from less than a day to six weeks [744]. Lateral prefrontal and intraparietal cortical regions were activated independently of the delay, and were suggested to be part of a system that evaluates both immediate and delayed rewards according to a rational temporal discounting system, while limbic regions including the ventral striatum and medial OFC were preferentially activated by the relatively immediate rewards, and were suggested to be part of a system that promotes the choice of imminent rewards without consideration of delayed alternatives. These limbic regions were more likely to be activated than the 'delay-independent' areas by trials in which an earlier reward was chosen. A knowledge of the operation of these neural systems may offer opportunities for pharmacological treatment of addiction [745], but probably would not change the fact that the simplest and most powerful way to influence these neural systems is often through conventional economic tools [692].

10. FUTURE IMPLICATIONS: NEW DRUGS, THEIR IMPACT AND MANAGEMENT

10.1 Predicting further drugs of abuse

Abused drugs of the future are likely to arise from:

- refinement of the properties of known drugs
- synthesis of novel therapeutic compounds with abuse potential, such as euphorigenic or cognition-enhancing effects
- synthesis of drugs acting on newly defined molecular targets, especially within relevant areas of the brain such as the reinforcement ('reward') system and cortical areas devoted to cognitive or affective processes.

10.1.1 Refinement of the properties of known addictive or cognition-enhancing drugs

Powerful and effective addictive drugs are readily available. It is not understood whether the very non-selective actions of some drugs, such as cocaine and amphetamine, which affect the release or reuptake of all the monoamines, enhance or limit their positive effects and therefore their abuse potential. It is frequently assumed that effects on the DA system are of paramount importance in their addictive potential and in mediating their positive effects. If this is the case, highly selective DA reuptake inhibitors (a 'super' cocaine) or releasers (a 'super' amphetamine) may have special abuse potential. By contrast, the very non-selective actions of these drugs may underlie their potent effects, in which case novel drugs will have broader, not more selective, actions. Direct agonists at specific receptors mediating the reinforcing effects of drugs by acting within the 'reward system', may also have abuse potential. Direct μ -opiate receptor agonists have exceptional efficacy, but DA receptor agonists are not generally abused, and this may represent a basic difference between the abuse potential of stimulants and CNS depressants such as opiates. However, DA receptor subtype-selective drugs, such as those acting at the D3 receptor, may be abused because of their selective actions within key circuitries. Novel non-peptidergic agonists at opiate receptors may also have great abuse potential, particularly if they are devoid of effects at downstream systems mediating tolerance and physical withdrawal. Similarly, non-peptidergic drugs (or drugs from other classes able to penetrate the brain) acting on known peptide transmitter systems within key structures, such as the Acb, may also have abuse potential. These might include drugs interacting with CCK, neurokinin and opioid peptide systems.

One of the key factors involved in addiction is the progressive development of neuroadaptations in the brain which may underlie withdrawal phenomena, impair the functioning of specific areas of the brain (e.g. the OFC and striatum) and induce persistent and maladaptive forms of learning. Limiting or preventing these neuroadaptations may enhance the abuse potential of known drugs.

Thus, the newly introduced CB1 receptor antagonist rimonabant may ameliorate opiate withdrawal and also the cognitive impairments and intoxication caused by smoking cannabis. Thus, the acute positive effects of heroin may be achieved without a severe withdrawal syndrome and cannabis may be smoked with less deleterious effects through use of drugs such as rimonabant. In general, drugs that might prevent long-term neuroadaptations to chronic drug intake could enhance the potential for acute use by reducing the chances of dependence. In particular, combining addictive drugs such as heroin or cocaine with others designed to prevent or reverse neuroadaptive changes in intracellular signalling cascades (Section 5, see also below) may be especially powerful, either as a way of minimising harm and managing abuse or of countering the adaptations, through tolerance, that minimise the acute hedonic effects. This notion can be seen as a form of 'combination drug use', rather as heroin and cocaine are already combined

by some addicts to limit the adverse effects of one drug while enhancing those of the other (the aversive effects of cocaine and the sedating effects of heroin). There is great potential for combining drugs from different classes to enhance the positive subjective effects and the advent of new agents will amplify this potential.

GABA-A receptor subtype-selective benzodiazepines (BZD) and related compounds are now being developed and have specific effects. For example, alpha-1 subtype-selective compounds are hypnotic but not anxiolytic; alpha-5 subtype-selective compounds affect cognition, but are not hypnotic or anxiolytic. There is considerable interest in producing specific anxiolytic compounds that not only have no sedative or cognition-impairing effects, but also have no abuse potential – ie no euphorogenic effects and no dependence liability. Understanding the mechanisms of BZD dependence may result in the development of more effective anxiolytics, and define the targets for novel BZD ligands with non-anxiolytic abuse potential.

It seems likely that understanding the genetic determinants of the responses to drugs will enhance therapeutics by allowing 'individualised' medicine. This may allow individuals to identify their own risks, possibly via counselling, for adverse effects of specific drugs, and find drugs that are 'safer' to abuse. This may be achieved in conjunction with information derived from functional markers, such as cognitive test performance and brain neuroimaging. Genetic polymorphisms affecting the 5-HT transporter can already be used to predict responses to SSRIs and also the likely susceptibility to depression following chronic MDMA abuse [621]. Understanding the polymorphisms in genes encoding proteins that regulate the efficiency of chemical neurotransmitter systems is a major goal for future tailored therapeutics, but will also carry the risk of more optimal selection of drugs for abuse by individuals to minimise harm or maximise positive effects.

10.1.2 Novel therapeutic compounds with abuse potential

Intense research activity is directed towards the development of conceptually novel antidepressant drugs. The majority of today's antidepressants are designed to treat depressed mood and sadness, rather than the dysphoria or anhedonia which also characterises depression. Drugs that reverse these symptoms may therefore have hedonic effects and considerable abuse potential. Indeed, there is a growing interest in pro-dopaminergic drugs to target anhedonia, such as bupropion, which has weak antidepressant effects but is also used to diminish cravings in smoking cessation. But a DA-selective reuptake inhibitor may alleviate the apathy and anhedonia of depression while carrying marked abuse potential (see above). Whether such drugs have this potential will depend on their pharmacokinetic properties, since rapid-onset short-half-life stimulant drugs are those most readily abused and have greater addictive potential. Thus pro-dopaminergic drugs with more favourable (slower) pharmacokinetics may be effective therapeutically, but have limited abuse potential. Cannabinoid receptor agonists developed for their analgesic and other properties may carry abuse potential. If they have appropriate pharmacodynamics, they may be safer than smoking cannabis but bring with them the risk of inducing psychosis in vulnerable individuals. Drugs primarily targeted at appetite reduction or weight loss (e.g. CB1 receptor antagonists, leptins) will become more available and may be abused.

It is interesting to speculate whether our knowledge of the modulation of central neurotransmitters (cholinergic, serotonergic and dopaminergic) by dietary manipulation [746; 747] could become sufficiently sophisticated to allow significant subjective or cognitive effects in normal subjects. Similarly, novel drugs that enhance cognition are likely also to carry abuse potential, perhaps especially for short-term advantage under conditions of high demand such as examinations. Such drugs might affect glutamatergic transmission directly or indirectly via cholinergic

or catecholaminergic neuromodulation, or by novel mechanisms of action (e.g. modafinil, CREB pathway memory consolidators). However, we do not anticipate major overlap between future recreational drugs and cognition enhancers for the workplace because of their generally distinct neural domains of action.

10.1.3 Synthesis of novel psychoactive compounds having euphorigenic or cognition-enhancing effects

As indicated in this project's review of Pharmacology and Treatments new drugs with abuse potential will always be synthesised either by the pharmaceutical industry or by illicit laboratories. Many of these drugs will be directed at known targets but it is likely that new targets will also be discovered – either new chemical transmitters or new receptors that have no known endogenous ligand ('orphan receptors'). The presence of these transmitter systems and novel receptors within the mesolimbic DA system, Acb or limbic cortical areas, such as the orbital prefrontal cortex, that define the neural systems underlying reward, hedonics and addiction, or the underlying cognitive processes, will be especially interesting targets for new psychoactive compounds for therapeutic or recreational use.

10.2 Future management of psychoactive substances: impact of neuroscience and neurobehavioural economics

Addiction is not an all-or-nothing problem, and it will not be sensible to search for a single cure. If drug use continues at a relatively high level or if it increases further, then policy makers should seek methods to reduce consumption and minimise the harm from drug taking. Focusing only on prevalence (the number of people using a drug) may be inappropriate. A strategy of total harm reduction should also consider ways to reduce the average quantity used and the amount of harm per use.

Many neuroscientific addiction theories focus on the way in which drugs change the brain. As Kelley and Berridge [178] recently noted, drugs may activate the same circuits as natural rewards, perhaps in a more potent manner; they may create new states, such as the motivational state of withdrawal; and they may differentially affect the balance of processes that normally contribute to responding for natural rewards, such as habits, goal-directed actions and cue-induced motivation. There may be other effects too. Food makes you full and exercise makes you tired, but not all drugs will satiate you to the same extent [695]. Acute intoxication impairs decision making, so the decision to have the sixth pint of beer may not be made in the same way as the decision to have the first. Chronic use of some drugs may alter the brain so as to impair the ability to make good choices [125]. Some forms of brain damage may make you more likely to choose impulsively, maximising short-term rather than long-term gain [207]. Future treatment strategies will focus on these effects, attempting to reduce drug consumption and reduce the frequency of relapse.

Neuroscientific advances may contribute to the diagnostic process and the matching of treatments to addicts. Techniques ranging from genetics to functional neuroimaging may become useful as a way of predicting which treatments will work best for an individual patient, and in assessing the likely efficacy of that treatment at preventing relapse before the patient is discharged. Both would be important advances.

However, neuroscientific strategies are just one avenue of attack. Once addictive behaviours are recognised to be sensitive to drug price and to the relative value of drugs and other activities, it is clear that many options currently available may be further refined. When treating individual addicts, it is important to realise that neuroscientific strategies may be increasingly interpreted in economic terms, allowing their comparison with other macroeconomic strategies. Pharmacological techniques can already reduce the

value of specific drugs. For example, methadone treats opiate withdrawal symptoms and reduces the 'high' produced by concurrently-administered heroin, thus reducing the value of heroin. Heroin prescriptions [748] reduce the value of contaminated, street heroin. Nicotine patches treat nicotine withdrawal, reducing the value of nicotine. Disulfiram alters ethanol metabolism temporarily so that ethanol consumption induces illness, and so reduces the value of alcohol. Vaccination against cocaine is being tried at the moment [749]. This reduces the 'high' and therefore the value of cocaine. All of these can be seen as self-control tactics, and depend on the choices made by the addict. Because the addict would prefer a drug-free lifestyle in the long term, they adopt a strategy (e.g. taking disulfiram) that reduces the future value of the drug. It is also possible to target the brain's motivational systems directly. Thus, chemicals that reduce drug seeking in animals (e.g. D3 receptor agents [252]) may be another line of therapy.

Better knowledge of the risks of drug taking could also help reduce the perceived value of drugs [695], and effective advertising of risk should take advantage of human reasoning biases [750], perhaps by using vivid images of the potential unpleasant outcomes of drug use [751]. Taken to the opposite extreme, overestimation of the risks of drug taking may also help some people avoid addiction. A personal theory that cocaine use inevitably leads to full-blown destructive addiction might not be true [692–695], but this belief is a self-control device that may stop some people taking any cocaine [111]. Misinformation is clearly not a useful public health strategy, since the credibility of advisers depends on providing accurate information, but clear and vivid statements of genuine risks are of value.

Finally, the addict pays for drugs with money and therefore forfeits alternative commodities. They may also forfeit commodities that cannot be bought with money, such as social support. Therefore, other strategies can be used to treat addiction [689]. For example, making it easier for an addict to obtain substitutes for drugs may in the future be as effective as making it harder for the addict to obtain drugs [689; 752; 753]. Rewarding abstinence directly with money or other tangible rewards also promotes abstinence [695; 754]. Addicts may also learn to use self-control techniques such as pre-commitment to improve their sensitivity to the long term [111].

Neuroscientific research aims to understand the neural mechanisms behind addiction. In the long run, this research is likely to identify a series of molecular mechanisms that operate to promote drug taking in the addicted brain. Some will prove to be therapeutic targets, for example, to reduce drug craving, and may be useful in the treatment of established addiction. Some potential therapies may be specific to the effects of drugs of abuse, but others will not – for example, reducing strong cravings for all reinforcers, not just abused drugs. The potential to erase drug-related memories selectively [425] might be of substantial benefit if it can be translated to clinical practice. Other molecular markers may indicate individual vulnerability to addiction, indicating to potential users which drugs might be relatively safe to use and which would be likely to lead to strong addictions. Furthermore, techniques may become available to predict which treatments will be best suited to an individual addict by analysing the patient's genetic make-up or neural responses. Thus, the most important policy decision to be made regarding the neuroscience of addiction will be how much to spend on research that may lead to treatments, and how much to spend on the treatment of addicts who seek help. However, we predict that the overall level of consumption of addictive drugs, and therefore the harm to society that such drugs cause, will be determined instead by macroeconomic decisions about drug regulation.

ACKNOWLEDGEMENTS

The authors thank Nicola Allanson for skilled assistance in the preparation of this manuscript.

REFERENCES

1. Cooper, J. R., Bloom, F. E. and Roth, R. H. (2002). *The biochemical basis of neuropharmacology*, 8th edition. Oxford University Press, New York.
2. Feldman, R. S., Meyer, J. S. and Quenzer, L. F. (1997). *Principles of neuropsychopharmacology*, Sinauer, Sunderland, Massachusetts.
3. Civelli, O., Reinscheid, R. K. and Nothacker, H. P. (1999). Orphan receptors, novel neuropeptides and reverse pharmaceutical research. *Brain Res* **848**: 27 Nov 63–25.
4. Preskorn, S. H. (2001). The human genome project and drug discovery in psychiatry: identifying novel targets. *Journal of Psychiatric Practice*: 133–137.
5. Cools, R., Barker, R., Sahakian, B. J. and Robbins, T. W. (2001). Enhanced or impaired cognitive function in Parkinson's disease as a function of dopaminergic medication and task demands. *Cerebral Cortex* **11**: 1136–1143.
6. Lawrence, A. D., Evans, A. H. and Lees, A. J. (2003). Compulsive use of dopamine replacement therapy in Parkinson's disease: reward systems gone awry? *Lancet Neurol* **2**: 595–604.
7. Walter, B. L. and Vitek, J. L. (2004). Surgical treatment for Parkinson's disease. *Lancet Neurol* **3**: 719–728.
8. Levin, E. D. (2002). Nicotinic receptor subtypes and cognitive function. *J Neurobiol* **53**: 633–640.
9. Citron, M. (2002). Alzheimer's disease: treatments in discovery and development. *Nat Neurosci* **5 Suppl**: Nov 1055–1057.
10. Solanto, M. V., Arnsten, A. F. and Castellanos, F. X. (2001). *Stimulant drugs and ADHD: Basic and clinical neuroscience*, Oxford University Press, New York.
11. Duman, R. S. (2004). Depression: a case of neuronal life and death? *Biol Psychiatry* **56**: 140–145.
12. Thomas, M. J. and Malenka, R. C. (2003). Synaptic plasticity in the mesolimbic dopamine system. *Philos Trans R Soc Lond B Biol Sci* **358**: 815–819.
13. Lynch, G. (2002). Memory enhancement: the search for mechanism-based drugs. *Nat Neurosci* **5 Suppl**: 1035–1038.
14. Curran, H. V. and Morgan, C. A. (2000). Cognitive, dissociative and psychotogenic effects of ketamine in recreational users on the night of drug use and 3 days later. *Addiction* **95**: 575–590.
15. Tully, T., Bourchouladze, R., Scott, R. and Tallman, J. (2003). Targeting the CREB pathway for memory enhancers. *Nat Rev Drug Discov* **2**: 267–277.
16. Arnsten, A. F. and Robbins, T. W. (2002). Neurochemical modulation of prefrontal cortical function in humans and animals. In *Principles of frontal lobe function* (Stuss, D. T. and Knight, R. T., eds.), pp. 51–84. Oxford University Press, New York.
17. Mignot, E., Taheri, S. and Nishino, S. (2002). Sleeping with the hypothalamus: emerging therapeutic targets for sleep disorders. *Nat Neurosci* **5 Suppl**: 1071–1075.
18. Turner, D. C., Clark, L. J., Robbins, T. W. and Sahakian, B. J. (2004). Modafinil improves cognition and response inhibition in adult ADHD. *Biological Psychiatry* **55**: 1031–1039.
19. Mattay, V. S., Goldberg, T. E., Fera, F., Hariri, A. R., Tessitore, A., Egan, M. F., Kolachana, B., Callicott, J. H. and Weinberger, D. R. (2003). Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. *Proc Natl Acad Sci U S A* **100**: 6186–6191.
20. Volkow, N. D., Fowler, J. S. and Wang, G. J. (1999). Imaging studies on the role of dopamine in cocaine reinforcement and addiction in humans. *J Psychopharmacol* **13**: 337–345.
21. Reuter, J., Raedler, T., Rose, M., Hand, I., Glascher, J. and Buchel, C. (2005). Pathological gambling is linked to reduced activation of the mesolimbic reward system. *Nat Neurosci* **8**: 147–148.
22. Thorndike, E. L. (1911). *Animal intelligence: experimental studies*, Macmillan, New York.
23. Minsky, M. L. (1961). Steps towards artificial intelligence. *Proceedings of the Institute of Radio Engineers* **9**: 8–30.
24. Haykin, S. (1999). *Neural Networks: A Comprehensive Foundation*, Prentice-Hall, Upper Saddle River, New Jersey.
25. Russell, S. J. and Norvig, P. N. (1995). *Artificial Intelligence: a modern approach*, Prentice-Hall, Upper Saddle River, New Jersey.
26. Grindley, G. C. (1932). The formation of a simple habit in guinea pigs. *British Journal of Psychology* **23**: 127–147.
27. Guthrie, E. R. (1935). *The psychology of learning*, Harper, New York.
28. Hull, C. L. (1943). *Principles of behavior*, Appleton-Century-Crofts, New York.
29. Skinner, B. F. (1938). *The behavior of organisms: an experimental analysis*, Appleton, New York.
30. Thorndike, E. L. (1905). *The Elements of Psychology*, Seiler, New York.
31. Skinner, B. F. (1953). *Science and Human Behavior*, Macmillan, New York.
32. Toates, F. (1986). *Motivational systems*, Cambridge University Press, Cambridge.
33. Ferguson, E. D. (2000). *Motivation: a biosocial and cognitive integration of motivation and emotion*, Oxford University Press, Oxford.
34. Erwin, R. J. and Ferguson, E. D. (1979). The effect of food and water deprivation and satiation on recognition. *American Journal of Psychology* **92**: 611–626.
35. Dickinson, A. (1994). Instrumental conditioning. In *Animal Learning and Cognition* (Mackintosh, N. J., ed.), pp. 45–79. Academic Press, San Diego.
36. Dickinson, A. and Balleine, B. (1994). Motivational control of goal-directed action. *Animal Learning and Behavior* **22**: 1–18.
37. Colwill, R. M. and Rescorla, R. A. (1990). Evidence for the hierarchical structure of instrumental learning. *Animal Learning and Behavior* **18**: 71–82.
38. Rescorla, R. A. (1990). The role of information about the response-outcome relation in instrumental discrimination learning. *Journal of Experimental Psychology: Animal Behavior Processes* **16**: 262–270.
39. Rescorla, R. A. (1990). Evidence for an association between the discriminative stimulus and the response-outcome association in instrumental learning. *Journal of Experimental Psychology: Animal Behavior Processes* **16**: 326–334.
40. Balleine, B. and Dickinson, A. (1991). Instrumental performance following reinforcer devaluation depends upon incentive learning. *Quarterly Journal of Experimental Psychology, Section B – Comparative and Physiological Psychology* **43**: 279–296.
41. Garcia, J. (1989). Food for Tolman: Cognition and cathexis in concert. In *Aversion, avoidance and anxiety* (Archer, T. and Nilsson, L.-G., eds.), pp. 45–85. Erlbaum, Hillsdale, New Jersey.
42. Balleine, B. (1992). Instrumental performance following a shift in primary motivation depends on incentive learning. *Journal of Experimental Psychology: Animal Behavior Processes* **18**: 236–250.
43. Adams, C. D. (1982). Variations in the sensitivity of instrumental responding to reinforcer devaluation. *Quarterly Journal of Experimental Psychology, Section B – Comparative and Physiological Psychology* **34**: 77–98.
44. Cardinal, R. N., Parkinson, J. A., Hall, J. and Everitt, B. J. (2002). Emotion and motivation: the role of the amygdala, ventral striatum, and prefrontal cortex. *Neuroscience and Biobehavioral Reviews* **26**: 321–352.

45. Lovibond, P. F. (1983). Facilitation of instrumental behavior by a Pavlovian appetitive conditioned stimulus. *Journal of Experimental Psychology: Animal Behavior Processes* **9**: 225–247.
46. Estes, W. K. (1948). Discriminative conditioning. II. Effects of a Pavlovian conditioned stimulus upon a subsequently established operant response. *Journal of Experimental Psychology* **38**: 173–177.
47. Wikler, A. (1965). Conditioning factors in opiate addiction and relapse. In *Narcotics* (Wilner, D. I. and Kessenbaum, G. G., eds.), pp. 85–100. McGraw-Hill, New York.
48. Wikler, A. (1973). Dynamics of drug dependence: Implications of a conditioning theory for research and treatment. *Archives of General Psychiatry* **28**: 611–616.
49. Altman, J., Everitt, B. J., Glautier, S., Markou, A., Nutt, D., Oretti, R., Phillips, G. D. and Robbins, T. W. (1996). The biological, social and clinical bases of drug addiction: commentary and debate. *Psychopharmacology* **125**: 285–345.
50. Khantzian, E. J. (1985). The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence. *Am J Psychiatry* **142**: 1259–1264.
51. Markou, A., Kosten, T. R. and Koob, G. F. (1998). Neurobiological similarities in depression and drug dependence: a self-medication hypothesis. *Neuropsychopharmacology* **18**: 135–174.
52. Weiss, R. D. and Mirin, S. M. (1986). Subtypes of cocaine abusers. *Psychiatr Clin North Am* **9**: 491–501.
53. Newhouse, P. A., Potter, A. and Singh, A. (2004). Effects of nicotinic stimulation on cognitive performance. *Curr Opin Pharmacol* **4**: 36–46.
54. Castaneda, R., Lifshutz, H., Galanter, M. and Franco, H. (1994). Empirical assessment of the self-medication hypothesis among dually diagnosed inpatients. *Compr Psychiatry* **35**: May–Jun 180–184.
55. Mitchell, S. H., Laurent, C. L. and de Wit, H. (1996). Interaction of expectancy and the pharmacological effects of d-amphetamine: subjective effects and self-administration. *Psychopharmacology (Berl)* **125**: 371–378.
56. de Wit, H., Uhlhuth, E. H. and Johanson, C. E. F. (1986). Individual differences in the reinforcing and subjective effects of amphetamine and diazepam. *Drug Alcohol Depend* **16**: 341–360.
57. Uhlhuth, E. H., Johanson, C. E., Kilgore, K. and Kobasa, S. C. (1981). Drug preference and mood in humans: preference for d-amphetamine and subject characteristics. *Psychopharmacology (Berl)* **74**: 191–194.
58. Fischman, M. W. (1989). Relationship between self-reported drug effects and their reinforcing effects: studies with stimulant drugs. *NIDA Res Monogr* **92**: 211–230.
59. Siegel, S. (1976). Morphine analgesic tolerance: its situation specificity supports a Pavlovian conditioning model. *Science* **193**: 323–325.
60. Siegel, S. (1999). Evidence from rats that morphine tolerance is a learned response. *J Comp Physiol Psychol* **89**: 498–506.
61. Dafters, R. and Anderson, G. (1982). Conditioned tolerance to the tachycardia effect of ethanol in humans. *Psychopharmacology (Berl)* **78**: 365–367.
62. Krasnegor, N. A. (1978). Behavioral tolerance: research and treatment implications: introduction. *NIDA Res Monogr*: 1–3.
63. Siegel, S. (1999). Drug anticipation and drug addiction. The 1998 H. David Archibald Lecture. *Addiction* **94**: 1113–1124.
64. Solomon, R. L. and Corbit, J. D. (1974). An opponent-process theory of motivation. I. Temporal dynamics of affect. *Psychol Rev* **81**: 119–145.
65. Koob, G. F., Stinus, L., Le Moal, M. and Bloom, F. E. (1989). Opponent process theory of motivation: neurobiological evidence from studies of opiate dependence. *Neuroscience and Biobehavioral Reviews* **13**: 135–140.
66. Epping-Jordan, M. P., Watkins, S. S., Koob, G. F. and Markou, A. (1998). Dramatic decreases in brain reward function during nicotine withdrawal. *Nature* **393**: 76–79.
67. Weiss, F., Markou, A., Lorang, M. T. and Koob, G. F. (1992). Basal extracellular dopamine levels in the nucleus accumbens are decreased during cocaine withdrawal after unlimited-access self-administration. *Brain Research* **593**: 314–318.
68. Maisonneuve, I. M. and Kreek, M. J. (1994). Acute tolerance to the dopamine response induced by a binge pattern of cocaine administration in male rats: an *in vivo* microdialysis study. *Journal of Pharmacology and Experimental Therapeutics* **268**: 916–921.
69. Siegel, S., Hinson, R. E., Krank, M. D. and McCully, J. (1982). Heroin 'overdose' death: contribution of drug-associated environmental cues. *Science* **216**: 436–437.
70. Kenny, P. J., Koob, G. F. and Markou, A. (2003). Conditioned facilitation of brain reward function after repeated cocaine administration. *Behav Neurosci* **117**: 1103–1107.
71. Siegel, S. (1988). Drug anticipation and the treatment of dependence. *NIDA Res Monogr* **84**: 1–24.
72. Gawin, F. H. (1991). Cocaine addiction: psychology and neurophysiology. *Science* **251**: 1580–1586.
73. Tiffany, S. T. and Drobes, D. J. (1990). Imagery and smoking urges: the manipulation of affective content. *Addict Behav* **15**: 531–539.
74. O'Brien, C. P., Childress, A. R., Ehrman, R. and Robbins, S. J. (1998). Conditioning factors in drug abuse: can they explain compulsion? *Journal of Psychopharmacology* **12**: 15–22.
75. Robinson, T. E. and Berridge, K. C. (1993). The neural basis of drug craving: an incentive-sensitization theory of addiction. *Brain Research Reviews* **18**: 247–291.
76. Kalivas, P. W., Pierce, R. C., Cornish, J. and Sorg, B. A. (1998). A role for sensitization in craving and relapse in cocaine addiction. *Journal of Psychopharmacology* **12**: 49–53.
77. Post, R. M. and Weiss, S. R. (1988). Psychomotor stimulant vs. local anesthetic effects of cocaine: role of behavioral sensitization and kindling. *NIDA Res Monogr* **88**: 217–238.
78. Pettit, H. O., Pan, H. T., Parsons, L. H. and Justice, J. B., Jr. (1990). Extracellular concentrations of cocaine and dopamine are enhanced during chronic cocaine administration. *J Neurochem* **55**: 798–804.
79. Wyvell, C. L. and Berridge, K. C. (2001). Incentive sensitization by previous amphetamine exposure: increased cue-triggered 'wanting' for sucrose reward. *Journal of Neuroscience* **21**: 7831–7840.
80. Bechara, A., Nader, K. and van der Kooy, D. (1998). A two-separate-motivational-systems hypothesis of opioid addiction. *Pharmacol Biochem Behav* **59**: 1–17.
81. Bozarth, M. A. and Wise, R. A. (1984). Anatomically distinct opiate receptor fields mediate reward and physical dependence. *Science* **224**: 4 May 516–517.
82. Berridge, K. C. (1991). Modulation of taste affect by hunger, caloric satiety, and sensory-specific satiety in the rat. *Appetite* **16**: 103–120.
83. Hutcheson, D. M., Everitt, B. J., Robbins, T. W. and Dickinson, A. (2001). The role of withdrawal in heroin addiction: enhances reward or promotes avoidance? *Nat Neurosci* **4**: 943–947.
84. Cabanac, M. (1992). Pleasure: the common currency. *J Theor Biol* **155**: 21 Mar 173–200.
85. Goldberg, S. R. and Schuster, C. R. (1967). Conditioned suppression by a stimulus associated with nalorphine in morphine-dependent monkeys. *J Exp Anal Behav* **10**: 235–242.
86. O'Brien, C. P., Testa, T., O'Brien, T. J. and Greenstein, R. (1976). Conditioning in human opiate addicts. *Pavlov J Biol Sci* **11**: 195–202.
87. O'Brien, C. P., Testa, T., O'Brien, T. J., Brady, J. P. and Wells, B. (1977). Conditioned narcotic withdrawal in humans. *Science* **195**: 1000–1002.
88. O'Brien, C. P., O'Brien, T. J., Mintz, J. and Brady, J. P. (1975). Conditioning of narcotic abstinence symptoms in human subjects. *Drug Alcohol Depend* **1**: 115–123.
89. Knackstedt, L. A., Samimi, M. M. and Ettenberg, A. (2002). Evidence for opponent-process actions of intravenous cocaine and cocaethylene. *Pharmacol Biochem Behav* **72**: 931–936.
90. Koob, G. F. and Bloom, F. E. (1988). Cellular and molecular mechanisms of drug dependence. *Science* **242**: 715–723.

91. Koob, G. F., Caine, S. B., Parsons, L., Markou, A. and Weiss, F. (1997). Opponent process model and psychostimulant addiction. *Pharmacology Biochemistry and Behavior* **57**: 513–521.
92. Markou, A. and Koob, G. F. (1991). Postcocaine anhedonia. An animal model of cocaine withdrawal. *Neuropsychopharmacology* **4**: 17–26.
93. Solomon, R. L. (1980). The opponent-process theory of acquired motivation: the costs of pleasure and the benefits of pain. *Am Psychol* **35**: 691–712.
94. Solomon, R. L. (1980). Recent experiments testing an opponent-process theory of acquired motivation. *Acta Neurobiol Exp (Wars)* **40**: 271–289.
95. Solomon, R. L. and Corbit, J. D. (1973). An opponent-process theory of motivation. II. Cigarette addiction. *J Abnorm Psychol* **81**: 158–171.
96. Koob, G. F., Ahmed, S. H., Boutrel, B., Chen, S. A., Kenny, P. J., Markou, A., O'Dell, L. E., Parsons, L. H. and Sanna, P. P. (2004). Neurobiological mechanisms in the transition from drug use to drug dependence. *Neurosci Biobehav Rev* **27**: 739–749.
97. Robbins, T. W. and Everitt, B. J. (1999). Drug addiction: bad habits add up [news]. *Nature* **398**: 567–570.
98. Everitt, B. J., Dickinson, A. and Robbins, T. W. (2001). The neuropsychological basis of addictive behaviour. *Brain Research Reviews* **36**: 129–138.
99. Everitt, B. J. and Wolf, M. E. (2002). Psychomotor stimulant addiction: a neural systems perspective. *J Neurosci* **22**: 3312–3320.
100. O'Brien, C. P. and McLellan, A. T. (1996). Myths about the treatment of addiction. *Lancet* **347**: 237–240.
101. Tiffany, S. T. and Carter, B. L. (1998). Is craving the source of compulsive drug use? *J Psychopharmacol* **12**: 23–30.
102. Dickinson, A., Wood, N. and Smith, J. W. (2002). Alcohol seeking by rats: action or habit? *Q J Exp Psychol B* **55**: 331–348.
103. Olmstead, M. C., Lafond, M. V., Everitt, B. J. and Dickinson, A. (2001). Cocaine seeking by rats is a goal-directed action. *Behav Neurosci* **115**: 394–402.
104. Miles, F. J., Everitt, B. J. and Dickinson, A. (2003). Oral cocaine seeking by rats: Action or habit? *Behav Neurosci* **117**: 927–938.
105. Vanderschuren, L. J. and Everitt, B. J. (2004). Drug seeking becomes compulsive after prolonged cocaine self-administration. *Science* **305**: 1017–1019.
106. APA (1994). *Diagnostic and Statistical Manual of Mental Disorders, version IV (DSM-IV)*, American Psychiatric Association, Washington DC.
107. Koob, G. F., Rocio, M., Carrera, A., Gold, L. H., Heyser, C. J., Maldonado-Irizarry, C., Markou, A., Parsons, L. H., Roberts, A. J., Schulteis, G., Stinus, L., Walker, J. R., Weissenborn, R. and Weiss, F. (1998). Substance dependence as a compulsive behavior. *Journal of Psychopharmacology* **12**: 39–48.
108. Leshner, A. I. (1997). Addiction is a brain disease, and it matters. *Science* **278**: 45–47.
109. Becker, G. S. and Murphy, K. M. (1988). A theory of rational addiction. *Journal of Political Economy* **96**: 675–700.
110. Stigler, G. and Becker, G. S. (1977). De gustibus non est disputandum. *American Economic Review* **67**: 76–90.
111. Ainslie, G. (2001). *Breakdown of Will*, Cambridge University Press, Cambridge, UK.
112. Ainslie, G. (1992). *Picoeconomics: the strategic interaction of successive motivational states within the person*, Cambridge University Press, Cambridge, UK.
113. Ainslie, G. (1975). Specious reward: a behavioral theory of impulsiveness and impulse control. *Psychological Bulletin* **82**: 463–496.
114. Herrnstein, R. J. and Prelec, D. (1992). A theory of addiction. In *Choice Over Time* (Loewenstein, G. and Elster, J., eds.), pp. 331–361. Russell Sage Press, New York.
115. Heyman, G. M. (1996). Resolving the contradictions of addiction. *Behavioral and Brain Sciences* **19**: 561–610.
116. Rachlin, H. (1997). Four teleological theories of addiction. *Psychonomic Bulletin and Review* **4**: 462–473.
117. Rachlin, H. (2000). The lonely addict. In *Reframing health behavior change with behavioral economics* (Bickel, W. K. and Vuchinich, R. E., eds.), pp. 145–166. Lawrence Erlbaum Associates, Mahwah, NJ.
118. Vuchinich, R. E. and Heather, N. (2003). Introduction: overview of behavioural economic perspectives on substance use and addiction. In *Choice, Behavioral Economics and Addiction* (Heather, N. and Vuchinich, R. E., eds.), pp. 1–31. Elsevier, Oxford.
119. Ainslie, G. and Monterosso, J. (2003). Hyperbolic discounting as a factor in addiction: a critical analysis. In *Choice, Behavioral Economics and Addiction* (Heather, N. and Vuchinich, R. E., eds.), pp. 35–61, 67–69. Elsevier, Oxford.
120. Mitchell, S. H. (2003). Discounting the value of commodities according to different types of cost. In *Choice, Behavioral Economics and Addiction* (Heather, N. and Vuchinich, R. E., eds.), pp. 339–357. Elsevier, Oxford.
121. Bickel, W. K. and Johnson, M. W. (2003). Junk time: pathological behavior as the interaction of evolutionary and cultural forces. In *Choice, Behavioral Economics and Addiction* (Heather, N. and Vuchinich, R. E., eds.), pp. 249–271, 276–278. Elsevier, Oxford.
122. Petry, N. M., Bickel, W. K. and Arnett, M. (1998). Shortened time horizons and insensitivity to future consequences in heroin addicts. *Addiction* **93**: 729–738.
123. Bickel, W. K., Odum, A. L. and Madden, G. J. (1999). Impulsivity and cigarette smoking: delay discounting in current, never, and ex-smokers. *Psychopharmacology* **146**: 447–454.
124. Madden, G. J., Bickel, W. K. and Jacobs, E. A. (1999). Discounting of delayed rewards in opioid-dependent outpatients: exponential or hyperbolic discounting functions? *Exp Clin Psychopharmacol* **7**: 284–293.
125. Rogers, R. D., Everitt, B. J., Baldacchino, A., Blackshaw, A. J., Swainson, R., Wynne, K., Baker, N. B., Hunter, J., Carthy, T., Booker, E., London, M., Deakin, J. F., Sahakian, B. J. and Robbins, T. W. (1999). Dissociable deficits in the decision-making cognition of chronic amphetamine abusers, opiate abusers, patients with focal damage to prefrontal cortex, and tryptophan-depleted normal volunteers: evidence for monoaminergic mechanisms. *Neuropsychopharmacology* **20**: 322–339.
126. Heather, N. (1998). A conceptual framework for explaining drug addiction. *J Psychopharmacol* **12**: 3–7.
127. Bozarth, M. A. and Wise, R. A. (1981). Intracranial self-administration of morphine into the ventral tegmental area in rats. *Life Sci* **28**: 2 Feb 551–555.
128. Lamb, R. J., Preston, K. L., Schindler, C. W., Meisch, R. A., Davis, F., Katz, J. L., Henningfield, J. E. and Goldberg, S. R. (1991). The reinforcing and subjective effects of morphine in post-addicts: a dose-response study. *J Pharmacol Exp Ther* **259**: 1165–1173.
129. Volkow, N. D. and Li, T. K. (2004). Science and Society: Drug addiction: the neurobiology of behaviour gone awry. *Nat Rev Neurosci* **5**: 963–970.
130. Phillips, A. G., Ahn, S. and Howland, J. G. (2003). Amygdalar control of the mesocorticolimbic dopamine system: parallel pathways to motivated behavior. *Neurosci Biobehav Rev* **27**: 543–554.
131. White, N. M. (1996). Addictive drugs as reinforcers: multiple partial actions on memory systems. *Addiction* **91**(7): 921–949.
132. Tiffany, S. T. (1990). A cognitive model of drug urges and drug-use-behavior: Role of automatic and nonautomatic processes. *Psychological Review* **97**: 147–168.
133. Grace, A. A. (1995). The tonic/phasic model of dopamine system regulation: its relevance for understanding how stimulant abuse can alter basal ganglia function. *Drug and Alcohol Dependence* **37**: 111–129.
134. Olds, J. and Milner, P. (1954). Positive reinforcement produced by electrical stimulation of septal area and other regions of rat brain. *Journal of Comparative and Physiological Psychology* **47**: 419–427.
135. Fibiger, H. C., LePiane, F. G., Jakubovic, A. and Phillips, A. G. (1987). The role of dopamine in intracranial self-stimulation of the ventral tegmental area. *J Neurosci* **7**: 3888–3896.
136. Reynolds, J. N., Hyland, B. I. and Wickens, J. R. (2001). A cellular mechanism of reward-related learning. *Nature* **413**: 67–70.
137. George, M. S. (2003). Stimulating the brain. *Sci Am* **289**: 66–73.

138. Schneider, F., Habel, U., Volkman, J., Regel, S., Kornischka, J., Sturm, V. and Freund, H. J. (2003). Deep brain stimulation of the subthalamic nucleus enhances emotional processing in Parkinson disease. *Arch Gen Psychiatry* **60**: 296–302.
139. Wise, R. A. (1981). Brain dopamine and reward. In *Theory in Psychopharmacology Volume 1* (Cooper, S. J., ed.), pp. 103–122. Academic Press, London.
140. Wise, R. A. (1982). Neuroleptics and operant behavior: the anhedonia hypothesis. *Behavioral and Brain Sciences* **5**: 39–87.
141. Wise, R. A. and Bozarth, M. A. (1985). Brain mechanisms of drug reward and euphoria. *Psychiatr Med* **3**: 445–460.
142. Schultz, W. and Dickinson, A. (2000). Neuronal coding of prediction errors. *Annual Review of Neuroscience* **23**: 473–500.
143. Schultz, W., Dayan, P. and Montague, P. R. (1997). A neural substrate of prediction and reward. *Science* **275**: 1593–1599.
144. Schultz, W. (1998). Predictive reward signal of dopamine neurons. *J Neurophysiol* **80**: 1–27.
145. Schultz, W., Tremblay, L. and Hollerman, J. R. (1998). Reward prediction in primate basal ganglia and frontal cortex. *Neuropharmacology* **37**: 421–429.
146. Carelli, R. M. and Wightman, R. M. (2004). Functional microcircuitry in the accumbens underlying drug addiction: insights from real-time signaling during behavior. *Curr Opin Neurobiol* **14**: Dec 763–768.
147. Berridge, K. C. and Robinson, T. E. (1998). What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? *Brain Research Reviews* **28**: 309–369.
148. Ito, R., Dalley, J. W., Robbins, T. W. and Everitt, B. J. (2002). Dopamine release in the dorsal striatum during cocaine-seeking behavior under the control of a drug-associated cue. *J Neurosci* **22**: 6247–6253.
149. Young, A. M. (2004). Increased extracellular dopamine in nucleus accumbens in response to unconditioned and conditioned aversive stimuli: studies using 1 min microdialysis in rats. *J Neurosci Methods* **138**: 57–63.
150. Datla, K. P., Ahier, R. G., Young, A. M., Gray, J. A. and Joseph, M. H. N. (2002). Conditioned appetitive stimulus increases extracellular dopamine in the nucleus accumbens of the rat. *Eur J Neurosci* **16**: 1987–1993.
151. Wilson, C., Nomikos, G. G., Collu, M. and Fibiger, H. C. (1995). Dopaminergic correlates of motivated behavior: importance of drive. *J Neurosci* **15**: 5169–5178.
152. Fiorino, D. F., Coury, A., Fibiger, H. C. and Phillips, A. G. (1993). Electrical stimulation of reward sites in the ventral tegmental area increases dopamine transmission in the nucleus accumbens of the rat. *Behav Brain Res* **55**: 131–141.
153. Phillips, G. D., Robbins, T. W. and Everitt, B. J. (1994). Bilateral intra-accumbens self-administration of d-amphetamine: antagonism with intra-accumbens SCH-23390 and sulpiride. *Psychopharmacology (Berl)* **114**: 477–485.
154. Pettit, H. O. and Justice, J. B., Jr. (1989). Dopamine in the nucleus accumbens during cocaine self-administration as studied by in vivo microdialysis. *Pharmacol Biochem Behav* **34**: 899–904.
155. Pettit, H. O., Ettenberg, A., Bloom, F. E. and Koob, G. F. (1984). Destruction of dopamine in the nucleus accumbens selectively attenuates cocaine but not heroin self-administration in rats. *Psychopharmacology (Berl)* **84**: 167–173.
156. Salamone, J. D. and Correa, M. (2002). Motivational views of reinforcement: implications for understanding the behavioral functions of nucleus accumbens dopamine. *Behav Brain Res* **137**: 3–25.
157. Salamone, J. D., Correa, M., Mingote, S. M. and Weber, S. M. (2003). Nucleus accumbens dopamine and the regulation of effort in food-seeking behavior: implications for studies of natural motivation, psychiatry, and drug abuse. *J Pharmacol Exp Ther* **305**: 1–8.
158. Ikemoto, S. and Panksepp, J. (1999). The role of nucleus accumbens dopamine in motivated behavior: a unifying interpretation with special reference to reward-seeking. *Brain Research Reviews* **31**: 6–41.
159. Parkinson, J. A., Dalley, J. W., Cardinal, R. N., Bamford, A., Fehner, B., Lachenal, G., Rudarakanchana, N., Halkerston, K. M., Robbins, T. W. and Everitt, B. J. (2002). Nucleus accumbens dopamine depletion impairs both acquisition and performance of appetitive Pavlovian approach behaviour: implications for mesoaccumbens dopamine function. *Behavioural Brain Research* **137**: 149–163.
160. Dickinson, A., Smith, J. and Mirenowicz, J. (2000). Dissociation of Pavlovian and instrumental incentive learning under dopamine antagonists. *Behavioral Neuroscience* **114**: 468–483.
161. Baker, D. A., Fuchs, R. A., Specio, S. E., Khroyan, T. V. and Neisewander, J. L. (1998). Effects of intraaccumbens administration of SCH-23390 on cocaine-induced locomotion and conditioned place preference. *Synapse* **30**: Oct 181–193.
162. Caine, S. B. and Koob, G. F. (1994). Effects of mesolimbic dopamine depletion on responding maintained by cocaine and food. *J Exp Anal Behav* **61**: Mar 213–221.
163. Robbins, T. W. and Everitt, B. J. (1992). Functions of dopamine in the dorsal and ventral striatum. *Seminars in the Neurosciences* **4**: 119–127.
164. Fibiger, H. C. and Phillips, A. G. (1988). Mesocorticolimbic dopamine systems and reward. *Ann N Y Acad Sci* **537**: 206–215.
165. Ettenberg, A., Pettit, H. O., Bloom, F. E. and Koob, G. F. (1982). Heroin and cocaine intravenous self-administration in rats: mediation by separate neural systems. *Psychopharmacology (Berl)* **78**: 204–209.
166. Horvitz, J. C. (2000). Mesolimbocortical and nigrostriatal dopamine responses to salient non-reward events. *Neuroscience* **96**: 651–656.
167. Salamone, J. D. (1994). The involvement of nucleus accumbens dopamine in appetitive and aversive motivation. *Behavioural Brain Research* **61**: 117–133.
168. Brown, P. L. and Jenkins, H. M. (1968). Auto-shaping of the pigeon's keypeck. *Journal of the Experimental Analysis of Behavior* **11**: 1–8.
169. Parkinson, J. A., Olmstead, M. C., Burns, L. H., Robbins, T. W. and Everitt, B. J. (1999). Dissociation in effects of lesions of the nucleus accumbens core and shell on appetitive Pavlovian approach behavior and the potentiation of conditioned reinforcement and locomotor activity by d-amphetamine. *Journal of Neuroscience* **19**: 2401–2411.
170. Parkinson, J. A., Robbins, T. W. and Everitt, B. J. (1999). Selective excitotoxic lesions of the nucleus accumbens core and shell differentially affect aversive Pavlovian conditioning to discrete and contextual cues. *Psychobiology* **27**: 256–266.
171. Parkinson, J. A., Willoughby, P. J., Robbins, T. W. and Everitt, B. J. (2000). Disconnection of the anterior cingulate cortex and nucleus accumbens core impairs Pavlovian approach behavior: Further evidence for limbic cortical-ventral striatopallidum systems. *Behavioral Neuroscience* **114**: 42–63.
172. Parkinson, J. A., Robbins, T. W. and Everitt, B. J. (2000). Dissociable roles of the central and basolateral amygdala in appetitive emotional learning. *European Journal of Neuroscience* **12**: 405–413.
173. Cardinal, R. N., Parkinson, J. A., Lachenal, G., Halkerston, K. M., Rudarakanchana, N., Hall, J., Morrison, C. H., Howes, S. R., Robbins, T. W. and Everitt, B. J. (2002). Effects of selective excitotoxic lesions of the nucleus accumbens core, anterior cingulate cortex, and central nucleus of the amygdala on autoshaping performance in rats. *Behav Neurosci* **116**: Aug 553–567.
174. Hall, J., Parkinson, J. A., Connor, T. M., Dickinson, A. and Everitt, B. J. (2001). Involvement of the central nucleus of the amygdala and nucleus accumbens core in mediating Pavlovian influences on instrumental behaviour. *European Journal of Neuroscience* **13**: 1984–1992.
175. Pecina, S., Cagniard, B., Berridge, K. C., Aldridge, J. W. and Zhuang, X. (2003). Hyperdopaminergic mutant mice have higher 'wanting' but not 'liking' for sweet rewards. *J Neurosci* **23**: 9395–9402.
176. Pecina, S., Berridge, K. C. and Parker, L. A. (1997). Pimozide does not shift palatability: Separation of anhedonia from sensorimotor suppression by taste reactivity. *Pharmacology Biochemistry and Behavior* **58**: 801–811.
177. Berridge, K. C. (2000). Measuring hedonic impact in animals and infants: microstructure of affective taste reactivity patterns. *Neuroscience and Biobehavioral Reviews* **24**: 173–198.
178. Kelley, A. E. and Berridge, K. C. (2002). The neuroscience of natural rewards: relevance to addictive drugs. *J Neurosci* **22**: 3306–3311.
179. Will, M. J., Franzblau, E. B. and Kelley, A. E. (2003). Nucleus accumbens mu-opioids regulate intake of a high-fat diet via activation of a distributed brain network. *J Neurosci* **23**: 2882–2888.

180. Zhang, M. and Kelley, A. E. (2002). Intake of saccharin, salt, and ethanol solutions is increased by infusion of a mu opioid agonist into the nucleus accumbens. *Psychopharmacology (Berl)* **159**: 415–423.
181. Kelley, A. E., Bakshi, V. P., Haber, S. N., Steininger, T. L., Will, M. J. and Zhang, M. (2002). Opioid modulation of taste hedonics within the ventral striatum. *Physiol Behav* **76**: 365–377.
182. Zhang, M. and Kelley, A. E. (2000). Enhanced intake of high-fat food following striatal mu-opioid stimulation: microinjection mapping and fos expression. *Neuroscience* **99**: 267–277.
183. Zhang, M., Gosnell, B. A. and Kelley, A. E. (1998). Intake of high-fat food is selectively enhanced by mu opioid receptor stimulation within the nucleus accumbens. *Journal of Pharmacology and Experimental Therapeutics* **285**: 908–914.
184. Kelley, A. E., Will, M. J., Steininger, T. L., Zhang, M. and Haber, S. N. (2003). Restricted daily consumption of a highly palatable food (chocolate Ensure(R)) alters striatal enkephalin gene expression. *Eur J Neurosci* **18**: 2592–2598.
185. Reynolds, J. N. and Wickens, J. R. (2002). Dopamine-dependent plasticity of corticostriatal synapses. *Neural Netw* **15**: 507–521.
186. Elliott, R., Newman, J. L., Longe, O. A. and Deakin, J. F. (2003). Differential response patterns in the striatum and orbitofrontal cortex to financial reward in humans: a parametric functional magnetic resonance imaging study. *J Neurosci* **23**: 303–307.
187. Zink, C. F., Pagnoni, G., Martin-Skurski, M. E., Chappelow, J. C. and Berns, G. S. (2004). Human striatal responses to monetary reward depend on saliency. *Neuron* **42**: 509–517.
188. de la Fuente-Fernandez, R., Phillips, A. G., Zamburlini, M., Sossi, V., Calne, D. B., Ruth, T. J. and Stoessl, A. J. N. (2002). Dopamine release in human ventral striatum and expectation of reward. *Behav Brain Res* **136**: 359–363.
189. McClure, S. M., Berns, G. S. and Montague, P. R. (2003). Temporal prediction errors in a passive learning task activate human striatum. *Neuron* **38**: 339–346.
190. Knutson, B., Adams, C. M., Fong, G. W. and Hommer, D. (2001). Anticipation of increasing monetary reward selectively recruits nucleus accumbens. *J Neurosci* **21**: RC159.
191. Breiter, H. C., Aharon, I., Kahneman, D., Dale, A. and Shizgal, P. (2001). Functional imaging of neural responses to expectancy and experience of monetary gains and losses. *Neuron* **30**: May 619–639.
192. Miyazaki, K., Mogi, E., Araki, N. and Matsumoto, G. (1998). Reward-quality dependent anticipation in rat nucleus accumbens. *Neuroreport* **9**: 3943–3948.
193. Schultz, W., Apicella, P., Scarnati, E. and Ljungberg, T. (1992). Neuronal activity in monkey ventral striatum related to the expectation of reward. *Journal of Neuroscience* **12**: 4595–4610.
194. Bjork, J. M., Knutson, B., Fong, G. W., Caggiano, D. M., Bennett, S. M. and Hommer, D. W. (2004). Incentive-elicited brain activation in adolescents: similarities and differences from young adults. *J Neurosci* **24**: 25 Feb 1793–1802.
195. Martin, P. D. and Ono, T. (2000). Effects of reward anticipation, reward presentation, and spatial parameters on the firing of single neurons recorded in the subiculum and nucleus accumbens of freely moving rats. *Behav Brain Res* **116**: 23–38.
196. Cromwell, H. C. and Schultz, W. J. (2003). Effects of expectations for different reward magnitudes on neuronal activity in primate striatum. *J Neurophysiol* **89**: 2823–2838.
197. Schultz, W., Tremblay, L. and Hollerman, J. R. (2000). Reward processing in primate orbitofrontal cortex and basal ganglia. *Cereb Cortex* **10**: 272–284.
198. Schultz, W. (2004). Neural coding of basic reward terms of animal learning theory, game theory, microeconomics and behavioural ecology. *Curr Opin Neurobiol* **14**: 139–147.
199. Fiorillo, C. D., Tobler, P. N. and Schultz, W. (2003). Discrete coding of reward probability and uncertainty by dopamine neurons. *Science* **299**: 1898–1902.
200. Kelley, A. E., Smith-Roe, S. L. and Holahan, M. R. (1997). Response-reinforcement learning is dependent on N-methyl-D-aspartate receptor activation in the nucleus accumbens core. *Proc Natl Acad Sci U S A* **94**: 12174–12179.
201. Baldwin, A. E., Sadeghian, K., Holahan, M. R. and Kelley, A. E. (2002). Appetitive instrumental learning is impaired by inhibition of cAMP-dependent protein kinase within the nucleus accumbens. *Neurobiol Learn Mem* **77**: Jan 44–62.
202. Smith-Roe, S. L. and Kelley, A. E. (2000). Coincident activation of NMDA and dopamine D1 receptors within the nucleus accumbens core is required for appetitive instrumental learning. *J Neurosci* **20**: 7737–7742.
203. Hernandez, P. J., Sadeghian, K. and Kelley, A. E. (2002). Early consolidation of instrumental learning requires protein synthesis in the nucleus accumbens. *Nat Neurosci* **5**: 1327–1331.
204. Corbit, L. H., Muir, J. L. and Balleine, B. W. (2001). The role of the nucleus accumbens in instrumental conditioning: evidence of a functional dissociation between accumbens core and shell. *Journal of Neuroscience* **21**: 3251–3260.
205. de Borchgrave, R., Rawlins, J. N., Dickinson, A. and Balleine, B. W. M. (2002). Effects of cytotoxic nucleus accumbens lesions on instrumental conditioning in rats. *Exp Brain Res* **144**: 50–68.
206. Balleine, B. and Killcross, S. (1994). Effects of ibotenic acid lesions of the nucleus accumbens on instrumental action. *Behavioural Brain Research* **65**: 181–193.
207. Cardinal, R. N., Pennicott, D. R., Sugrathapala, C. L., Robbins, T. W. and Everitt, B. J. (2001). Impulsive choice induced in rats by lesions of the nucleus accumbens core. *Science* **292**: 2499–2501.
208. Cardinal, R. N. and Cheung, T. H. C. (2005). Nucleus accumbens core lesions retard instrumental learning and performance with delayed reinforcement in the rat. *BMC Neuroscience* **6**: 9.
209. Wyvell, C. L. and Berridge, K. C. (2000). Intra-accumbens amphetamine increases the conditioned incentive salience of sucrose reward: enhancement of reward 'wanting' without enhanced 'liking' or response reinforcement. *Journal of Neuroscience* **20**: 8122–8130.
210. Burns, L. H., Everitt, B. J., Kelley, A. E. and Robbins, T. W. (1994). Glutamate–dopamine interactions in the ventral striatum: role in locomotor activity and responding with conditioned reinforcement. *Psychopharmacology (Berl)* **115**: 516–528.
211. Cador, M., Robbins, T. W. and Everitt, B. J. (1989). Involvement of the amygdala in stimulus–reward associations: interaction with the ventral striatum. *Neuroscience* **30**: 77–86.
212. Everitt, B. J. and Robbins, T. W. (2000). Second-order schedules of drug reinforcement in rats and monkeys: measurement of reinforcing efficacy and drug-seeking behaviour. *Psychopharmacology (Berl)* **153**: 17–30.
213. Mogenson, G. J., Jones, D. L. and Yim, C. Y. (1980). From motivation to action: functional interface between the limbic system and the motor system. *Progress in Neurobiology* **14**: 69–97.
214. Knutson, B., Burgdorf, J. and Panksepp, J. (1999). High-frequency ultrasonic vocalizations index conditioned pharmacological reward in rats. *Physiology and Behavior* **66**: 639–643.
215. Balleine, B. W. and Dickinson, A. (1998). Goal-directed instrumental action: contingency and incentive learning and their cortical substrates. *Neuropharmacology* **37**: 407–419.
216. Corbit, L. H. and Balleine, B. W. N. (2003). The role of prelimbic cortex in instrumental conditioning. *Behav Brain Res* **146**: 145–157.
217. Baldwin, A. E., Sadeghian, K. and Kelley, A. E. (2002). Appetitive instrumental learning requires coincident activation of NMDA and dopamine D1 receptors within the medial prefrontal cortex. *J Neurosci* **22**: 1 Feb 1063–1071.
218. Myers, K. M. and Davis, M. (2002). Behavioral and neural analysis of extinction. *Neuron* **36**: 567–584.
219. Mackintosh, N. J. (1974). *The Psychology of Animal Learning*. Academic Press, London.
220. Delamater, A. R. A. (2004). Experimental extinction in Pavlovian conditioning: behavioural and neuroscience perspectives. *Q J Exp Psychol B* **57**: 97–132.
221. Morgan, M. A., Romanski, L. M. and LeDoux, J. E. (1993). Extinction of emotional learning: contribution of medial prefrontal cortex. *Neurosci Lett* **163**: 109–113.

222. Morgan, M. A. and LeDoux, J. E. (1995). Differential contribution of dorsal and ventral medial prefrontal cortex to the acquisition and extinction of conditioned fear in rats. *Behavioral Neuroscience* **109**: 681–688.
223. Morgan, M. A. and LeDoux, J. E. (1999). Contribution of ventrolateral prefrontal cortex to the acquisition and extinction of conditioned fear in rats. *Neurobiol Learn Mem* **72**: 244–251.
224. LeDoux, J. E. (2000). The amygdala and emotion: a view through fear. In *The amygdala: a functional analysis*, 2nd edition (Aggleton, J. P., ed.), pp. 289–310. Oxford University Press, New York.
225. Davis, M. (2000). The role of the amygdala in conditioned and unconditioned fear and anxiety. In *The amygdala: a functional analysis*, 2nd edition (Aggleton, J. P., ed.), pp. 213–287. Oxford University Press, New York.
226. Garcia, R., Vouimba, R. M., Baudry, M. and Thompson, R. F. (1999). The amygdala modulates prefrontal cortex activity relative to conditioned fear. *Nature* **402**: 294–296.
227. Rosenkranz, J. A., Moore, H. and Grace, A. A. (2003). The prefrontal cortex regulates lateral amygdala neuronal plasticity and responses to previously conditioned stimuli. *J Neurosci* **23**: 11054–11064.
228. Quirk, G. J., Likhtik, E., Pelletier, J. G. and Pare, D. (2003). Stimulation of medial prefrontal cortex decreases the responsiveness of central amygdala output neurons. *J Neurosci* **23**: 8800–8807.
229. Pickens, C. L., Sadoris, M. P., Setlow, B., Gallagher, M., Holland, P. C. and Schoenbaum, G. (2003). Different roles for orbitofrontal cortex and basolateral amygdala in a reinforcer devaluation task. *J Neurosci* **23**: 11078–11084.
230. Lindgren, J. L., Gallagher, M. and Holland, P. C. (2003). Lesions of basolateral amygdala impair extinction of CS motivational value, but not of explicit conditioned responses, in Pavlovian appetitive second-order conditioning. *European Journal of Neuroscience* **17**: 160–166.
231. Balleine, B. W., Killcross, A. S. and Dickinson, A. (2003). The effect of lesions of the basolateral amygdala on instrumental conditioning. *J Neurosci* **23**: 15 Jan 666–675.
232. O'Doherty, J. P. (2004). Reward representations and reward-related learning in the human brain: insights from neuroimaging. *Curr Opin Neurobiol* **14**: 769–776.
233. Gottfried, J. A. and Dolan, R. J. (2004). Human orbitofrontal cortex mediates extinction learning while accessing conditioned representations of value. *Nat Neurosci* **7**: 1144–1152.
234. Parkinson, J. A., Cardinal, R. N. and Everitt, B. J. (2000). Limbic cortical-ventral striatal systems underlying appetitive conditioning. *Progress in Brain Research* **126**: 263–285.
235. Everitt, B. J., Cardinal, R. N., Hall, J., Parkinson, J. A. and Robbins, T. W. (2000). Differential involvement of amygdala subsystems in appetitive conditioning and drug addiction. In *The amygdala: a functional analysis*, 2nd edition (Aggleton, J. P., ed.), pp. 353–390. Oxford University Press, New York.
236. Pitkänen, A. (2000). Connectivity of the rat amygdaloid complex. In *The amygdala: a functional analysis*, 2nd edition (Aggleton, J. P., ed.), pp. 31–115. Oxford University Press, New York.
237. Coutureau, E., Dix, S. L. and Killcross, A. S. (2000). Involvement of the medial prefrontal cortex-basolateral amygdala pathway in fear-related behaviour in rats. *European Journal of Neuroscience* **12** (supplement 11): 156.
238. Holland, P. C. and Gallagher, M. (2004). Amygdala–frontal interactions and reward expectancy. *Curr Opin Neurobiol* **14**: 148–155.
239. Gottfried, J. A., O'Doherty, J. and Dolan, R. J. (2003). Encoding predictive reward value in human amygdala and orbitofrontal cortex. *Science* **301**: 1104–1107.
240. Arana, F. S., Parkinson, J. A., Hinton, E., Holland, A. J., Owen, A. M. and Roberts, A. C. (2003). Dissociable contributions of the human amygdala and orbitofrontal cortex to incentive motivation and goal selection. *J Neurosci* **23**: 22 Oct, 9632–9638.
241. Pavlov, I. P. (1927). *Conditioned Reflexes*, Oxford University Press, Oxford.
242. Di Chiara, G. (2002). Nucleus accumbens shell and core dopamine: differential role in behavior and addiction. *Behav Brain Res* **137**: 75–114.
243. Di Chiara, G. (1998). A motivational learning hypothesis of the role of mesolimbic dopamine in compulsive drug use. *Journal of Psychopharmacology* **12**: 54–67.
244. Cador, M., Bjiou, Y. and Stinus, L. (1995). Evidence of a complete independence of the neurobiological substrates for the induction and expression of behavioral sensitization to amphetamine. *Neuroscience* **65**: 385–395.
245. Harmer, C. J. and Phillips, G. D. (1999). Enhanced dopamine efflux in the amygdala by a predictive, but not a non-predictive, stimulus: Facilitation by prior repeated D-amphetamine. *Neuroscience* **90**: 119–130.
246. Taylor, J. R. and Horger, B. A. (1999). Enhanced responding for conditioned reward produced by intra-accumbens amphetamine is potentiated after cocaine sensitization. *Psychopharmacology* **142**: 31–40.
247. Hutcheson, D. M., Parkinson, J. A., Robbins, T. W. and Everitt, B. J. (2001). The effects of nucleus accumbens core and shell lesions on intravenous heroin self-administration and the acquisition of drug-seeking behaviour under a second-order schedule of heroin reinforcement. *Psychopharmacology (Berl)* **153**: 464–472.
248. Di Ciano, P. and Everitt, B. J. (2001). Dissociable effects of antagonism of NMDA and AMPA/KA receptors in the nucleus accumbens core and shell on cocaine-seeking behavior. *Neuropsychopharmacology* **25**: 341–360.
249. Sokoloff, P., Giros, B., Martres, M. P., Bouthenet, M. L. and Schwartz, J. C. (1990). Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. *Nature* **347**: 146–151.
250. Di Ciano, P., Underwood, R. J., Hagan, J. J. and Everitt, B. J. (2003). Attenuation of cue-controlled cocaine-seeking by a selective D3 dopamine receptor antagonist SB-277011-A. *Neuropsychopharmacology* **28**: 329–338.
251. Vorel, S. R., Ashby, C. R., Jr., Paul, M., Liu, X., Hayes, R., Hagan, J. J., Middlemiss, D. N., Stemp, G. and Gardner, E. L. (2002). Dopamine D3 receptor antagonism inhibits cocaine-seeking and cocaine-enhanced brain reward in rats. *J Neurosci* **22**: 9595–9603.
252. Pilla, M., Perachon, S., Sautel, F., Garrido, F., Mann, A., Wermuth, C. G., Schwartz, J. C., Everitt, B. J. and Sokoloff, P. (1999). Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist. *Nature* **400**: 371–375.
253. Cervo, L., Carnovali, F., Stark, J. A. and Mennini, T. (2003). Cocaine-seeking behavior in response to drug-associated stimuli in rats: involvement of D3 and D2 dopamine receptors. *Neuropsychopharmacology* **28**: Jun 1150–1159.
254. Sax, K. W. and Strakowski, S. M. (2001). Behavioral sensitization in humans. *J Addict Dis* **20**: 55–65.
255. Olausson, P., Jentsch, J. D. and Taylor, J. R. (2003). Repeated Nicotine Exposure Enhances Reward-Related Learning in the Rat. *Neuropsychopharmacology* **28**: 1264–1271.
256. American Psychiatric Association (2000). *Diagnostic and Statistical Manual of Mental Disorders*, 4th edition, text revision (DSM-IV-TR), American Psychiatric Association, Washington DC.
257. Vezina, P. (2004). Sensitization of midbrain dopamine neuron reactivity and the self-administration of psychomotor stimulant drugs. *Neurosci Biobehav Rev* **27**: 827–839.
258. Taylor, J. R. and Robbins, T. W. (1984). Enhanced behavioural control by conditioned reinforcers following microinjections of d-amphetamine into the nucleus accumbens. *Psychopharmacology* **84**: 405–412.
259. Kruzich, P. J., Congleton, K. M. and See, R. E. (2001). Conditioned reinstatement of drug-seeking behavior with a discrete compound stimulus classically conditioned with intravenous cocaine. *Behav Neurosci* **115**: 1086–1092.
260. Deroche-Gamonet, V., Piat, F., Le Moal, M. and Piazza, P. V. (2002). Influence of cue-conditioning on acquisition, maintenance and relapse of cocaine intravenous self-administration. *Eur J Neurosci* **15**: 1363–1370.
261. Di Ciano, P. and Everitt, B. J. (2003). Differential control over drug-seeking behavior by drug-associated conditioned reinforcers and discriminative stimuli predictive of drug availability. *Behav Neurosci* **117**: 952–960.

262. Parkinson, J. A., Roberts, A. C., Everitt, B. J. and Di Ciano, P. (2005). Acquisition of instrumental conditioned reinforcement is resistant to the devaluation of the unconditioned stimulus. *The Quarterly Journal of Experimental Psychology* **58B**: 19–30.
263. Semenova, S. and Markou, A. (2003). Cocaine-seeking behavior after extended cocaine-free periods in rats: role of conditioned stimuli. *Psychopharmacology (Berl)* **168**: 192–200.
264. Caggiula, A. R., Donny, E. C., White, A. R., Chaudhri, N., Booth, S., Gharib, M. A., Hoffman, A., Perkins, K. A. and Sved, A. F. (2002). Environmental stimuli promote the acquisition of nicotine self-administration in rats. *Psychopharmacology (Berl)* **163**: Sep 230–237.
265. Shahan, T. A. (2002). The observing-response procedure: a novel method to study drug-associated conditioned reinforcement. *Exp Clin Psychopharmacol* **10**: 3–9.
266. Shahan, T. A., Magee, A. and Dobberstein, A. (2003). The resistance to change of observing. *J Exp Anal Behav* **80**: 273–293.
267. Di Ciano, P. and Everitt, B. J. (2004). Conditioned reinforcing properties of stimuli paired with self-administered cocaine, heroin or sucrose. *Neuropharmacology* **47**: 202–213.
268. Whitelaw, R. B., Markou, A., Robbins, T. W. and Everitt, B. J. (1996). Excitotoxic lesions of the basolateral amygdala impair the acquisition of cocaine-seeking behaviour under a second-order schedule of reinforcement. *Psychopharmacology* **127**: 213–224.
269. Ito, R., Robbins, T. W. and Everitt, B. J. (2004). Differential control over drug seeking behavior by nucleus accumbens core and shell. *Nature Neuroscience* **17**: 389–397.
270. Di Ciano, P. and Everitt, B. J. (2004). Direct interactions between the basolateral amygdala and nucleus accumbens core underlie cocaine seeking behavior by rats. *The Journal of Neuroscience* **24**: 7167–7173.
271. Grant, S., London, E. D., Newlin, D. B., Villemagne, V. L., Liu, X., Contoreggi, C., Phillips, R. L., Kimes, A. S. and Margolin, A. (1996). Activation of memory circuits during cue-elicited cocaine craving. *Proc Natl Acad Sci U S A* **93**: 12040–12045.
272. Childress, A. R., Mozley, P. D., McElgin, W., Fitzgerald, J., Reivich, M. and O'Brien, C. P. (1999). Limbic activation during cue-induced cocaine craving. *American Journal of Psychiatry* **156**: 11–18.
273. Sell, L. A., Morris, J., Bearn, J., Frackowiak, R. S., Friston, K. J. and Dolan, R. J. (1999). Activation of reward circuitry in human opiate addicts. *Eur J Neurosci* **11**: 1042–1048.
274. Garavan, H., Pankiewicz, J., Bloom, A., Cho, J. K., Sperry, L., Ross, T. J., Salmeron, B. J., Risinger, R., Kelley, D. and Stein, E. A. (2000). Cue-induced cocaine craving: Neuroanatomical specificity for drug users and drug stimuli. *American Journal of Psychiatry* **157**: 1789–1798.
275. Packard, M. G. and McGaugh, J. L. (1996). Inactivation of hippocampus or caudate nucleus with lidocaine differentially affects expression of place and response learning. *Neurobiology of Learning and Memory* **65**: 65–72.
276. Killcross, A. S. and Coutureau, E. (2003). Coordination of actions and habits in the medial prefrontal cortex of rats. *Cerebral Cortex* **13**: 400–408.
277. O'Doherty, J., Dayan, P., Schultz, J., Deichmann, R., Friston, K. and Dolan, R. J. (2004). Dissociable roles of ventral and dorsal striatum in instrumental conditioning. *Science* **304**: 452–454.
278. Ito, R., Dalley, J. W., Howes, S. R., Robbins, T. W. and Everitt, B. J. (2000). Dissociation in conditioned dopamine release in the nucleus accumbens core and shell in response to cocaine cues and during cocaine-seeking behavior in rats. *Journal of Neuroscience* **20**: 7489–7495.
279. Nader, M. A., Daunais, J. B., Moore, T., Nader, S. H., Moore, R. J., Smith, H. R., Friedman, D. P. and Porrino, L. J. (2002). Effects of cocaine self-administration on striatal dopamine systems in rhesus monkeys: Initial and chronic exposure. *Neuropsychopharmacology* **27**: 35–46.
280. Porrino, L. J., Lyons, D., Smith, H. R., Daunais, J. B. and Nader, M. A. (2004). Cocaine self-administration produces a progressive involvement of limbic, association, and sensorimotor striatal domains. *J Neurosci* **24**: 3554–3562.
281. Haber, S. N., Fudge, J. L. and McFarland, N. R. (2000). Striatonigrostriatal pathways in primates form an ascending spiral from the shell to the dorsolateral striatum. *Journal of Neuroscience* **20**: 2369–2382.
282. Shaham, Y., Shalev, U., Lu, L., De Wit, H. and Stewart, J. (2003). The reinstatement model of drug relapse: history, methodology and major findings. *Psychopharmacology (Berl)* **168**: 3–20.
283. O'Brien, C. P., Childress, A. R., McLellan, T. and Ehrman, R. (1990). Integrating systemic cue exposure with standard treatment in recovering drug dependent patients. *Addict Behav* **15**: 355–365.
284. O'Brien, C., Childress, A. R., Ehrman, R., Robbins, S. and McLellan, A. T. (1992). Conditioning mechanisms in drug dependence. *Clin Neuropharmacol* **15 Suppl 1 Pt A**: 66A–67A.
285. Kalivas, P. W. and McFarland, K. (2003). Brain circuitry and the reinstatement of cocaine-seeking behavior. *Psychopharmacology (Berl)* **168**: 44–56.
286. Kalivas, P. W., McFarland, K., Bowers, S., Szumlinski, K., Xi, Z. X. and Baker, D. (2003). Glutamate transmission and addiction to cocaine. *Ann N Y Acad Sci* **1003**: 169–175.
287. Meil, W. M. and See, R. E. (1997). Lesions of the basolateral amygdala abolish the ability of drug associated cues to reinstate responding during withdrawal from self-administered cocaine. *Behavioural Brain Research* **87**: 139–148.
288. Fuchs, R. A., Evans, K. A., Parker, M. P. and See, R. E. (2004). Differential involvement of orbitofrontal cortex subregions in conditioned cue-induced and cocaine-primed reinstatement of cocaine seeking in rats. *J Neurosci* **24**: 6600–6610.
289. Ciccocioppo, R., Sanna, P. P. and Weiss, F. (2001). Cocaine-predictive stimulus induces drug-seeking behavior and neural activation in limbic brain regions after multiple months of abstinence: reversal by D(1) antagonists. *Proc Natl Acad Sci U S A* **98**: 1976–1981.
290. See, R. E., Kruzich, P. J. and Grimm, J. W. (2001). Dopamine, but not glutamate, receptor blockade in the basolateral amygdala attenuates conditioned reward in a rat model of relapse to cocaine-seeking behavior. *Psychopharmacology (Berl)* **154**: 301–310.
291. Vorel, S. R., Liu, X., Hayes, R. J., Spector, J. A. and Gardner, E. L. (2001). Relapse to cocaine-seeking after hippocampal theta burst stimulation. *Science* **292**: 1175–1178.
292. Fuchs, R. A., Evans, K. A., Ledford, C. C., Parker, M. P., Case, J. M., Mehta, R. H. and See, R. E. (2005). The role of the dorsomedial prefrontal cortex, basolateral amygdala, and dorsal hippocampus in contextual reinstatement of cocaine seeking in rats. *Neuropsychopharmacology* **30**: 296–309.
293. McDonald, R. J. and White, N. M. (1993). A triple dissociation of memory systems: hippocampus, amygdala, and dorsal striatum. *Behavioral Neuroscience* **107**: 3.
294. Selden, N. R., Everitt, B. J., Jarrard, L. E. and Robbins, T. W. (1991). Complementary roles for the amygdala and hippocampus in aversive conditioning to explicit and contextual cues. *Neuroscience* **42**: 335–350.
295. Blaha, C. D., Yang, C. R., Floresco, S. B., Barr, A. M. and Phillips, A. G. (1997). Stimulation of the ventral subiculum of the hippocampus evokes glutamate receptor-mediated changes in dopamine efflux in the rat nucleus accumbens. *Eur J Neurosci* **9**: May 902–911.
296. Di Ciano, P., Blaha, C. D. and Phillips, A. G. (1998). Conditioned changes in dopamine oxidation currents in the nucleus accumbens of rats by stimuli paired with self-administration or yoked-administration of d-amphetamine. *Eur J Neurosci* **10**: 1121–1127.
297. Floresco, S. B., Todd, C. L. and Grace, A. A. (2001). Glutamatergic afferents from the hippocampus to the nucleus accumbens regulate activity of ventral tegmental area dopamine neurons. *J Neurosci* **21**: 4915–4922.
298. O'Donnell, P. and Grace, A. A. (1995). Synaptic interactions among excitatory afferents to nucleus accumbens neurons: hippocampal gating of prefrontal cortical input. *J Neurosci* **15**: 3622–3639.
299. Pennartz, C. M., McNaughton, B. L. and Mulder, A. B. (2000). The glutamate hypothesis of reinforcement learning. *Prog Brain Res* **126**: 231–253.

300. McFarland, K. and Kalivas, P. W. (2001). The circuitry mediating cocaine-induced reinstatement of drug-seeking behavior. *J Neurosci* **21**: 8655–8663.
301. Grimm, J. W., Hope, B. T., Wise, R. A. and Shaham, Y. (2001). Neuroadaptation. Incubation of cocaine craving after withdrawal. *Nature* **412**: 141–142.
302. Lu, L., Hope, B. T., Dempsey, J., Liu, S. Y., Bossert, J. M. and Shaham, Y. (2005). Central amygdala ERK signaling pathway is critical to incubation of cocaine craving. *Nat Neurosci* **8**: 212–219.
303. Shaham, Y. and Stewart, J. (1996). Effects of opioid and dopamine receptor antagonists on relapse induced by stress and re-exposure to heroin in rats. *Psychopharmacology (Berl)* **125**: 385–391.
304. Cornish, J. L., Duffy, P. and Kalivas, P. W. (1999). A role for nucleus accumbens glutamate transmission in the relapse to cocaine-seeking behavior. *Neuroscience* **93**: 1359–1367.
305. Cornish, J. L. and Kalivas, P. W. (2000). Glutamate transmission in the nucleus accumbens mediates relapse in cocaine addiction. *The Journal of Neuroscience* **20**: RC89 81–85.
306. Self, D. W. and Nestler, E. J. (1998). Relapse to drug-seeking: neural and molecular mechanisms. *Drug Alcohol Depend* **51**: 49–60.
307. Stewart, J. and Vezina, P. (1988). A comparison of the effects of intra-accumbens injections of amphetamine and morphine on reinstatement of heroin intravenous self-administration behavior. *Brain Res* **457**: 287–294.
308. Le, A. D., Poulos, C. X., Harding, S., Watchus, J., Juzysch, W. and Shaham, Y. (1999). Effects of naltrexone and fluoxetine on alcohol self-administration and reinstatement of alcohol seeking induced by priming injections of alcohol and exposure to stress. *Neuropsychopharmacology* **21**: 435–444.
309. De Vries, T. J., Shaham, Y., Homberg, J. R., Crombag, H., Schuurman, K., Dieben, J., Vanderschuren, L. J. and Schoffelmeer, A. N. O. (2001). A cannabinoid mechanism in relapse to cocaine seeking. *Nat Med* **7**: 1151–1154.
310. McFarland, K., Davidge, S. B., Lapish, C. C. and Kalivas, P. W. (2004). Limbic and motor circuitry underlying footshock-induced reinstatement of cocaine-seeking behavior. *J Neurosci* **24**: 1551–1560.
311. Aston-Jones, G., Delfs, J. M., Druhan, J. and Zhu, Y. (1999). The bed nucleus of the stria terminalis. A target site for noradrenergic actions in opiate withdrawal. *Ann N Y Acad Sci* **877**: 29 Jun 486–498.
312. Shaham, Y., Erb, S. and Stewart, J. (2000). Stress-induced relapse to heroin and cocaine seeking in rats: a review. *Brain Research Reviews* **33**: 13.
313. Shaham, Y., Highfield, D., Delfs, J., Leung, S. and Stewart, J. (2000). Clonidine blocks stress-induced reinstatement of heroin seeking in rats: an effect independent of locus coeruleus noradrenergic neurons. *Eur J Neurosci* **12**: 292–302.
314. Brebner, K., Childress, A. R. and Roberts, D. C. (2002). A potential role for GABA(B) agonists in the treatment of psychostimulant addiction. *Alcohol Alcohol* **37**: Sep–Oct 478–484.
315. Koob, G. F. and Nestler, E. J. (1997). The neurobiology of drug addiction. *Journal of Neuropsychiatry and Clinical Neurosciences* **9**: 482–497.
316. Asher, O., Cunningham, T. D., Yao, L., Gordon, A. S. and Diamond, I. (2002). Ethanol stimulates cAMP-responsive element (CRE)-mediated transcription via CRE-binding protein and cAMP-dependent protein kinase. *J Pharmacol Exp Ther* **301**: Apr 66–70.
317. Carlezon, W. A., Jr., Thome, J., Olson, V. G., Lane-Ladd, S. B., Brodtkin, E. S., Hiroi, N., Duman, R. S., Neve, R. L. and Nestler, E. J. (1998). Regulation of cocaine reward by CREB. *Science* **282**: 18 Dec 2272–2275.
318. Cole, R. L., Konradi, C., Douglass, J. and Hyman, S. E. A. (1995). Neuronal adaptation to amphetamine and dopamine: molecular mechanisms of prodynorphin gene regulation in rat striatum. *Neuron* **14**: 813–823.
319. Duman, R. S., Tallman, J. F. and Nestler, E. J. (1988). Acute and chronic opiate-regulation of adenylate cyclase in brain: specific effects in locus coeruleus. *J Pharmacol Exp Ther* **246**: 1033–1039.
320. Guitart, X., Thompson, M. A., Mirante, C. K., Greenberg, M. E. and Nestler, E. J. (1992). Regulation of cyclic AMP response element-binding protein (CREB) phosphorylation by acute and chronic morphine in the rat locus coeruleus. *J Neurochem* **58**: 1168–1171.
321. Konradi, C., Cole, R. L., Heckers, S. and Hyman, S. E. (1994). Amphetamine regulates gene expression in rat striatum via transcription factor CREB. *J Neurosci* **14**: 5623–5634.
322. Ortiz, J., Fitzgerald, L. W., Charlton, M., Lane, S., Trevisan, L., Guitart, X., Shoemaker, W., Duman, R. S. and Nestler, E. J. (1995). Biochemical actions of chronic ethanol exposure in the mesolimbic dopamine system. *Synapse* **21**: 289–298.
323. Rubino, T., Vigano, D., Massi, P., Spinello, M., Zagato, E., Giagnoni, G. and Parolaro, D. (2000). Chronic delta-9-tetrahydrocannabinol treatment increases cAMP levels and cAMP-dependent protein kinase activity in some rat brain regions. *Neuropharmacology* **39**: 1331–1336.
324. Shaw-Lutchman, T. Z., Impey, S., Storm, D. and Nestler, E. J. (2003). Regulation of CRE-mediated transcription in mouse brain by amphetamine. *Synapse* **48**: 10–17.
325. Terwilliger, R. Z., Beitner-Johnson, D., Sevarino, K. A., Crain, S. M. and Nestler, E. J. (1991). A general role for adaptations in G-proteins and the cyclic AMP system in mediating the chronic actions of morphine and cocaine on neuronal function. *Brain Res* **548**: 100–110.
326. Turgeon, S. M., Pollack, A. E. and Fink, J. S. (1997). Enhanced CREB phosphorylation and changes in c-Fos and FRA expression in striatum accompany amphetamine sensitization. *Brain Res* **749**: 120–126.
327. Unterwald, E. M., Cox, B. M., Kreek, M. J., Cote, T. E. and Izenwasser, S. (1993). Chronic repeated cocaine administration alters basal and opioid-regulated adenylyl cyclase activity. *Synapse* **15**: 33–38.
328. De Cesare, D. and Sassone-Corsi, P. (2000). Transcriptional regulation by cyclic AMP-responsive factors. *Prog Nucleic Acid Res Mol Biol* **64**: 343–369.
329. Shaywitz, A. J. and Greenberg, M. E. (1999). CREB: a stimulus-induced transcription factor activated by a diverse array of extracellular signals. *Annu Rev Biochem* **68**: 821–861.
330. Childers, S. R. (1991). Opioid receptor-coupled second messenger systems. *Life Sci* **48**: 1991–2003.
331. Dill, J. A. and Howlett, A. C. (1988). Regulation of adenylate cyclase by chronic exposure to cannabimimetic drugs. *J Pharmacol Exp Ther* **244**: 1157–1163.
332. Yang, X., Diehl, A. M. and Wand, G. S. (1996). Ethanol exposure alters the phosphorylation of cyclic AMP responsive element binding protein and cyclic AMP responsive element binding activity in rat cerebellum. *J Pharmacol Exp Ther* **278**: 338–346.
333. Pliakas, A. M., Carlson, R. R., Neve, R. L., Konradi, C., Nestler, E. J. and Carlezon, W. A., Jr. (2001). Altered responsiveness to cocaine and increased immobility in the forced swim test associated with elevated cAMP response element-binding protein expression in nucleus accumbens. *J Neurosci* **21**: 7397–7403.
334. Self, D. W., Genova, L. M., Hope, B. T., Barnhart, W. J., Spencer, J. J. and Nestler, E. J. (1998). Involvement of cAMP-dependent protein kinase in the nucleus accumbens in cocaine self-administration and relapse of cocaine-seeking behavior. *J Neurosci* **18**: 1848–1859.
335. Watts, V. J. (2002). Molecular mechanisms for heterologous sensitization of adenylate cyclase. *J Pharmacol Exp Ther* **302**: 1–7.
336. Liu, J. G. and Anand, K. J. (2001). Protein kinases modulate the cellular adaptations associated with opioid tolerance and dependence. *Brain Res Brain Res Rev* **38**: 1–19.
337. Chao, J. R., Ni, Y. G., Bolanos, C. A., Rahman, Z., DiLeone, R. J. and Nestler, E. J. (2002). Characterization of the mouse adenylyl cyclase type VIII gene promoter: regulation by cAMP and CREB. *Eur J Neurosci* **16**: Oct 1284–1294.
338. Daunais, J. B. and McGinty, J. F. S. (1994). Acute and chronic cocaine administration differentially alters striatal opioid and nuclear transcription factor mRNAs. *Synapse* **18**: 35–45.

339. Lane-Ladd, S. B., Pineda, J., Boundy, V. A., Pfeuffer, T., Krupinski, J., Aghajanian, G. K. and Nestler, E. J. (1997). CREB (cAMP response element-binding protein) in the locus coeruleus: biochemical, physiological, and behavioral evidence for a role in opiate dependence. *J Neurosci* **17**: 7890–7901.
340. Shippenberg, T. S. and Rea, W. (1997). Sensitization to the behavioral effects of cocaine: modulation by dynorphin and kappa-opioid receptor agonists. *Pharmacol Biochem Behav* **57**: 449–455.
341. Hurd, Y. L. and Herkenham, M. (1993). Molecular alterations in the neostriatum of human cocaine addicts. *Synapse* **13**: 357–369.
342. Vanderschuren, L. J. M. J. and Kalivas, P. W. (2000). Alterations in dopaminergic and glutamatergic transmission in the induction and expression of behavioral sensitization: a critical review of preclinical studies. *Psychopharmacology* **151**: 99–120.
343. Churchill, L., Swanson, C. J., Urbina, M. and Kalivas, P. W. (1999). Repeated cocaine alters glutamate receptor subunit levels in the nucleus accumbens and ventral tegmental area of rats that develop behavioral sensitization. *J Neurochem* **72**: Jun 2397–2403.
344. Henry, D. J. and White, F. J. (1995). The persistence of behavioral sensitization to cocaine parallels enhanced inhibition of nucleus accumbens neurons. *J Neurosci* **15**: 6287–6299.
345. Thomas, M. J., Beurrier, C., Bonci, A. and Malenka, R. C. (2001). Long-term depression in the nucleus accumbens: a neural correlate of behavioral sensitization to cocaine. *Nat Neurosci* **4**: 1217–1223.
346. Carlezon, W. A., Jr. and Nestler, E. J. (2002). Elevated levels of GluR1 in the midbrain: a trigger for sensitization to drugs of abuse? *Trends Neurosci* **25**: Dec 610–615.
347. Licata, S. C. and Pierce, R. C. (2003). The roles of calcium/calmodulin-dependent and Ras/mitogen-activated protein kinases in the development of psychostimulant-induced behavioral sensitization. *J Neurochem* **85**: 14–22.
348. Seger, R. and Krebs, E. G. (1995). The MAPK signaling cascade. *Faseb J* **9**: 726–735.
349. Pierce, R. C., Pierce-Bancroft, A. F. and Prasad, B. M. (1999). Neurotrophin-3 contributes to the initiation of behavioral sensitization to cocaine by activating the Ras/Mitogen-activated protein kinase signal transduction cascade. *J Neurosci* **19**: 8685–8695.
350. Szumlanski, K. K., Dehoff, M. H., Kang, S. H., Frys, K. A., Lominac, K. D., Klugmann, M., Rohrer, J., Griffin, W., 3rd, Toda, S., Champiaux, N. P., Berry, T., Tu, J. C., Shealy, S. E., Duman, M. J., Middaugh, L. D., Worley, P. F. and Kalivas, P. W. (2004). Homer proteins regulate sensitivity to cocaine. *Neuron* **43**: 401–413.
351. Ghasemzadeh, M. B., Permenter, L. K., Lake, R. W. and Kalivas, P. W. (2003). Nucleus accumbens Homer proteins regulate behavioral sensitization to cocaine. *Ann N Y Acad Sci* **1003**: 395–397.
352. Hope, B. T., Nye, H. E., Kelz, M. B., Self, D. W., Iadarola, M. J., Nakabeppu, Y., Duman, R. S. and Nestler, E. J. (1994). Induction of a long-lasting AP-1 complex composed of altered Fos-like proteins in brain by chronic cocaine and other chronic treatments. *Neuron* **13**: 1235–1244.
353. Moratalla, R., Elibol, B., Vallejo, M. and Graybiel, A. M. (1996). Network-level changes in expression of inducible Fos-Jun proteins in the striatum during chronic cocaine treatment and withdrawal. *Neuron* **17**: 147–156.
354. Nye, H. E. and Nestler, E. J. (1996). Induction of chronic Fos-related antigens in rat brain by chronic morphine administration. *Mol Pharmacol* **49**: 636–645.
355. Nestler, E. J. (2001). Molecular basis of long-term plasticity underlying addiction. *Nat Rev Neurosci* **2**: 119–128.
356. Kelz, M. B., Chen, J., Carlezon, W. A., Jr., Whisler, K., Gilden, L., Beckmann, A. M., Steffen, C., Zhang, Y. J., Marotti, L., Self, D. W., Tkatch, T., Baranaukas, G., Surmeier, D. J., Neve, R. L., Duman, R. S., Picciotto, M. R. and Nestler, E. J. (1999). Expression of the transcription factor deltaFosB in the brain controls sensitivity to cocaine. *Nature* **401**: 272–276.
357. Peakman, M. C., Colby, C., Perrotti, L. I., Tekumalla, P., Carle, T., Ulery, P., Chao, J., Duman, C., Steffen, C., Monteggia, L., Allen, M. R., Stock, J. L., Duman, R. S., McNeish, J. D., Barrot, M., Self, D. W., Nestler, E. J. and Schaeffer, E. (2003). Inducible, brain region-specific expression of a dominant negative mutant of c-Jun in transgenic mice decreases sensitivity to cocaine. *Brain Res* **970**: 73–86.
358. Hiroi, N., Brown, J. R., Haile, C. N., Ye, H., Greenberg, M. E. and Nestler, E. J. (1997). FosB mutant mice: loss of chronic cocaine induction of Fos-related proteins and heightened sensitivity to cocaine's psychomotor and rewarding effects. *Proc Natl Acad Sci U S A* **94**: 10397–10402.
359. Kelz, M. B. and Nestler, E. J. (2000). deltaFosB: a molecular switch underlying long-term neural plasticity. *Curr Opin Neurol* **13**: 715–720.
360. Bibb, J. A., Chen, J., Taylor, J. R., Svenningsson, P., Nishi, A., Snyder, G. L., Yan, Z., Sagawa, Z. K., Ouimet, C. C., Nairn, A. C., Nestler, E. J. and Greengard, P. (2001). Effects of chronic exposure to cocaine are regulated by the neuronal protein Cdk5. *Nature* **410**: 15 Mar 376–380.
361. Chen, J., Zhang, Y., Kelz, M. B., Steffen, C., Ang, E. S., Zeng, L. and Nestler, E. J. (2000). Induction of cyclin-dependent kinase 5 in the hippocampus by chronic electroconvulsive seizures: role of [Delta]FosB. *J Neurosci* **20**: 15 Dec 8965–8971.
362. Nestler, E. J. and Malenka, R. C. (2004). The addicted brain. *Sci Am* **290**: 78–85.
363. Newton, S. S., Thome, J., Wallace, T. L., Shirayama, Y., Schlesinger, L., Sakai, N., Chen, J., Neve, R., Nestler, E. J. and Duman, R. S. (2002). Inhibition of cAMP response element-binding protein or dynorphin in the nucleus accumbens produces an antidepressant-like effect. *J Neurosci* **22**: 10883–10890.
364. Self, D. W., Genova, L. M., Hope, B. T., Barnhart, W. J., Spencer, J. J. and Nestler, E. J. (1998). Involvement of cAMP-dependent protein kinase in the nucleus accumbens in cocaine self-administration and relapse to cocaine-seeking behavior. *Journal of Neuroscience* **18**: 1848.
365. Walters, C. L. and Blendy, J. A. (2001). Different requirements for cAMP response element binding protein in positive and negative reinforcing properties of drugs of abuse. *J Neurosci* **21**: 9438–9444.
366. Maldonado, R., Blendy, J. A., Tzavara, E., Gass, P., Roques, B. P., Hanoune, J. and Schutz, G. (1996). Reduction of morphine abstinence in mice with a mutation in the gene encoding CREB. *Science* **273**: 657–659.
367. Valverde, O., Mantamadiotis, T., Torrecilla, M., Ugedo, L., Pineda, J., Bleckmann, S., Gass, P., Kretz, O., Mitchell, J. M., Schutz, G. and Maldonado, R. (2004). Modulation of anxiety-like behavior and morphine dependence in CREB-deficient mice. *Neuropsychopharmacology* **29**: 1122–1133.
368. Bowers, M. S., McFarland, K., Lake, R. W., Peterson, Y. K., Lapish, C. C., Gregory, M. L., Lanier, S. M. and Kalivas, P. W. (2004). Activator of G protein signaling 3: a gatekeeper of cocaine sensitization and drug seeking. *Neuron* **42**: 22 Apr 269–281.
369. Baker, D. A., McFarland, K., Lake, R. W., Shen, H., Tang, X. C., Toda, S. and Kalivas, P. W. (2003). Neuroadaptations in cystine-glutamate exchange underlie cocaine relapse. *Nat Neurosci* **6**: Jul 743–749.
370. Grimm, J. W., Shaham, Y. and Hope, B. T. (2002). Effect of cocaine and sucrose withdrawal period on extinction behavior, cue-induced reinstatement, and protein levels of the dopamine transporter and tyrosine hydroxylase in limbic and cortical areas in rats. *Behav Pharmacol* **13**: 379–388.
371. Shalev, U., Morales, M., Hope, B., Yap, J. and Shaham, Y. (2001). Time-dependent changes in extinction behavior and stress-induced reinstatement of drug seeking following withdrawal from heroin in rats. *Psychopharmacology (Berl)* **156**: 98–107.
372. Shepard, J. D., Bossert, J. M., Liu, S. Y. and Shaham, Y. (2004). The anxiogenic drug yohimbine reinstates methamphetamine seeking in a rat model of drug relapse. *Biol Psychiatry* **55**: 1082–1089.
373. Berhow, M. T., Russell, D. S., Terwilliger, R. Z., Beitner-Johnson, D., Self, D. W., Lindsay, R. M. and Nestler, E. J. (1995). Influence of neurotrophic factors on morphine- and cocaine-induced biochemical changes in the mesolimbic dopamine system. *Neuroscience* **68**: Oct 969–979.

374. Lu, Y. and Wehner, J. M. (1997). Enhancement of contextual fear-conditioning by putative (+/-)-alpha- amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor modulators and N-methyl-D-aspartate (NMDA) receptor antagonists in DBA/2J mice. *Brain Res* **768**: 197–207.
375. Grimm, J. W., Lu, L., Hayashi, T., Hope, B. T., Su, T. P. and Shaham, Y. (2003). Time-dependent increases in brain-derived neurotrophic factor protein levels within the mesolimbic dopamine system after withdrawal from cocaine: implications for incubation of cocaine craving. *J Neurosci* **23**: 742–747.
376. Lu, L., Grimm, J. W., Shaham, Y. and Hope, B. T. (2003). Molecular neuroadaptations in the accumbens and ventral tegmental area during the first 90 days of forced abstinence from cocaine self-administration in rats. *J Neurochem* **85**: 1604–1613.
377. Lu, L., Dempsey, J., Liu, S. Y., Bossert, J. M. and Shaham, Y. (2004). A single infusion of brain-derived neurotrophic factor into the ventral tegmental area induces long-lasting potentiation of cocaine seeking after withdrawal. *J Neurosci* **24**: 1604–1611.
378. Lu, B. and Chow, A. (1999). Neurotrophins and hippocampal synaptic transmission and plasticity. *Journal of Neuroscience Research* **58**: 76–87.
379. Schinder, A. F. and Poo, M. M. (2000). The neurotrophin hypothesis for synaptic plasticity. *Trends in Neurosciences* **23**: 639–645.
380. Yamada, K., Mizuno, M. and Nabeshima, T. (2002). Role for brain-derived neurotrophic factor in learning and memory. *Life Sciences* **70**: 735–744.
381. Nestler, E. J. (2002). Common molecular and cellular substrates of addiction and memory. *Neurobiol Learn Mem* **78**: 637–647.
382. McAllister, A. K., Katz, L. C. and Lo, D. C. (1999). Neurotrophins and synaptic plasticity. *Annual Review of Neuroscience* **22**: 295–318.
383. Tyler, W. J., Alonso, M., Bramham, C. R. and Pozzo-Miller, L. D. (2002). From acquisition to consolidation: on the role of brain-derived neurotrophic factor signaling in hippocampal-dependent learning. *Learning and Memory* **9**: 224–237.
384. Horger, B. A., Iyasere, C. A., Berhow, M. T., Messer, C. J., Nestler, E. J. and Taylor, J. R. (1999). Enhancement of locomotor activity and conditioned reward to cocaine by brain-derived neurotrophic factor. *J Neurosci* **19**: 4110–4122.
385. Abraham, W. C., Dragunow, M. and Tate, W. P. (1991). The role of immediate early genes in the stabilization of long-term potentiation. *Molecular Neurobiology* **5**: 297–314.
386. Crombag, H. S., Jedyak, J. P., Redmond, K., Robinson, T. E. and Hope, B. T. N. (2002). Locomotor sensitization to cocaine is associated with increased Fos expression in the accumbens, but not in the caudate. *Behav Brain Res* **136**: 455–462.
387. Dudai, Y. (2002). Molecular bases of long-term memories: a question of persistence. *Curr Opin Neurobiol* **12**: 211–216.
388. Chao, J. and Nestler, E. J. (2004). Molecular neurobiology of drug addiction. *Annu Rev Med* **55**: 113–132.
389. Norrholm, S. D., Bibb, J. A., Nestler, E. J., Ouimet, C. C., Taylor, J. R. and Greengard, P. (2003). Cocaine-induced proliferation of dendritic spines in nucleus accumbens is dependent on the activity of cyclin-dependent kinase-5. *Neuroscience* **116**: 19–22.
390. Lee, M. K. and Cleveland, D. W. (1996). Neuronal intermediate filaments. *Annu Rev Neurosci* **19**: 187–217.
391. Toni, N., Buchs, P. A., Nikonenko, I., Bron, C. R. and Muller, D. (1999). LTP promotes formation of multiple spine synapses between a single axon terminal and a dendrite. *Nature* **402**: 421–425.
392. Beitner-Johnson, D., Guitart, X. and Nestler, E. J. (1992). Neurofilament proteins and the mesolimbic dopamine system: common regulation by chronic morphine and chronic cocaine in the rat ventral tegmental area. *J Neurosci* **12**: Jun 2165–2176.
393. Ferrer-Alcon, M., Garcia-Sevilla, J. A., Jaquet, P. E., La Harpe, R., Riederer, B. M., Walzer, C. and Guimon, J. (2000). Regulation of nonphosphorylated and phosphorylated forms of neurofilament proteins in the prefrontal cortex of human opioid addicts. *J Neurosci Res* **61**: 338–349.
394. Jaquet, P. E., Ferrer-Alcon, M., Ventayol, P., Guimon, J. and Garcia-Sevilla, J. A. (2001). Acute and chronic effects of morphine and naloxone on the phosphorylation of neurofilament-H proteins in the rat brain. *Neurosci Lett* **304**: 37–40.
395. Abrous, D. N., Adriani, W., Montaron, M. F., Aourasseau, C., Rougon, G., Le Moal, M. and Piazza, P. V. (2002). Nicotine self-administration impairs hippocampal plasticity. *J Neurosci* **22**: 1 May 3656–3662.
396. Crews, F. T. and Nixon, K. (2003). Alcohol, neural stem cells, and adult neurogenesis. *Alcohol Res Health* **27**: 197–204.
397. Eisch, A. J. and Mandyam, C. D. (2004). Drug dependence and addiction, II: Adult neurogenesis and drug abuse. *Am J Psychiatry* **161**: 426.
398. Nixon, K. and Crews, F. T. (2002). Binge ethanol exposure decreases neurogenesis in adult rat hippocampus. *J Neurochem* **83**: 1087–1093.
399. Yamaguchi, M., Suzuki, T., Seki, T., Namba, T., Juan, R., Arai, H., Hori, T. and Asada, T. (2004). Repetitive cocaine administration decreases neurogenesis in adult rat hippocampus. *Ann N Y Acad Sci* **1025**: 351–362.
400. Kempermann, G. and Kronenberg, G. (2003). Depressed new neurons—adult hippocampal neurogenesis and a cellular plasticity hypothesis of major depression. *Biol Psychiatry* **54**: 499–503.
401. Malberg, J. E. and Duman, R. S. (2003). Cell proliferation in adult hippocampus is decreased by inescapable stress: reversal by fluoxetine treatment. *Neuropsychopharmacology* **28**: 1562–1571.
402. Gould, E. and Gross, C. G. (2002). Neurogenesis in adult mammals: some progress and problems. *J Neurosci* **22**: 619–623.
403. Shors, T. J., Townsend, D. A., Zhao, M., Kozorovitskiy, Y. and Gould, E. (2002). Neurogenesis may relate to some but not all types of hippocampal-dependent learning. *Hippocampus* **12**: 578–584.
404. Blows, W. T. (2000). The neurobiology of antidepressants. *J Neurosci Nurs* **32**: Jun 177–180.
405. Castren, E. (2004). Neurotrophic effects of antidepressant drugs. *Curr Opin Pharmacol* **4**: Feb 58–64.
406. Hughes, J., Stead, L. and Lancaster, T. (2004). Antidepressants for smoking cessation. *Cochrane Database Syst Rev*: CD000031.
407. Szymanski, N., Peris, L., Mesias, B., Colis, P., Rosa, J. and Prieto, A. (2005). Reboxetine for the treatment of patients with Cocaine Dependence Disorder. *Hum Psychopharmacol* **20**: 189–192.
408. Gonzalez-Nicolini, V. and McGinty, J. F. (2002). Gene expression profile from the striatum of amphetamine-treated rats: a cDNA array and in situ hybridization histochemical study. *Brain Res Gene Expr Patterns* **1**: 193–198.
409. Li, M. D., Konu, O., Kane, J. K. and Becker, K. G. (2002). Microarray technology and its application on nicotine research. *Mol Neurobiol* **25**: 265–285.
410. Pollock, J. D. (2002). Gene expression profiling: methodological challenges, results, and prospects for addiction research. *Chem Phys Lipids* **121**: 241–256.
411. Thibault, C., Lai, C., Wilke, N., Duong, B., Olive, M. F., Rahman, S., Dong, H., Hodge, C. W., Lockhart, D. J. and Miles, M. F. (2000). Expression profiling of neural cells reveals specific patterns of ethanol-responsive gene expression. *Mol Pharmacol* **58**: 1593–1600.
412. Toda, S., McGinty, J. F. and Kalivas, P. W. (2002). Repeated cocaine administration alters the expression of genes in corticolimbic circuitry after a 3-week withdrawal: a DNA macroarray study. *J Neurochem* **82**: 1290–1299.
413. Nader, K., Schafe, G. E. and Le Douarin, J. E. (2000). Fear memories require protein synthesis in the amygdala for reconsolidation after retrieval. *Nature* **406**: 722–726.
414. Bozon, B., Davis, S. and Laroche, S. (2003). A requirement for the immediate early gene zif268 in reconsolidation of recognition memory after retrieval. *Neuron* **40**: 695–701.
415. Eisenberg, M., Kobilov, T., Berman, D. E. and Dudai, Y. (2003). Stability of retrieved memory: inverse correlation with trace dominance. *Science* **301**: 1102–1104.
416. Przybylski, J. and Sara, S. J. (1997). Reconsolidation of memory after its reactivation. *Behavioural Brain Research* **84**: 241–246.
417. Przybylski, J., Rouillet, P. and Sara, S. J. (1999). Attenuation of emotional and nonemotional memories after their reactivation: role of beta adrenergic receptors. *Journal of Neuroscience* **19**: 6623–6628.

418. Suzuki, A., Josselyn, S. A., Frankland, P. W., Masushige, S., Silva, A. J. and Kida, S. (2004). Memory reconsolidation and extinction have distinct temporal and biochemical signatures. *Journal of Neuroscience* **24**: 4787–4795.
419. Wang, S. H., Ostlund, S. B., Nader, K. and Balleine, B. W. (2005). Consolidation and reconsolidation of incentive learning in the amygdala. *J Neurosci* **25**: 830–835.
420. Walker, M. P., Brakefield, T., Hobson, J. A. and Stickgold, R. (2003). Dissociable stages of human memory consolidation and reconsolidation. *Nature* **425**: 616–620.
421. LeDoux, J. E. (2000). Emotion circuits in the brain. *Annual Review of Neuroscience* **23**: 155–184.
422. Hall, J., Thomas, K. L. and Everitt, B. J. (2001). Cellular imaging of zif268 expression in the hippocampus and amygdala during contextual and cued fear memory retrieval: selective activation of hippocampal CA1 neurons during the recall of contextual memories. *J Neurosci* **21**: 2186–2193.
423. Thomas, K. L., Arroyo, M. and Everitt, B. J. (2003). Induction of the learning and plasticity-associated gene Zif268 following exposure to a discrete cocaine-associated stimulus. *European Journal of Neuroscience* **17**: 1964–1972.
424. Lee, J. L., Everitt, B. J. and Thomas, K. L. (2004). Independent cellular processes for hippocampal memory consolidation and reconsolidation. *Science* **304**: 839–843.
425. Nader, K. (2003). Memory traces unbound. *Trends Neurosci* **26**: 65–72.
426. O'Brien, C. P., Ehrman, R. N. and Ternes, J. W. (1986). Classical conditioning in human opioid dependence. In *Behavioural analysis of drug dependence* (Goldberg, S. R. and Stolerman, I. P., eds.), pp. 329–356. Academic Press, London.
427. Piazza, P. V., Deroche-Gamonet, V., Rouge-Pont, F. and Le Moal, M. (2000). Vertical shifts in self-administration dose-response functions predict a drug-vulnerable phenotype predisposed to addiction. *The Journal of Neuroscience* **20**: 4226–4232.
428. Abi-Dargham, A., Kegeles, L. S., Martinez, D., Innis, R. B. and Laruelle, M. (2003). Dopamine mediation of positive reinforcing effects of amphetamine in stimulant naive healthy volunteers: results from a large cohort. *Eur Neuropsychopharmacol* **13**: Dec 459–468.
429. Fergusson, D. M., Horwood, L. J., Lynskey, M. T. and Madden, P. A. (2003). Early reactions to cannabis predict later dependence. *Archives of General Psychiatry* **60**: 1033–1039.
430. Volkow, N. D., Wang, G. J., Fowler, J. S., Logan, J., Gatley, S. J., Wong, C., Hitzemann, R. and Pappas, N. (1999). Reinforcing effects of psychostimulants in humans are associated with increases in brain dopamine and occupancy of D2 receptors. *The Journal of Pharmacology and Experimental Therapeutics* **291**: 409–415.
431. Leyton, M., Boileau, I., Benkelfat, C., Diksic, M., Baker, G. and Dagher, A. (2002). Amphetamine-induced increases in extracellular dopamine, drug wanting, and novelty seeking: a PET/[11C]raclopride study in healthy men. *Neuropsychopharmacology* **27**: 1027.
432. Piazza, P. V., Deroche, V., Rouge-Pont, F. and Le Moal, M. (1998). Behavioral and biological factors associated with individual vulnerability to psychostimulant abuse. *NIDA Research Monographs* **169**: 105–133.
433. Altman, J. and Das, G. D. (1966). Behavioral manipulations and protein metabolism of the brain: effects of motor exercise on the utilization of leucine-H 3. *Physiology and Behavior* **1**: 105.
434. Piazza, P. V., Deminiere, J. M., Maccari, S., Mormede, P., Le Moal, M. and Simon, H. (1990). Individual reactivity to novelty predicts probability of amphetamine self-administration. *Behav Pharmacol* **1**: 339–345.
435. Piazza, P. V., Maccari, S., Deminiere, J. M., Le Moal, M., Mormede, P. and Simon, H. (1991). Corticosterone levels determine individual vulnerability to amphetamine self-administration. *Proc Natl Acad Sci U S A* **88**: 2088–2092.
436. Marinelli, M. and White, F. J. (2000). Enhanced vulnerability to cocaine self-administration is associated with elevated impulse activity of midbrain dopamine neurons. *J Neurosci* **20**: 8876–8885.
437. Hooks, M. S., Jones, G. H., Smith, A. D., Neill, D. B. and Justice, J. B., Jr. (1991). Response to novelty predicts the locomotor and nucleus accumbens dopamine response to cocaine. *Synapse* **9**: 121–128.
438. Hooks, M. S., Jones, G. H., Smith, A. D., Neill, D. B. and Justice, J. B., Jr. (1991). Individual differences in locomotor activity and sensitization. *Pharmacology Biochemistry and Behavior* **38**: 467–470.
439. Hooks, M. S., Jones, G. H., Liem, B. J. and Justice, J. B. J. (1992). Sensitization and individual differences to IP amphetamine, cocaine, or caffeine following repeated intracranial amphetamine infusions. *Pharmacology, Biochemistry and Behavior* **43**: 815–823.
440. Kalinichev, M., White, D. A. and Holtzman, S. G. (2004). Individual differences in locomotor reactivity to a novel environment and sensitivity to opioid drugs in the rat. I. Expression of morphine-induced locomotor sensitization. *Psychopharmacology* **177**: 61–67.
441. Chefer, V. I., Zakharova, I. and Shippenberg, T. S. (2003). Enhanced responsiveness to novelty and cocaine is associated with decreased basal dopamine uptake and release in the nucleus accumbens: quantitative microdialysis in rats under transient conditions. *The Journal of Neuroscience* **23**: 3076–3084.
442. Hooks, M. S., Jones, G. H., Neill, D. B. and Justice, J. B., Jr. (2004). Individual differences in amphetamine sensitization: Dose-dependent effects. *Pharmacology Biochemistry and Behavior* **41**: 203–210.
443. Jodogne, C., Marinelli, M., Le Moal, M. and Piazza, P. V. (1994). Animals predisposed to develop amphetamine self-administration show higher susceptibility to develop contextual conditioning of both amphetamine-induced hyperlocomotion and sensitization. *Brain Res* **657**: 236–244.
444. Hooks, M. S., Colvin, A. C., Juncos, J. L. and Justice, J. B., Jr. (1992). Individual differences in basal and cocaine-stimulated extracellular dopamine in the nucleus accumbens using quantitative microdialysis. *Brain Research* **587**: 306–312.
445. Rouge-Pont, F., Piazza, P. V., Kharouby, M., leMoal, M. and Simon, H. (1993). Higher and longer stress-induced increase in dopamine concentrations in the nucleus accumbens of animals predisposed to amphetamine self-administration. A microdialysis study. *Brain Research* **602**: 169–174.
446. Piazza, P. V., Rouge-Pont, F., Deminiere, J. M., Kharoubi, M., Le Moal, M. and Simon, H. (1991). Dopaminergic activity is reduced in the prefrontal cortex and increased in the nucleus accumbens of rats predisposed to develop amphetamine self-administration. *Brain Res* **567**: 169–174.
447. Hooks, M. S., Juncos, J. L., Justice, J. B. J., Meiergard, S. M., Povlock, S. L., Schenk, J. O. and Kalivas, P. W. (1994). Individual locomotor response to novelty predicts selective alterations in D₁ and D₂ receptors and mRNAs. *The Journal of Neuroscience* **14**: 6144–6152.
448. Lucas, L. R., Angulo, J. A., Le Moal, M., McEwen, B. S. and Piazza, P. V. (1998). Neurochemical characterization of individual vulnerability to addictive drugs in rats. *Eur J Neurosci* **10**: 3153–3163.
449. Gordon, H. W. (2002). Early environmental stress and biological vulnerability to drug abuse. *Psychoneuroendocrinology* **27**: 115–126.
450. Meaney, M. J., Aitken, D. H., van Berkel, C., Bhatnagar, S. and Sapolsky, R. M. (1988). Effect of neonatal handling on age-related impairments associated with the hippocampus. *Science* **239**: 766.
451. Ogawa, T., Mikuni, M., Kuroda, Y., Muneoka, K., Mori, K. J. and Takahashi, K. (1994). Periodic maternal deprivation alters stress response in adult offspring: potentiates the negative feedback regulation of restraint stress-induced adrenocortical response and reduces the frequencies of open field-induced behaviors. *Pharmacology Biochemistry and Behavior* **49**: 961.
452. Wigger, A. and Neumann, I. D. (1999). Periodic maternal deprivation induces gender-dependent alterations in behavioral and neuroendocrine responses to emotional stress in adult rats. *Physiology and Behavior* **66**: 293–302.
453. Plotsky, P. M. and Meaney, M. J. (1993). Early, postnatal experience alters hypothalamic corticotropin-releasing factor (CRF) mRNA, median eminence CRF content and stress-induced release in adult rats. *Molecular Brain Research* **18**: 195–200.
454. Avishai-Eliner, S., Hatalski, C. G., Tabachnik, E., Eghbal-Ahmadi, M. and Baram, T. Z. (1999). Differential regulation of glucocorticoid receptor messenger RNA (GR-mRNA) by maternal deprivation in immature rat hypothalamus and limbic regions. *Brain Res Dev Brain Res* **114**: 14 May 265–268.

455. Noonan, L. R., Caldwell, J. D., Li, L., Walker, C. H., Pedersen, C. A. and Mason, G. A. (1994). Neonatal stress transiently alters the development of hippocampal oxytocin receptors. *Developmental Brain Research* **80**: 115–120.
456. Huot, R. L., Plotsky, P. M., Lenox, R. H. and McNamara, R. K. (2002). Neonatal maternal separation reduces hippocampal mossy fiber density in adult Long Evans rats. *Brain Research* **950**: 52–63.
457. Piazza, P. V. and Le Moal, M. L. (1996). Pathophysiological basis of vulnerability to drug abuse: role of an interaction between stress, glucocorticoids, and dopaminergic neurons. *Annu Rev Pharmacol Toxicol* **36**: 359–378.
458. Matthews, K., Wilkinson, L. S. and Robbins, T. W. (1996). Repeated maternal separation of preweanling rats attenuates behavioral responses to primary and conditioned incentives in adulthood. *Physiol Behav* **59**: 99–107.
459. Matthews, K., Hall, F. S., Wilkinson, L. S. and Robbins, T. W. (1996). Retarded acquisition and reduced expression of conditioned locomotor activity in adult rats following repeated early maternal separation: effects of prefeeding, d-amphetamine, dopamine antagonists and clonidine. *Psychopharmacology (Berl)* **126**: 75–84.
460. Matthews, K., Robbins, T. W., Everitt, B. J. and Caine, S. B. (1999). Repeated neonatal maternal separation alters intravenous cocaine self-administration in adult rats [In Process Citation]. *Psychopharmacology (Berl)* **141**: 123–134.
461. Kosten, T. A., Miserendino, M. J. and Kehoe, P. (2000). Enhanced acquisition of cocaine self-administration in adult rats with neonatal isolation stress experience. *Brain Res* **875**: 44–50.
462. Hall, F. S. (1998). Social deprivation of neonatal, adolescent, and adult rats has distinct neurochemical and behavioural consequences. *Critical Reviews in Neurobiology* **12**: 129–162.
463. Brake, W. G., Zhang, T. Y., Diorio, J., Meaney, M. J. and Gratton, A. (2004). Influence of early postnatal rearing conditions on mesocorticolimbic dopamine and behavioural responses to psychostimulants and stressors in adult rats. *European Journal of Neuroscience* **19**: 1863–1874.
464. Suomi, S. J., Rasmussen, K. L. R. and Higley, J. D. (1992). Primate models of behavioral and physiological change in adolescence. In *Textbook of Adolescent Medicine* (McAnerney, K., Kreipe, R. E., Orr, D. P. and Comerchi, G. D., eds.), pp. 135–140. W.B. Saunders, Philadelphia.
465. Higley, J. D., Suomi, S. J. and Linnoila, M. (1991). CSF monoamine metabolite concentrations vary according to age, rearing, and sex, and are influenced by the stressor of social separation in rhesus monkeys. *Psychopharmacology (Berl)* **103**: 551–556.
466. Higley, J. D., Hasert, M., Suomi, S. and Linnoila, M. (1991). Nonhuman primate model of alcohol abuse: effects of early experience, personality, and stress on alcohol consumption. **88**: 7261–7265.
467. Higley, J. D., Suomi, S. J. and Linnoila, M. (1996). A nonhuman primate model of type II excessive alcohol consumption? Part I. Low cerebrospinal fluid 5-hydroxyindoleacetic acid concentrations and diminished social competence correlate with excessive alcohol consumption. *Alcohol Clin Exp Res* **20**: 629–642.
468. Barr, C. S., Newman, T. K., Schwandt, M., Shannon, C., Dvoskin, R. L., Lindell, S. G., Taubman, J., Thompson, B., Champoux, M., Lesch, K. P., Goldman, D., Suomi, S. J. and Higley, J. D. (2004). Sexual dichotomy of an interaction between early adversity and the serotonin transporter gene promoter variant in rhesus macaques. **101**: 12358–12363.
469. Einon, D. F. and Sahakian, B. J. (1979). Environmentally induced differences in susceptibility of rats to CNS stimulants and CNS depressants: evidence against a unitary explanation. *Psychopharmacology* **61**: 299–307.
470. Sahakian, B. J. and Robbins, T. W. (1977). Isolation-rearing enhances tail pinch-induced oral behavior in rats. *Physiol Behav* **18**: 53–58.
471. Hall, F. S., Humby, T., Wilkinson, L. S. and Robbins, T. W. (1997). The effects of isolation-rearing of rats on behavioural responses to food and environmental novelty. *Physiol Behav* **62**: 281–290.
472. Phillips, G. D., Howes, S. R., Whitelaw, R. B., Wilkinson, L. S., Robbins, T. W. and Everitt, B. J. (1994). Isolation rearing enhances the locomotor response to cocaine and a novel environment, but impairs the intravenous self-administration of cocaine. *Psychopharmacology (Berl)* **115**: 407–418.
473. Smith, J. K., Neill, J. C. and Costall, B. (1997). Post-weaning housing conditions influence the behavioural effects of cocaine and d-amphetamine. *Psychopharmacology* **131**: 23–33.
474. Alexander, B. K., Coombs, R. B. and Hadaway, P. F. (1978). The effect of housing and gender on morphine self-administration in rats. *Psychopharmacology (Berl)* **58**: 6 Jul 175–179.
475. Alexander, B. K., Beyerstein, B. L., Hadaway, P. F. and Coombs, R. B. (1981). Effect of early and later colony housing on oral ingestion of morphine in rats. *Pharmacol Biochem Behav* **15**: Oct 571–576.
476. Bardo, M. T., Klebaur, J. E., Valone, J. M. and Deaton, C. (2001). Environmental enrichment decreases intravenous self-administration of amphetamine in female and male rats. *Psychopharmacology (Berl)* **155**: May 278–284.
477. Deatherage, G. (1972). Effects of housing density on alcohol intake in the rat. *Physiology and Behavior* **9**: 55–57.
478. Hadaway, P. F., Alexander, B. K., Coombs, R. B. and Beyerstein, B. L. (1979). The effect of housing and gender on preference for morphine-sucrose solutions in rats. *Psychopharmacology* **66**: 87–91.
479. Schenk, S., Lancelle, G., Gorman, K. and Amit, Z. (1987). Cocaine self-administration in rats influenced by environmental conditions: implications for the etiology of drug abuse. *Neuroscience Letters* **81**: 227–231.
480. Fowler, S. C., Johnson, J. S., Kallman, M. J., Liou, J. R., Wilson, M. C. and Hikal, A. H. (1993). In a drug discrimination procedure isolation-reared rats generalize to lower doses of cocaine and amphetamine than rats reared in an enriched environment. *Psychopharmacology* **110**: 115–118.
481. Green, T. A., Gehrke, B. J. and Bardo, M. T. (2002). Environmental enrichment decreases intravenous amphetamine self-administration in rats: dose-response functions for fixed- and progressive-ratio schedules. *Psychopharmacology* **162**: 373–378.
482. Hall, F. S., Humby, T., Wilkinson, L. S. and Robbins, T. W. The effects of isolation-rearing on preference by rats for a novel environment. *Physiology and Behavior* **62**: 299.
483. Howes, S. R., Dalley, J. W., Morrison, C. H., Robbins, T. W. and Everitt, B. J. (2000). Leftward shift in the acquisition of cocaine self-administration in isolation-reared rats: relationship to extracellular levels of dopamine, serotonin and glutamate in the nucleus accumbens and amygdala-striatal FOS expression. *Psychopharmacology* **151**: 55–63.
484. Phillips, G. D., Howes, S. R., Whitelaw, R. B., Robbins, T. W. and Everitt, B. J. (1994). Isolation Rearing Impairs the Reinforcing Efficacy of Intravenous Cocaine or Intraaccumbens D-Amphetamine – Impaired Response to Intraaccumbens D1 and D2/D3 Dopamine-Receptor Antagonists. *Psychopharmacology* **115**: 419–429.
485. Blanc, G., Herve, D., Simon, H., Lisoprawski, A., Glowinski, J. and Tassin, J. P. (1980). Response to stress of mesocortico-frontal dopaminergic neurones in rats after long-term isolation. *Nature* **284**: 265.
486. Heidbreder, C. A., Weiss, I. C., Domenech, A. M., Pryce, C., Homberg, J., Hedou, G., Feldon, J., Moran, M. C. and Nelson, P. (2000). Behavioral, neurochemical and endocrinological characterization of the early social isolation syndrome. *Neuroscience* **100**: 749–768.
487. Jones, G. H., Hernandez, T. D., Kendall, D. A., Marsden, C. A. and Robbins, T. W. (1992). Dopaminergic and serotonergic function following isolation rearing in rats: study of behavioural responses and postmortem and in vivo neurochemistry. *Pharmacology, Biochemistry and Behavior* **43**: 17–35.
488. Petkov, V. V., Konstantinova, E. and Grachovska, T. (1985). Changes in brain opiate receptors in rats with isolation syndrome. *Pharmacology Research Communications* **17**: 575–584.
489. Schenk, S., Britt, M. D. and Atalay, J. (1982). Isolation rearing decreases opiate receptor binding in rat brain. *Pharmacology Biochemistry and Behavior* **16**: 841–842.
490. Fone, K. C. F., Shalders, K., Fox, Z. D., Arthur, R. and Marsden, C. A. (1996). Increased 5-HT_{2C} receptor responsiveness occurs on rearing rats in social isolation. *Psychopharmacology* **123**: 346–352.

491. Fulford, A. J. and Marsden, C. A. (1998). Conditioned release of 5-hydroxytryptamine in vivo in the nucleus accumbens following isolation-rearing in the rat. *Neuroscience* **83**: 481.
492. Jaffe, E. H., De Frias, V. and Ibarra, C. (1993). Changes in basal and stimulated release of endogenous serotonin from different nuclei of rats subjected to two models of depression. *Neurosci Lett* **162**: 157–160.
493. St Popova, J. S. and Petkov, V. V. (1977). Changes in 5-HT 1 receptors in different brain structures of rats with isolation syndrome. *General Pharmacology* **18**: 223–225.
494. Whitaker-Azmitia, P., Zhou, F., Hobin, J. and Borella, A. (2000). Isolation-rearing of rats produces deficits as adults in the serotonergic innervation of hippocampus. *Peptides* **21**: 1755–1759.
495. Wright, I. K., Ismail, H., Upton, N. and Marsden, C. A. (1990). Effect of isolation-rearing on performance in the elevated plus-maze and open field behaviour. *British Journal of Pharmacology* **100**: 375P.
496. Bardo, M. T., Bowling, S. L., Rowlett, J. K., Manderscheid, P., Buxton, S. T. and Dwoskin, L. P. (1995). Environmental enrichment attenuates locomotor sensitization, but not in vitro dopamine release, induced by amphetamine. *Pharmacol Biochem Behav* **51**: Jun–Jul 397–405.
497. Guisado, E., Fernandez-Tome, P., Garzon, J. and del Rio, J. (1980). Increased dopamine receptor binding in the striatum of rats after long-term isolation. *European Journal of Pharmacology* **65**: 463–464.
498. Hall, F. S., Wilkinson, L. S., Humby, T., Inglis, W., Kendall, D. A., Marsden, C. A. and Robbins, T. W. (1998). Isolation rearing in rats: pre- and postsynaptic changes in striatal dopaminergic systems. *Pharmacology, Biochemistry and Behavior* **59**: 859–872.
499. Heidbreder, C. A., Foxton, R., Cilia, J., Hughes, Z. A., Shah, A. J., Atkins, A., Hunter, A. J., Hagan, J. J. and Jones, D. N. C. (2001). Increased responsiveness of dopamine to atypical, but not typical antipsychotics in the medial prefrontal cortex of rats reared in isolation. *Psychopharmacology* **156**: 338.
500. Thoa, N. B., Tizabi, Y. and Jacobowitz, D. M. (1977). The effect of isolation on catecholamine concentration and turnover in discrete areas of the rat brain. *Brain Research* **131**: 259–269.
501. Weinstock, M., Speiser, A. and Ashkenazi, R. (1978). Changes in brain catecholamine turnover and receptor sensitivity induced by social deprivation in rats. *Psychopharmacology* **56**: 205.
502. Bezard, E., Dovero, S., Belin, D., Duconger, S., Jackson-Lewis, V., Przedborski, S., Piazza, P. V., Gross, C. E. and Jaber, M. (2003). Enriched environment confers resistance to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and cocaine: Involvement of dopamine transporter and trophic factors. *Journal of Neuroscience* **23**: 10999.
503. Francis, D. D., Diorio, J., Plotsky, P. M. and Meaney, M. J. (2002). Environmental enrichment reverses the effects of maternal separation on stress reactivity. *The Journal of Neuroscience* **22**: 7840–7843.
504. Harvey, J. A. (2004). Cocaine effects on the developing brain: current status. *Neuroscience and Biobehavioral Reviews* **27**: 751.
505. Iqbal, U., Dringenberg, H. C., Brien, J. F. and Reynolds, J. N. (2004). Chronic prenatal ethanol exposure alters hippocampal GABA(A) receptors and impairs spatial learning in the guinea pig. *Behavioural Brain Research* **150**: 117–125.
506. Mattson, S. N., Schoenfeld, A. M. and Riley, E. P. (2001). Teratogenic effects of alcohol on brain and behavior. *Alcohol Research and Health* **25**: 185.
507. Buka, S. L., Shenessa, E. D. and Niaura, R. (2003). Elevated risk of tobacco dependence among offspring of mothers who smoked during pregnancy: a 30-year prospective study. *American Journal of Psychiatry* **160**: 1978–1984.
508. Smith, A. M., Fried, P. A., Hogan, M. J. and Cameron, I. (2004). Effects of prenatal marijuana on response inhibition: an fMRI study of young adults. *Neurotoxicology and Teratology* **26**: 533–542.
509. Vaglenova, J., Birru, S., Pandiella, N. M. and Breese, C. R. (2004). An assessment of the long-term developmental and behavioral teratogenicity of prenatal nicotine exposure. *Behavioural Brain Research* **150**: 159–170.
510. Baer, J. S., Sampson, P. D., Barr, H. M., Connor, P. D. and Streissguth, A. P. (2003). A 21-year longitudinal analysis of the effects of prenatal alcohol exposure on young adult drinking. *Arch Gen Psychiatry* **60**: Apr 377–385.
511. Hellstrom-Lindahl, E. and Norberg, A. (2002). Smoking during pregnancy: a way to transfer the addiction to the next generation? *Respiration* **69**: 289–293.
512. Chen, W. J., Maier, S. E. and West, J. R. (1997). Prenatal alcohol treatment attenuated postnatal cocaine-induced elevation of dopamine concentration in nucleus accumbens: a preliminary study. *Neurotoxicology and Teratology* **19**: 39–46.
513. Choong, K. and Shen, R. (2004). Prenatal ethanol exposure alters the postnatal development of the spontaneous electrical activity of dopamine neurons in the ventral tegmental area. *Neuroscience* **126**: 1083.
514. Shen, R. Y., Hannigan, J. H. and Kapatos, G. (1999). Prenatal ethanol reduces the activity of adult midbrain dopamine neurons. *Alcohol Clinical Experimental Research* **23**: 1801–1807.
515. Abreu-Vallica, Y., Seidler, F. J. and Slotkin, T. A. (2004). Does prenatal nicotine exposure sensitize the brain to nicotine-induced neurotoxicity in adolescence? *Neuropsychopharmacology* **29**: 1440–1450.
516. Abreu-Vallica, Y., Seidler, F. J., Tate, C. A., Cousins, M. M. and Slotkin, T. A. (2004). Prenatal nicotine exposure alters the response to nicotine administration in adolescence: effects on cholinergic systems during exposure and withdrawal. *Neuropsychopharmacology* **29**: 879–890.
517. Kane, V. B., Fu, Y., Matta, S. G. and Sharp, B. M. (2004). Gestational nicotine exposure attenuates nicotine-stimulated dopamine release in the nucleus accumbens shell of adolescent Lewis rats. *Journal of Pharmacology And Experimental Therapeutics* **308**: 521–528.
518. Hou, Y., Tan, Y., Belcheva, M. M., Clark, A. L., Zahm, D. S. and Coscia, C. J. (2004). Differential effects of gestational buprenorphine, naloxone, and methadone on mesolimbic mu opioid and ORL1 receptor G protein coupling. *Developmental Brain Research* **151**: 149–157.
519. Slotkin, T. A., Seidler, F. J. and Yanai, J. (2003). Heroin neuroteratogenicity: delayed-onset deficits in catecholaminergic synaptic activity. *Brain Research* **948**: 189–197.
520. Glatt, S. J., Trksak, G. H., Cohen, O. S., Simeone, B. P. and Jackson, D. (2004). Prenatal cocaine exposure decreases nigrostriatal dopamine release in vitro: effects of age and sex. *Synapse* **53**: 74–89.
521. Salvatore, M. F., Hudspeth, O., Arnold, L. E., Wilson, P. E., Stanford, J. A., Mactutus, C. F., Booze, R. M. and Gerhardt, G. A. (2004). Prenatal cocaine exposure alters potassium-evoked dopamine release dynamics in rat striatum. *Neuroscience* **123**: 481–490.
522. Wilkins, A. S., Genova, L. M., Posten, W. and Kosofsky, B. E. (1998). Transplacental cocaine exposure. 1: A rodent model. *Neurotoxicology and Teratology* **20**: 215–226.
523. Wilkins, A. S., Jones, K. and Kosofsky, B. E. (1998). Transplacental cocaine exposure. 2: Effects of cocaine dose and gestational timing. *Neurotoxicology and Teratology* **20**: 227–238.
524. Wilkins, A. S., Marota, J. J., Tabit, E. and Kosofsky, B. E. (1998). Transplacental cocaine exposure. 3: Mechanisms underlying altered brain development. *Neurotoxicology and Teratology* **20**: 239–249.
525. Gendle, M. H., Strawderman, M. S., Mactutus, C. F., Booze, R. M., Levitsky, D. A. and Strupp, B. J. (2003). Impaired sustained attention and altered reactivity to errors in an animal model of prenatal cocaine exposure. *Developmental Brain Research* **147**: 85–96.
526. Keller, R. W., LeFevre, R., Raucci, J. and Carlson, J. N. (1996). Enhanced cocaine self-administration in adult rats prenatally exposed to cocaine. *Neuroscience Letters* **205**: 153.
527. Rocha, B. A., Mead, A. N. and Kosofsky, B. E. (2002). Increased vulnerability to self-administer cocaine in mice prenatally exposed to cocaine. *Psychopharmacology (Berl)* **163**: 221–229.
528. Ranaldi, R., Baucu, P., McCormick, S., Cools, A. R. and Wise, R. A. (2001). Equal sensitivity to cocaine reward in addiction-prone and addiction-resistant rat genotypes. *Behavioural Pharmacology* **12**: 527.

529. Ramsey, N. F., Niesink, R. J. and Van Ree, J. M. (1993). Prenatal exposure to morphine enhances cocaine and heroin self-administration in drug-naïve rats. *Drug and Alcohol Dependence* **33**: 41.
530. Giedd, J. N., Blumenthal, J., Jeffries, N. O., Castellanos, F. X., Liu, H., Zijdenbos, A., Paus, T., Evans, A. C. and Rapoport, J. (1999). Brain development during childhood and adolescence: a longitudinal MRI study. *Nature Neuroscience* **2**: 861–863.
531. Spear, L. P. (2000). The adolescent brain and age-related behavioral manifestations. *Neuroscience and Biobehavioral Reviews* **24**: 417.
532. Stansfield, K. H., Philpot, R. M. and Kirstein, C. L. (2004). An animal model of sensation seeking: The adolescent rat. *Annals of the New York Academy of Sciences* **1021**: 453.
533. Estroff, T. W., Schwartz, R. H. and Hoffman, N. G. (1989). Adolescent cocaine abuse: addictive potential, behavioral and psychiatric effects. *Clinical Pediatrics* **28**: 550–555.
534. Kelley, A. E., Schochet, T. and Landry, C. F. (2004). Risk taking and novelty seeking in adolescence. *Annals of the New York Academy of Sciences* **1021**: 27.
535. Achat-Mendes, C., Anderson, K. L. and Itzhak, Y. (2003). Methylphenidate and MDMA adolescent exposure in mice: long-lasting consequences on cocaine-induced reward and psychomotor stimulation in adulthood. *Neuropharmacology* **45**: Jul 106–115.
536. Brandon, C. L., Marinelli, M. V. and White, F. J. (2003). Adolescent exposure to methylphenidate alters the activity of rat midbrain dopamine neurons. *Biological Psychiatry* **54**: 1338–1344.
537. Collins, S. L., Montano, R. and Izenwasser, S. (2004). Nicotine treatment produces persistent increases in amphetamine-stimulated locomotor activity in periadolescent male but not female or adult male rats. *Developmental Brain Research* **153**: 175–187.
538. Kelley, B. M. and Rowan, J. D. (2004). Long-term, low-level adolescent nicotine exposure produces dose-dependent changes in cocaine sensitivity and reward in adult mice. *International Journal of Developmental Neuroscience* **22**: 339–348.
539. Schochet, T., Kelley, A. E. and Landry, C. F. (2004). Differential behavioral effects of nicotine exposure in adolescent and adult rats. *Psychopharmacology* **175**: 265–273.
540. Pistis, M., Perra, S., Pillola, G., Melis, M., Muntoni, A. L. and Gessa, G. L. (2004). Adolescent exposure to cannabinoids induces long-lasting changes in the response to drugs of abuse of rat midbrain dopamine neurons. *Biological Psychiatry* **56**: 86–94.
541. Morley-Fletcher, S., Bianchi, M., Gerra, G. and Laviola, G. (2002). Acute and carryover effects in mice of MDMA (ecstasy) administration during periadolescence. *European Journal of Pharmacology* **448**: 31.
542. Philpot, R. M. and Kirstein, C. L. (2004). Developmental differences in the accumbal dopaminergic response to repeated ethanol exposure. *Annals of the New York Academy of Sciences* **1021**: 422–426.
543. White, A. M. and Swartzwelder, H. S. (2004). Hippocampal function during adolescence: a unique target of ethanol effects. *Annals of the New York Academy of Sciences* **1021**: 206.
544. Tsuang, M. T., Lyons, M. J., Harley, R. M., Xian, H., Eisen, S., Goldberg, J., True, W. R. and Faraone, S. V. (1999). Genetic and environmental influences on transitions in drug use. *Behavioural Genetics* **29**: 473.
545. Uhl, G. R. (1999). Molecular genetics of substance abuse vulnerability: a current approach. *Neuropsychopharmacology* **20**: 3–9.
546. Uhl, G. R. (2004). Molecular genetic underpinnings of human substance abuse vulnerability: likely contributions to understanding addiction as a mnemonic process. *Neuropharmacology* **47**: 140.
547. Comings, D. E., Gade, R., Wu, S., Chiu, C., Dietz, G. and Muhleman, D. (1997). Studies of the potential role of the dopamine D1 receptor gene in addictive behaviors. *Molecular Psychiatry* **2**: 44–56.
548. Comings, D. E., Muhleman, D., Ahn, C., Gysin, R. and Flanagan, S. (1994). The dopamine D2 receptor gene: a genetic risk factor in substance abuse. *Drug and Alcohol Dependence* **34**: 175–180.
549. O'Hara, B. F., Smith, S. S., Bird, G., Persico, A. M. and Suarez, B. K. (1993). Dopamine D2 receptor RFLPs, haplotypes and their association with substance use in black and Caucasian research volunteers. *Human Heredity* **43**: 209–218.
550. Smith, S. S., O'Hara, B. F., Persico, A. M., Gorelick, M. A., Newlin, D. B. and Vlahov, D. (1992). Genetic vulnerability to drug abuse, the D2 dopamine receptor Taq 1 B1 restriction fragment length polymorphism appears more frequently in polysubstance abusers. *Archives of General Psychiatry* **49**: 723–727.
551. Smits, B. M. G., D'Souza, U. M., Berezikov, E., Cuppen, E. and Sluyter, F. (2004). Identifying polymorphisms in the *Rattus norvegicus* D3 dopamine receptor gene and regulatory region. **3**: 138–148.
552. De Jong, I. E. M. and de Kloet, E. R. (2004). Glucocorticoids and vulnerability to psychostimulant drugs: Toward substrate and mechanism. *Annals of the New York Academy of Sciences* **1018**: 192.
553. Gorwood, P., Martres, M. P., Ades, J., Sokoloff, P. H., Noble, E. P., Geijer, T., Blum, K., Neiman, J., Jonsson, E. and Feingold, J. (1995). Lack of association between alcohol-dependence and D3 dopamine receptor gene in three independent samples. *American Journal of Medical Genetics* **60**: 529–531.
554. Ebstein, R. P., Novick, O., Umansky, R., Priel, B., Osher, Y. and Blaine, D. (1996). Dopamine D4 receptor exon III polymorphism associated with the human personality trait of novelty seeking. *Nature Genetics* **12**: 78–80.
555. Hutchison, K. E., McGeary, J., Smolen, A., Bryan, A. and Swift, R. M. (2002). The DRD4 VNTR polymorphism moderates craving after alcohol consumption. *Health Psychology* **21**: 139–146.
556. Hutchison, K. E., Wooden, A., Swift, R. M., Smolen, A., McGeary, J., Adler, L. and Paris, L. (2003). Olanzapine reduces craving for alcohol: a DRD4 VNTR polymorphism by pharmacotherapy interaction. *Neuropsychopharmacology* **28**: 1882–1888.
557. Suzuki, T., George, F. and Meisch, R. (1988). Differential establishment and maintenance of oral ethanol reinforced behavior in Lewis and Fischer 344 inbred rat strains. *Journal of Pharmacology And Experimental Therapeutics* **245**: 164–170.
558. Suzuki, T., George, F. and Meisch, R. (1992). Etonitazene delivered orally serves as a reinforcer for Lewis but not Fischer 344 rats. *Pharmacology Biochemistry and Behavior* **42**: 579–586.
559. Suzuki, T., Otani, Y., Koike, M. and Misawa, M. (1998). Genetic differences in preferences for morphine and codeine in Lewis and Fischer 344 inbred rat strains. *Japanese Journal of Pharmacology* **47**: 425–431.
560. Ambrosio, E., Goldberg, S. and Elmer, G. (1995). Behavior genetic investigation of the relationship between spontaneous locomotor activity and the acquisition of morphine self-administration behavior. *Behavioural Pharmacology* **6**: 229.
561. Kosten, T. A., Miserendino, M. J. D., Haile, C. N., DeCaprio, J. L., Jatlow, P. I. and Nestler, E. J. (1997). Acquisition and maintenance of intravenous cocaine self-administration in Lewis and Fischer inbred rat strains. *Brain Research* **778**: 418–429.
562. Guittart, X., Beitner-Johnson, D. B., Marby, D. W., Kosten, T. A. and Nestler, E. J. (1992). Fischer and Lewis rat strains differ in basal levels of neurofilament proteins and their regulation by chronic morphine in the mesolimbic dopamine system. *Synapse* **12**: 242.
563. Kosten, T. A., Miserendino, M. J., Chi, S. and Nestler, E. J. (1994). Fischer and Lewis rat strains show differential cocaine effects in conditioned place preference and behavioral sensitization but not in locomotor activity or conditioned taste aversion. *J Pharmacol Exp Ther* **269**: 137–144.
564. Camp, D. M., Browman, K. E. and Robinson, T. E. (1994). The effects of methamphetamine and cocaine on motor behavior and extracellular dopamine in the ventral striatum of Lewis versus Fischer 344 rats. *Brain Research* **668**: 180–193.
565. Strecker, R. E., Eberle, C. A. and Ashby, C. R., Jr. (2004). Extracellular dopamine and its metabolites in the nucleus accumbens of Fischer and Lewis rats: basal levels and cocaine-induced changes. *Science* **56**: 135.
566. Minabe, Y., Emori, K. and Ashby, C. R., Jr. (1995). Significant differences in the activity of midbrain dopamine neurons between male Fischer 344 (F344) and Lewis rats: an in vivo electrophysiological study. *Life Sciences* **56**: 261.
567. Haile, C. N., Hiroi, N., Nestler, E. J. and Kosten, T. A. (2001). Differential behavioral responses to cocaine are associated with dynamics of mesolimbic dopamine proteins in Lewis and Fischer 344 rats. *Synapse* **41**: 179–190.

568. Dhabhar, F. S., McEwen, B. S. and Spencer, R. L. (1993). Stress response, adrenal steroid receptor levels and corticosteroid-binding globulin levels – a comparison between Sprague-Dawley, Fischer 344 and Lewis rats. *Brain Research* **616**: 89–98.
569. Cabib, S., Orsini, C., Le Moal, M. and Piazza, P. V. (2000). Abolition and reversal of strain differences in behavioral responses to drugs of abuse after a brief experience. *Science* **289**: 463–465.
570. Conversi, D., Orsini, C. and Cabib, S. (2004). Distinct patterns of Fos expression induced by systemic amphetamine in the striatal complex of C57BL/6JICo and DBA/2JICo inbred strains of mice. *Brain Research* **1025**: 59–66.
571. Cunningham, C. L., Niehus, D. R., Malott, D. H. and Prather, L. K. (1992). Genetic differences in the rewarding and activating effects of morphine and ethanol. *Psychopharmacology* **107**: 385–393.
572. Henricks, K. K., Miner, L. L. and Marley, R. J. (1997). Differential cocaine sensitivity between two closely related substrains of C57BL mice. *Psychopharmacology* **132**: 161–168.
573. He, M. and Shippenberg, T. S. (2000). Strain differences in basal and cocaine-evoked dopamine dynamics in mouse striatum. *Journal of Pharmacology And Experimental Therapeutics* **293**: 121–127.
574. Kuzmin, A. and Johansson, B. (2000). Reinforcing and neurochemical effects of cocaine: differences among C57, DBA, and 129 mice. *Pharmacology Biochemistry and Behavior* **65**: 399–406.
575. Murphy, N. P., Lam, H. A. and Maidment, N. T. (2001). A comparison of morphine-induced locomotor activity and mesolimbic dopamine release in C57BL/6, 129Sv and DBA2 mice. *Journal of Neurochemistry* **79**: 626–635.
576. Orsini, C., Buchini, F., Piazza, P. V., Puglisi-Allegra, S. and Cabib, S. (2004). Susceptibility to amphetamine-induced place preference is predicted by locomotor response to novelty and amphetamine in the mouse. *Psychopharmacology* **172**: 264.
577. Ventura, R., Alcaro, A., Cabib, S., Conversi, D., Mandolesi, S. and Puglisi-Allegra, S. (2004). Dopamine in the medial prefrontal cortex controls genotype-dependent effects of amphetamine on mesoaccumbens dopamine release and locomotion. *Neuropsychopharmacology* **29**: 72.
578. Zocchi, A., Orsini, C., Cabib, S. and Puglisi-Allegra, S. (1998). Parallel strain-dependent effect of amphetamine on locomotor activity and dopamine release in the nucleus accumbens: an in vivo study in mice. *Neuroscience* **82**: 521–528.
579. Samhsa (2000). Substance Abuse and Mental Health Services Administration, 2001. Summary of findings from the 2000 National Household Survey on Drug Abuse. (SMA) 01–3549.
580. Brady, K. T. and Randall, C. L. (1999). Gender differences in substance use disorders. *Psychiatr Clin North Am* **22**: Jun 241–252.
581. Evans, S. M., Haney, M., Fischman, M. W. and Foltin, R. W. (1999). Limited sex differences in response to 'binge' smoked cocaine use in humans. *Neuropsychopharmacology* **21**: 445–454.
582. Justice, A. J. and de Wit, H. (1999). Acute effects of d-amphetamine during the follicular and luteal phases of the menstrual cycle in women. *Psychopharmacology* **145**: 67–75.
583. Sofuoglu, M., Dudish-Poulsen, S., Nelson, D., Pentel, P. R. and Hatsukami, D. K. (1999). Sex and menstrual cycle differences in the subjective effects from smoked cocaine in humans. *Experimental and Clinical Psychopharmacology* **7**: 274–283.
584. Anglin, M. D., Hser, Y. I. and McGlothlin, W. H. (1987). Sex differences in addict careers. 2. Becoming addicted. *Drug and Alcohol Dependence* **13**: 59.
585. Haas, A. L. and Peters, R. H. (2000). Development of substance abuse problems among drug-involved offenders. Evidence for the telescoping effect. *Journal of Substance Abuse* **12**: 241.
586. Lex, B. (1991). Gender differences and substance abuse. *Advances in Substance Abuse* **4**: 225.
587. Lex, B. (1991). Some gender differences in alcohol and polysubstance users. *Health Psychology* **10**: 121–132.
588. Bjornson, W., Rand, C., Connett, J. E., Lindgren, P., Nides, M., Pope, F., Buist, A. S., Hoppe-Ryan, C. and OHara, P. (1995). Gender differences in smoking cessation after 3 years in the Lung Health Study. *Am J Public Health* **85**: Feb 223–230.
589. Longshore, D., Hsieh, S. and Anglin, M. D. (1993). Ethnic and gender differences in drug users' perceived need for treatment. *International Journal of Addictions* **28**: 539–558.
590. McCance-Katz, E. F., Carroll, K. M. and Rounsaville, B. J. (1999). Gender differences in treatment-seeking cocaine abusers-implications for treatment and prognosis. *American Journal of Addiction* **8**: 300.
591. Hernandez-Avila, C. A., Rounsaville, B. J. and Kranzler, H. R. (2004). Opioid-, cannabis- and alcohol-dependent women show more rapid progression to substance abuse treatment. *Drug and Alcohol Dependence* **74**: 265–272.
592. Carroll, M. E., Morgan, A. D., Campbell, U. C., Lynch, W. D. and Doss, N. K. (2002). Cocaine and heroin i.v. self-administration in rats selectively bred for differential saccharin intake: phenotype and sex differences. *Psychopharmacology* **161**: 304.
593. Donny, E. C., Caggiola, A. R., Rowell, P. P., Gharib, M. A., Maldovan, V., Booth, S., Mielke, M. M., Hoffman, A. and McCallum, S. (2000). Nicotine self-administration in rats: estrous cycle effects, sex differences and nicotinic receptor binding. *Psychopharmacology (Berl)* **151**: 392–405.
594. Lynch, W. J. and Carroll, M. E. (1999). Sex differences in the acquisition of intravenously self-administered cocaine and heroin in rats. *Psychopharmacology* **144**: 77–82.
595. Roth, M. E. and Carroll, M. E. (2004). Acquisition and maintenance of i.v. self-administration of methamphetamine in rats: effects of sex and estrogen. *Psychopharmacology* **172**: 443–449.
596. Carroll, M. E., Lynch, W. J., Roth, M. E., Morgan, A. D. and Cosgrove, K. P. (2004). Sex and estrogen influence drug abuse. *Trends Pharmacol Sci* **25**: 273–179.
597. Lynch, W. J. and Carroll, M. E. (2000). Reinstatement of cocaine self-administration in rats: sex differences. *Psychopharmacology* **148**: 196–200.
598. Roth, M. E., Cosgrove, K. P. and Carroll, M. E. (2004). Sex differences in the vulnerability to drug abuse: a review of preclinical studies. *Neuroscience and Behavioral Reviews* **28**: 533–546.
599. Carrol, M. E., Campbell, U. C. and Heideman, P. (2001). Ketoconazole suppresses food restriction-induced increases in heroin self-administration in rats: sex differences. *Experimental and Clinical Psychopharmacology* **9**: 307.
600. Sircar, R., Mallinson, K., Goldbloom, L. M. and Kehoe, P. (2001). Postnatal stress selectively upregulates striatal N -methyl-D-aspartate receptors in male rats. *Brain Research* **904**: 145–148.
601. Barr, C. S., Newman, T. K., Lindell, S., Becker, M. L., Shannon, C., Champoux, M., Suomi, S. J. and Higley, J. D. (2004). Early experience and sex interact to influence limbic-hypothalamic-pituitary-adrenal-axis function after acute alcohol administration in rhesus macaques (*Macaca mulatta*). *Alcohol Clin Exp Res* **28**: 1114–1119.
602. Justice, A. J. and De Wit, H. (2000). Acute effects of d-amphetamine during the early and late follicular phases of the menstrual cycle in women. *Pharmacology Biochemistry and Behavior* **66**: 509–515.
603. White, T. L., Justice, A. J. and de Wit, H. (2002). Differential subjective effects of D-amphetamine by gender, hormone levels and menstrual cycle phase. *Pharmacology Biochemistry and Behavior* **73**: 729–741.
604. Roberts, D. C. S., Bennet, S. A. L. and Vickers, G. (1989). The estrous cycle affects cocaine self-administration on a progressive ratio schedule of reinforcement in rats. *Psychopharmacology* **98**: 408–411.
605. Lynch, W. J., Roth, M. E., Mickelberg, J. L. and Carroll, M. E. (2001). Role of estrogen in the acquisition of intravenously self-administered cocaine in female rats. *Pharmacology Biochemistry and Behavior* **68**: 641–646.
606. Hu, M., Crombag, H. S., Robinson, T. E. and Becker, J. B. (2004). Biological basis of sex differences in the propensity to self-administer cocaine. *Neuropsychopharmacology* **29**: 81–85.
607. Becker, J. B. (1999). Gender differences in dopaminergic function in striatum and nucleus accumbens. *Pharmacol Biochem Behav* **64**: Dec 803–812.

608. Di Paolo, T., Poyet, P. and Labrie, F. (1981). Effect of chronic estradiol and haloperidol treatment on striatal dopamine receptors. *European Journal of Pharmacology* **73**: 105.
609. Thompson, T. L. (1999). Attenuation of dopamine uptake in vivo following priming with estradiol benzoate. *Brain Research* **834**: 164–167.
610. Jentsch, J. D., Olsson, P., De La Garza, R., 2nd and Taylor, J. R. (2002). Impairments of reversal learning and response perseveration after repeated, intermittent cocaine administrations to monkeys. *Neuropsychopharmacology* **26**: 183–190.
611. Dalley, J. W., Theobald, D. E., Berry, D., Milstein, J. A., Laane, K., Everitt, B. J. and Robbins, T. W. (2004). Cognitive sequelae of intravenous amphetamine self-administration in rats: evidence for selective effects on attentional performance. *Neuropsychopharmacology* **30**: 525–537.
612. Robinson, T. E. and Kolb, B. (1999). Alterations in the morphology of dendrites and dendritic spines in the nucleus accumbens and prefrontal cortex following repeated treatment with amphetamine or cocaine. *Eur J Neurosci* **11**: 1598–1604.
613. Kolb, B., Gorny, G., Li, Y., Samaha, A. N. and Robinson, T. E. (2003). Amphetamine or cocaine limits the ability of later experience to promote structural plasticity in the neocortex and nucleus accumbens. *Proc Natl Acad Sci U S A* **100**: 10523–10528.
614. Rogers, R. D. and Robbins, T. W. (2001). Investigating the neurocognitive deficits associated with chronic drug misuse. *Curr Opin Neurobiol* **11**: 250–257.
615. Lew, R. and Malberg, J. (1997). Evidence for and mechanism of action of neurotoxicity of amphetamine-related compounds. In *Highly Selective Neurotoxins: Basic and Clinical Applications* (Kostrzewa, R., ed.), pp. 235–268. Human Press Inc., Totowa, N.J.
616. Hanson, G. R., Rau, K. S. and Fleckenstein, A. E. (2004). The methamphetamine experience: a NIDA partnership. *Neuropharmacology* **47 Suppl 1**: 92–100.
617. Wilson, J. M., Kalasinsky, K. S., Levey, A. I., Bergeron, C., Reiber, G., Anthony, R. M., Schmunk, G. A., Shannak, K., Haycock, J. W. and Kish, S. J. (1996). Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. *Nat Med* **2**: 699–703.
618. Ricaurte, G. A., Martello, A. L., Katz, J. L. and Martello, M. B. (1992). Lasting effects of (+)-3,4-methylenedioxymethamphetamine (MDMA) on central serotonergic neurons in nonhuman primates: neurochemical observations. *J Pharmacol Exp Ther* **261**: 616–622.
619. McCann, U. D., Szabo, Z., Scheffel, U., Dannals, R. F. and Ricaurte, G. A. (1998). Positron emission tomographic evidence of toxic effect of MDMA (Ecstasy) on brain serotonin neurons in human beings. *Lancet* **352**: 1433–1437.
620. Fantegrossi, W. E., Woolverton, W. L., Kilbourn, M., Sherman, P., Yuan, J., Hatzidimitriou, G., Ricaurte, G. A., Woods, J. H. and Winger, G. (2004). Behavioral and neurochemical consequences of long-term intravenous self-administration of MDMA and its enantiomers by rhesus monkeys. *Neuropsychopharmacology* **29**: 1270–1281.
621. Roiser, J., Cook, L., Cooper, J., Runinsztein, D. and B. J., S. (2005). A functional polymorphism in the serotonin transporter gene is associated with abnormal emotional processing in ecstasy users. *American Journal of Psychiatry* **162**: 609–612.
622. Allen, D. N., Goldstein, G. and Seaton, B. E. (1997). Cognitive rehabilitation of chronic alcohol abusers. *Neuropsychol Rev* **7**: Mar 21–39.
623. Oscar-Berman, M. and Marinkovic, K. (2003). Alcoholism and the brain: an overview. *Alcohol Res Health* **27**: 125–133.
624. Charness, M. E., Simon, R. P. and Greenberg, D. A. (1989). Ethanol and the nervous system. *N Engl J Med* **321**: 17 Aug 442–454.
625. Bellinger, F. P., Davidson, M. S., Bedi, K. S. and Wilce, P. A. (2002). Neonatal ethanol exposure reduces AMPA but not NMDA receptor levels in the rat neocortex. *Brain Res Dev Brain Res* **136**: 30 May 77–84.
626. Pinder, R. M. and Sandler, M. (2004). Alcohol, wine and mental health: focus on dementia and stroke. *J Psychopharmacol* **18**: 449–456.
627. Arseneault, L., Cannon, M., Witton, J. and Murray, R. M. (2004). Causal association between cannabis and psychosis: examination of the evidence. *Br J Psychiatry* **184**: Feb 110–117.
628. Adolphs, R. (2003). Cognitive neuroscience of human social behaviour. *Nat Rev Neurosci* **4**: Mar 165–178.
629. Blakemore, S. J., Winston, J. and Frith, U. (2004). Social cognitive neuroscience: where are we heading? *Trends Cogn Sci* **8**: May 216–222.
630. Ochsner, K. N. (2004). Current directions in social cognitive neuroscience. *Curr Opin Neurobiol* **14**: 254–258.
631. Cacioppo, J. T. and Berntson, G. G. (2002). Social neuroscience. In *Foundations in social neuroscience* (Cacioppo, J. T., Berntson, G. G., Adolphs, R., Carter, C. S., Davidson, R. J., McClintock, M., McEwen, B. S., Meaney, M. J., Schacter, D. L., Sternberg, E. M., Suomi, S. S. and Taylor, S. E., eds.), pp. MIT Press, Cambridge, MA.
632. Harmon-Jones, E. and Devine, P. G. (2003). Introduction to the special section on social neuroscience: promise and caveats. *J Pers Soc Psychol* **85**: 589–593.
633. Grady, C. L. and Keightley, M. L. (2002). Studies of altered social cognition in neuropsychiatric disorders using functional neuroimaging. *Can J Psychiatry* **47**: 327–336.
634. Spence, S. A. and Frith, C. (1999). Towards a functional anatomy of volition. *Consciousness Studies* **6**: 11–29.
635. Klein, S. B. and Kihlstrom, J. F. (1998). On bridging the gap between social-personality psychology and neuropsychology. *Pers Soc Psychol Rev* **2**: 228–242.
636. Ochsner, K. N. and Lieberman, M. D. (2001). The emergence of social cognitive neuroscience. *Am Psychol* **56**: 717–734.
637. Levesque, J., Joannette, Y., Mensour, B., Beaudoin, G., Leroux, J. M., Bourgouin, P. and Beauregard, M. (2004). Neural basis of emotional self-regulation in childhood. *Neuroscience* **129**: 361–369.
638. Ochsner, K. N., Bunge, S. A., Gross, J. J. and Gabrieli, J. D. (2002). Rethinking feelings: an fMRI study of the cognitive regulation of emotion. *J Cogn Neurosci* **14**: 1215–1229.
639. Klein, S. B., Rozendal, K. and Cosmides, L. (2002). A social-cognitive neuroscience analysis of the self. *Social Cognition* **20**: 105–135.
640. Kelley, W. M., Macrae, C. N., Wyland, C. L., Caglar, S., Inati, S. and Heatherton, T. F. (2002). Finding the self? An event-related fMRI study. *J Cogn Neurosci* **14**: 785–794.
641. O'Doherty, J. P., Dayan, P., Friston, K., Critchley, H. and Dolan, R. J. (2003). Temporal difference models and reward-related learning in the human brain. *Neuron* **38**: 329–337.
642. Samson, D., Apperly, I. A., Chiavarino, C. and Humphreys, G. W. (2004). Left temporoparietal junction is necessary for representing someone else's belief. *Nat Neurosci* **7**: 499–500.
643. Dolan, R. J. (2002). Emotion, cognition, and behavior. *Science* **298**: 1191–1194.
644. Ochsner, K. N. and Feldman, B. L. (2001). A multiprocess perspective on the neuroscience of emotion. In *Emotions: Current issues and future directions* (Mayne, T. J. and Gossanno, G. A., eds.), pp. 38–81. Guilford Press, New York.
645. Spence, S. A., Hunter, M. D., Farrow, T. F., Green, R. D., Leung, D. H., Hughes, C. J. and Ganesan, V. (2004). A cognitive neurobiological account of deception: evidence from functional neuroimaging. *Philos Trans R Soc Lond B Biol Sci* **359**: 1755–1762.
646. Decety, J. and Jackson, P. L. J. (2004). The functional architecture of human empathy. *Behav Cogn Neurosci Rev* **3**: 71–100.
647. Stuss, D. T., Gallup, G. G., Jr. and Alexander, M. P. (2001). The frontal lobes are necessary for 'theory of mind'. *Brain* **124**: 279–286.
648. MacDonald, A. W., Cohen, J. D., Stenger, V. A. and Carter, C. S. (2000). Dissociating the role of the dorsolateral prefrontal and anterior cingulate cortex in cognitive control. *Science* **288**: 1835–1838.
649. Lieberman, M. D. (2000). Intuition: a social cognitive neuroscience approach. *Psychol Bull* **126**: 109–137.
650. Kroll, J. and Egan, E. (2004). Psychiatry, moral worry, and the moral emotions. *J Psychiatr Pract* **10**: 352–360.
651. Lieberman, M. D., Schreiber, D. and Ochsner, K. N. (2003). Is political sophistication like riding a bicycle? How cognitive neuroscience can inform research on political attitudes and decision-making. *Political Psychology* **24**: 681–704.
652. Glimcher, P. W. and Rustichini, A. (2004). Neuroeconomics: the consilience of brain and decision. *Science* **306**: 447–452.

653. Blum, K., Braverman, E. R., Holder, J. M., Lubar, J. F., Monastra, V. J., Miller, D., Lubar, J. O., Chen, T. J. and Comings, D. E. (2000). Reward deficiency syndrome: a biogenetic model for the diagnosis and treatment of impulsive, addictive, and compulsive behaviors. *J Psychoactive Drugs* **32 Suppl**: Nov i–iv, 1–112.
654. Volkow, N. D., Fowler, J. S. and Wang, G. J. (2003). Positron emission tomography and single-photon emission computed tomography in substance abuse research. *Semin Nucl Med* **33**: 114–128.
655. Volkow, N. D., Fowler, J. S. and Wang, G. J. (2003). The addicted human brain: insights from imaging studies. *J Clin Invest* **111**: 1444–1451.
656. Drummond, D. C. (2001). Theories of drug craving, ancient and modern. *Addiction* **96**: 33–46.
657. Niaura, R. (2000). Cognitive social learning and related perspectives on drug craving. *Addiction* **95 Suppl 2**: S155–163.
658. Goldstein, R. Z. and Volkow, N. D. (2002). Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex. *Am J Psychiatry* **159**: 1642–1652.
659. Stone, V. E., Cosmides, L., Tooby, J., Kroll, N. and Knight, R. T. (2002). Selective impairment of reasoning about social exchange in a patient with bilateral limbic system damage. *Proc Natl Acad Sci U S A* **99**: 11531–11536.
660. Kaufman, J. N., Ross, T. J., Stein, E. A. and Garavan, H. (2003). Cingulate hypoactivity in cocaine users during a GO-NOGO task as revealed by event-related functional magnetic resonance imaging. *J Neurosci* **23**: 7839–7843.
661. Hester, R. and Garavan, H. (2004). Executive dysfunction in cocaine addiction: evidence for discordant frontal, cingulate, and cerebellar activity. *J Neurosci* **24**: 11017–11022.
662. Bolla, K. I., Eldreth, D. A., London, E. D., Kiehl, K. A., Mouratidis, M., Contoreggi, C., Matochik, J. A., Kurian, V., Cadet, J. L., Kimes, A. S., Funderburk, F. R. and Ernst, M. (2003). Orbitofrontal cortex dysfunction in abstinent cocaine abusers performing a decision-making task. *Neuroimage* **19**: Jul 1085–1094.
663. Ersche, K. D., Fletcher, P. C., Lewis, S. W. G., Clark, L., Stocks-Gee, G., London, M., Deakin, J. B., Robbins, T. W. and Sahakian, B. (2005). Abnormal frontal activations related to decision-making in current and former amphetamine and opiate dependent individuals. *Psychopharmacology (Berl)* **In press**.
664. Bechara, A. and Damasio, H. (2002). Decision-making and addiction (part I): impaired activation of somatic states in substance dependent individuals when pondering decisions with negative future consequences. *Neuropsychologia* **40**: 1675–1689.
665. Peoples, L. L. (2002). Neuroscience. Will, anterior cingulate cortex, and addiction. *Science* **296**: 1623–1624.
666. Morse, S. J. (2004). Medicine and morals, craving and compulsion. *Subst Use Misuse* **39**: 437–460.
667. Volkow, N. D. and Li, T. K. (2004). Drug addiction: the neurobiology of behaviour gone awry. *Nat Rev Neurosci* **5**: 963–970.
668. Campbell, W. G. (2003). Addiction: a disease of volition caused by a cognitive impairment. *Can J Psychiatry* **48**: Nov 669–674.
669. Frith, C. D., Friston, K., Liddle, P. F. and Frackowiak, R. S. (1991). Willed action and the prefrontal cortex in man: a study with PET. *Proceedings of the Royal Society of London, Series B – Biological Sciences* **244**: 241–246.
670. Zhu, J. (2004). Understanding volition. *Philosophical Psychology* **17**: 247–273.
671. Spence, S. A., Hirsch, S. R., Brooks, D. J. and Grasby, P. M. (1998). Prefrontal cortex activity in people with schizophrenia and control subjects. Evidence from positron emission tomography for remission of 'hypofrontality' with recovery from acute schizophrenia. *Br J Psychiatry* **172**: 316–323.
672. Marshall, J. C., Halligan, P. W., Fink, G. R., Wade, D. T. and Frackowiak, R. S. (1997). The functional anatomy of a hysterical paralysis. *Cognition* **64**: B1–8.
673. Ward, N. S., Oakely, D. A., Frackowiak, R. S. J. and Halligan, P. W. (2003). Differential brain activations during intentionally simulated and subjectively experienced paralysis. *Cog. Neuropsychiatry* **8**: 295–312.
674. Brody, H. (1998). Ethics in managed care. A matter of focus, a matter of integrity. *Mich Med* **97**: Dec 28–32.
675. Hall, W., Carter, L. and Morley, K. I. (2004). Neuroscience research on the addictions: a prospectus for future ethical and policy analysis. *Addict Behav* **29**: 1481–1495.
676. Adler, M. W. (1995). Human subject issues in drug abuse research. College on Problems of Drug Dependence. *Drug Alcohol Depend* **37**: Feb 167–175.
677. Gorelick, D. A., Pickens, R. W. and Benkovsky, F. O. (1999). Clinical research in substance abuse: human subjects issues. In *Ethics in Psychiatric Research: A resource manual for human subjects protection* (Pincus, H. A., Lieberman, J. A. and Ferris, S., eds.). American Psychiatric Association, Washington, D.C.
678. Cohen, P. J. S. (2002). Untreated addiction imposes an ethical bar to recruiting addicts for non-therapeutic studies of addictive drugs. *J Law Med Ethics* **30**: 73–81.
679. Rinn, W., Desai, N., Rosenblatt, H. and Gastfriend, D. R. (2002). Addiction denial and cognitive dysfunction: a preliminary investigation. *J Neuropsychiatry Clin Neurosci* **14**: 52–57.
680. McGlynn, S. M. and Schacter, D. L. (1989). Unawareness of deficits in neuropsychological syndromes. *J Clin Exp Neuropsychol* **11**: 143–205.
681. Barco, P. P., Crosson, B., Bolesta, M. M., Werts, D. and Stout, R. (1991). Levels of awareness and compensation in cognitive rehabilitation. In *Cognitive Rehabilitation for Persons With Traumatic Brain Injury: A Functional Approach* (Kreutzer, J. S. and Wehman, P. H., eds.), pp. 129–146. P. H. Brookes, Baltimore.
682. Rachlin, H., Green, L., Kagel, J. and Battalio, R. (1976). Economic demand theory and psychological studies of choice. In *The Psychology of Learning and Motivation* (Bower, G., ed.), pp. 129–154. Academic Press, New York.
683. Allison, J. (1979). Demand economics and experimental psychology. *Behavioral Science* **24**: 403–415.
684. von Neumann, J. and Morgenstern, O. (1947). *Theory of games and economic behavior*, Princeton University Press, Princeton, New Jersey.
685. Shizgal, P. (1997). Neural basis of utility estimation. *Current Opinion in Neurobiology* **7**: 198–208.
686. Arnauld, A. and Nicole, P. (1662). *La logique, ou l'art de penser [Logic, or the Art of Thinking; the Port-Royal Logic]*.
687. Friedman, D. D. (1990). *Price Theory: An Intermediate Text*, South-Western.
688. Williams, B. A. (1994). Reinforcement and choice. In *Animal Learning and Cognition* (Mackintosh, N. J., ed.), pp. 81–108. Academic Press, San Diego.
689. Rachlin, H. (2003). Economic concepts in the behavioral study of addiction. In *Choice, Behavioral Economics and Addiction* (Heather, N. and Vuchinich, R. E., eds.), pp. 129–149. Elsevier, Oxford.
690. Heyman, G. M., Gendel, K. and Goodman, J. (1999). Inelastic demand for alcohol in rats. *Psychopharmacology (Berl)* **144**: 213–219.
691. Heyman, G. M. (2000). An economic approach to animal models of alcoholism. *Alcohol Res Health* **24**: 132–139.
692. MacCoun, R. (2003). Is the addiction concept useful for drug policy? In *Choice, Behavioral Economics and Addiction* (Heather, N. and Vuchinich, R. E., eds.), pp. 383–401, 407. Elsevier, Oxford.
693. NHSDA (2001). Summary of Findings from the 2000 National Household Survey on Drug Abuse [DHHS Publication Number (SMA) 01–3549]. Substance Abuse and Mental Health Services Administration (Department of Health and Human Services, USA).
694. Warner, L. A., Kessler, R. C., Hughes, M., Anthony, J. C. and Nelson, C. B. (1995). Prevalence and correlates of drug use and dependence in the United States. Results from the National Comorbidity Survey. *Arch Gen Psychiatry* **52**: 219–229.
695. Heyman, G. M. (2003). Consumption dependent changes in reward value: a framework for understanding addiction. In *Choice, Behavioral Economics and Addiction* (Heather, N. and Vuchinich, R. E., eds.), pp. 95–121. Elsevier, Oxford.
696. Chaloupka, F. J., Emery, S. and Liang, L. (2003). Evolving models of addictive behaviour: from neoclassical to behavioral economics. In *Choice, Behavioral Economics and Addiction* (Heather, N. and Vuchinich, R. E., eds.), pp. 71–89. Elsevier, Oxford.

697. Gruber, J., Sen, A. and Stabile, M. (2002). Estimating price elasticities when there is smuggling: the sensitivity of smoking to price in Canada [Working Paper 8962]. National Bureau of Economic Research.
698. Bickel, W. K., DeGrandpre, R. J., Higgins, S. T., Hughers, J. R. and Badger, G. (1995). Effects of simulated employment and recreation on drug taking: a behavioral economic analysis. *Experimental and Clinical Psychopharmacology* **3**: 467–476.
699. DeGrandpre, R. J. and Bickel, W. K. (1995). Human drug self-administration in a medium of exchange. *Experimental and Clinical Psychopharmacology* **3**: 349–357.
700. Smith, Z. (1999). The revenue effect of changing alcohol duties. Institute for Fiscal Studies.
701. Saffer, H. and Chaloupka, F. J. (1995). The demand for illicit drugs [Working Paper 5238]. National Bureau of Economic Research.
702. Hursh, S. R. (1978). The economics of daily consumption controlling food- and water-reinforced responding. *Journal of the Experimental Analysis of Behavior* **29**: 475–491.
703. Madden, G. J. and Bickel, W. K. (1999). Abstinence and price effects on demand for cigarettes: a behavioral-economic analysis. *Addiction* **94**: 577–588.
704. Bickel, W. K., DeGrandpre, R. J. and Higgins, S. T. (1995). The behavioral economics of concurrent drug reinforcers: a review and reanalysis of drug self-administration research. *Psychopharmacology (Berl)* **118**: Apr 250–259.
705. MacCoun, R. (2003). Comments on Chaloupka, Emery, and Liang. In *Choice, Behavioral Economics and Addiction* (Heather, N. and Vuchinich, R. E., eds.), pp. 90–94. Elsevier, Oxford.
706. Winston, G. C. (1980). Addiction and backsliding: a theory of compulsive consumption. *Journal of Economic Behavior and Organization* **1**: 295–324.
707. Kahneman, D., Slovic, P. and Tversky, A., Eds. (1982). *Judgement Under Uncertainty: Heuristics and Biases*. New York: Cambridge University Press.
708. Chase, V. M., Hertwig, R. and Gigerenzer, G. (1998). Visions of rationality. *Trends in Cognitive Sciences* **2**: 206–214.
709. Heckerman, D. E., Horvitz, E. J. and Nathwani, B. N. (1992). Toward normative expert systems: Part I. The Pathfinder project. *Methods of Information in Medicine* **31**: 90–105.
710. Mullainathan, S. (2002). Behavioral economics. In *International Encyclopedia of the Social and Behavioral Sciences* (Baltes, P. B. and Smelser, N. J., eds.). Pergamon, Oxford.
711. Mazur, J. E. (1987). An adjusting procedure for studying delayed reinforcement. In *Quantitative Analyses of Behavior: V. The Effect of Delay and of Intervening Events on Reinforcement Value* (Commons, M. L., Mazur, J. E., Nevin, J. A. and Rachlin, H., eds.), pp. 55–73. Lawrence Erlbaum, Hillsdale, New Jersey.
712. Mazur, J. E., Stellar, J. R. and Waraczynski, M. (1987). Self-control choice with electrical stimulation of the brain as a reinforcer. *Behavioural Processes* **15**: 143–153.
713. Richards, J. B., Mitchell, S. H., de Wit, H. and Seiden, L. S. (1997). Determination of discount functions in rats with an adjusting-amount procedure. *Journal of the Experimental Analysis of Behavior* **67**: 353–366.
714. Grace, R. C. (1996). Choice between fixed and variable delays to reinforcement in the adjusting-delay procedure and concurrent chains. *Journal of Experimental Psychology: Animal Behavior Processes* **22**: 362–383.
715. Bradshaw, C. M. and Szabadi, E. (1992). Choice between delayed reinforcers in a discrete-trials schedule – the effect of deprivation level. *Quarterly Journal of Experimental Psychology, Section B – Comparative and Physiological Psychology* **44B**: 1–16.
716. Homer (~800 BC). *Odyssey*.
717. Skog, O.-J. (2003). Addiction: definitions and mechanisms. In *Choice, Behavioral Economics and Addiction* (Heather, N. and Vuchinich, R. E., eds.), pp. 157–175, 182. Elsevier, Oxford.
718. Schaler, J. A. (2000). *Addiction is a choice*. Open Court Publishing, Chicago, Illinois.
719. Gruber, J. and Mullainathan, S. (2002). Do cigarette taxes make smokers happier? [Working Paper 8872]. National Bureau of Economic Research.
720. Rachlin, H. and Green, L. (1972). Commitment, choice and self-control. *Journal of the Experimental Analysis of Behavior* **17**: 15–22.
721. Ainslie, G. (1974). Impulse control in pigeons. *Journal of the Experimental Analysis of Behavior* **21**: 485–489.
722. Ainslie, G. and Herrnstein, R. J. (1981). Preference reversal and delayed reinforcement. *Animal Learning and Behavior* **9**: 476–482.
723. Berridge, K. C. (1996). Food reward: Brain substrates of wanting and liking. *Neuroscience and Biobehavioral Reviews* **20**: 1–25.
724. Balleine, B. W. and Dickinson, A. (2000). The effect of lesions of the insular cortex on instrumental conditioning: evidence for a role in incentive memory. *Journal of Neuroscience* **20**: 8954–8964.
725. Yin, H. H., Knowlton, B. J. and Balleine, B. W. (2004). Lesions of dorsolateral striatum preserve outcome expectancy but disrupt habit formation in instrumental learning. *Eur J Neurosci* **19**: 181–189.
726. Kheramin, S., Body, S., Ho, M., Velazquez-Martinez, D. N., Bradshaw, C. M., Szabadi, E., Deakin, J. F. and Anderson, I. M. (2003). Role of the orbital prefrontal cortex in choice between delayed and uncertain reinforcers: a quantitative analysis. *Behav Processes* **64**: 239–250.
727. Mobini, S., Body, S., Ho, M. Y., Bradshaw, C. M., Szabadi, E., Deakin, J. F. and Anderson, I. M. (2002). Effects of lesions of the orbitofrontal cortex on sensitivity to delayed and probabilistic reinforcement. *Psychopharmacology* **160**: 290–298.
728. Anderson, I. M., Richell, R. A. and Bradshaw, C. M. (2003). The effect of acute tryptophan depletion on probabilistic choice. *J Psychopharmacol* **17**: Mar 3–7.
729. Walton, M. E., Bannerman, D. M., Alterescu, K. and Rushworth, M. F. (2003). Functional specialization within medial frontal cortex of the anterior cingulate for evaluating effort-related decisions. *J Neurosci* **23**: 6475–6479.
730. Walton, M. E., Bannerman, D. M. and Rushworth, M. F. (2002). The role of rat medial frontal cortex in effort-based decision making. *J Neurosci* **22**: 10996–11003.
731. Winstanley, C. A., Theobald, D. E., Cardinal, R. N. and Robbins, T. W. (2004). Contrasting roles of basolateral amygdala and orbitofrontal cortex in impulsive choice. *J Neurosci* **24**: 4718–4722.
732. Rogers, R. D., Blackshaw, A. J., Middleton, H. C., Matthews, K., Hawtin, K., Crowley, C., Hopwood, A., Wallace, C., Deakin, J. F., Sahakian, B. J. and Robbins, T. W. (1999). Tryptophan depletion impairs stimulus-reward learning while methylphenidate disrupts attentional control in healthy young adults: implications for the monoaminergic basis of impulsive behaviour. *Psychopharmacology (Berl)* **146**: 482–491.
733. Rogers, R. D., Tunbridge, E. M., Bhagwagar, Z., Drevets, W. C., Sahakian, B. J. and Carter, C. S. (2003). Tryptophan depletion alters the decision-making of healthy volunteers through altered processing of reward cues. *Neuropsychopharmacology* **28**: 153–162.
734. Poulos, C. X., Parker, J. L. and Le, A. D. (1996). Dextfenfluramine and 8-OH-DPAT modulate impulsivity in a delay-of-reward paradigm: implications for a correspondence with alcohol consumption. *Behavioural Pharmacology* **7**: 395–399.
735. Wogar, M. A., Bradshaw, C. M. and Szabadi, E. (1993). Effect of lesions of the ascending 5-hydroxytryptaminergic pathways on choice between delayed reinforcers. *Psychopharmacology* **111**: 239–243.
736. Richards, J. B. and Seiden, L. S. (1995). Serotonin depletion increases impulsive behavior in rats. *Society for Neuroscience Abstracts* **21**: 1693.
737. Bizot, J., Le Bihan, C., Puech, A. J., Hamon, M. and Thiébot, M. (1999). Serotonin and tolerance to delay of reward in rats. *Psychopharmacology* **146**: 400–412.
738. Wade, T. R., de Wit, H. and Richards, J. B. (2000). Effects of dopaminergic drugs on delayed reward as a measure of impulsive behavior in rats. *Psychopharmacology* **150**: 90–101.
739. O'Doherty, J., Critchley, H., Deichmann, R. and Dolan, R. J. (2003). Dissociating valence of outcome from behavioral control in human orbital and ventral prefrontal cortices. *J Neurosci* **23**: 7931–7939.

Neuroscience and Drugs of Addiction

740. Gjelsvik, O. (2003). Reason and addiction. In *Choice, Behavioral Economics and Addiction* (Heather, N. and Vuchinich, R. E., eds.), pp. 219–238, 245–247. Elsevier, Oxford.
741. Cardinal, R. N., Robbins, T. W. and Everitt, B. J. (2003). Choosing delayed rewards: perspectives from learning theory, neurochemistry, and neuroanatomy. In *Choice, Behavioral Economics and Addiction* (Heather, N. and Vuchinich, R. E., eds.), pp. 183–213, 217–218. Elsevier, Oxford.
742. Loewenstein, G. (1996). Out of control: visceral influences on behavior. *Organizational Behavior and Human Decision Processes* **63**: 272–292.
743. Loewenstein, G. F. and O'Donoghue, T. (2004). Animal Spirits: Affective and Deliberative Processes in Economic Behavior [<http://ssrn.com/abstract=539843>].
744. McClure, S. M., Laibson, D. I., Loewenstein, G. and Cohen, J. D. (2004). Separate neural systems value immediate and delayed monetary rewards. *Science* **306**: 503–507.
745. O'Brien, C. P. (1997). A range of research-based pharmacotherapies for addiction. *Science* **278**: 66–70.
746. Harmer, C. J., McTavish, S. F., Clark, L., Goodwin, G. M. and Cowen, P. J. (2001). Tyrosine depletion attenuates dopamine function in healthy volunteers. *Psychopharmacology (Berl)* **154**: 105–111.
747. Park, S. B., Coull, J. T., McShane, R. H., Young, A. H., Sahakian, B. J., Robbins, T. W. and Cowen, P. J. (1994). Tryptophan depletion in normal volunteers produces selective impairments in learning and memory. *Neuropharmacology* **33**: 575–588.
748. Uchtenhagen, A. (1997). Summary of the Synthesis Report. Institute for Social and Preventive Medicine at the University of Zurich.
749. Kantak, K. M. (2003). Vaccines against drugs of abuse: a viable treatment option? *Drugs* **63**: 341–352.
750. Slovic, P., Fischhoff, B. and Lichtenstein, S. (1982). Facts versus fears: understanding perceived risk. In *Judgement Under Uncertainty: Heuristics and Biases* (Kahneman, D., Slovic, P. and Tversky, A., eds.), pp. 463–489. Cambridge University Press, New York.
751. British Heart Foundation (2004). Give Up Before You Clog Up [anti-smoking advertising campaign], UK.
752. McCollister, K. E. and French, M. T. (2003). The relative contribution of outcome domains in the total economic benefit of addiction interventions: a review of first findings. *Addiction* **98**: 1647–1659.
753. Green, L. and Fisher, E. B. (2000). Economic substitutability: some implications for health behavior. In *Reframing health behavior change with behavioral economics* (Bickel, W. K. and Vuchinich, R. E., eds.), pp. 115–144. Erlbaum, Mahwah, NJ.
754. Higgins, S. T., Alessi, S. M. and Dantona, R. L. (2002). Voucher-based incentives. A substance abuse treatment innovation. *Addict Behav* **27**: 887–910.
755. Volkow, N. D., Wang, G. J., Fowler, J. S., Logan, J., Gatley, S. J., Gifford, A., Hitzemann, R., Ding, Y. S. and Pappas, N. (1999). Prediction of reinforcing responses to psychostimulants in humans by brain dopamine D2 receptor levels. *Am J Psychiatry* **156**: 1440–1443.
756. Rachlin, H. (2000). *The science of self-control*, Harvard University Press, Cambridge, Massachusetts.